id	sid	tid	token	lemma	pos
aji-63	1	1	_	_	PUNCT
aji-63	2	1	_	_	PUNCT
aji-63	3	1	_	_	PUNCT
aji-63	4	1	_	_	PUNCT
aji-63	5	1	_	_	PUNCT
aji-63	6	1	_	_	PUNCT
aji-63	7	1	_	_	PUNCT
aji-63	8	1	_	_	PUNCT
aji-63	9	1	_	_	PUNCT
aji-63	10	1	_	_	PUNCT
aji-63	11	1	_	_	PUNCT
aji-63	12	1	_	_	PUNCT
aji-63	13	1	_	_	PUNCT
aji-63	14	1	_	_	PUNCT
aji-63	15	1	_	_	PUNCT
aji-63	16	1	_	_	PUNCT
aji-63	17	1	_	_	PUNCT
aji-63	18	1	_	_	PUNCT
aji-63	19	1	_	_	PUNCT
aji-63	20	1	_	_	PUNCT
aji-63	21	1	_	_	PUNCT
aji-63	22	1	_	_	PUNCT
aji-63	23	1	_	_	PUNCT
aji-63	24	1	_	_	PUNCT
aji-63	25	1	_	_	PUNCT
aji-63	26	1	_	_	PUNCT
aji-63	27	1	_	_	PUNCT
aji-63	28	1	_	_	PUNCT
aji-63	29	1	_	_	PUNCT
aji-63	30	1	_	_	PUNCT
aji-63	31	1	_	_	PUNCT
aji-63	32	1	_	_	PUNCT
aji-63	33	1	_	_	PUNCT
aji-63	34	1	_	_	PUNCT
aji-63	35	1	_	_	PUNCT
aji-63	36	1	_	_	PUNCT
aji-63	37	1	_	_	PUNCT
aji-63	38	1	_	_	PUNCT
aji-63	39	1	_	_	PUNCT
aji-63	40	1	_	_	PUNCT
aji-63	41	1	_	_	PUNCT
aji-63	42	1	_	_	PUNCT
aji-63	43	1	_	_	PUNCT
aji-63	44	1	_	_	PUNCT
aji-63	45	1	_	_	PUNCT
aji-63	46	1	_	_	PUNCT
aji-63	47	1	_	_	PUNCT
aji-63	48	1	_	_	PUNCT
aji-63	49	1	_	_	PUNCT
aji-63	50	1	_	_	PUNCT
aji-63	51	1	_	_	PUNCT
aji-63	52	1	_	_	PUNCT
aji-63	53	1	_	_	PUNCT
aji-63	54	1	_	_	PUNCT
aji-63	55	1	_	_	PUNCT
aji-63	56	1	_	_	PUNCT
aji-63	57	1	_	_	PUNCT
aji-63	58	1	_	_	PUNCT
aji-63	59	1	_	_	PUNCT
aji-63	60	1	_	_	PUNCT
aji-63	61	1	_	_	PUNCT
aji-63	62	1	_	_	PUNCT
aji-63	63	1	_	_	PUNCT
aji-63	64	1	_	_	PUNCT
aji-63	65	1	_	_	PUNCT
aji-63	66	1	_	_	PUNCT
aji-63	67	1	_	_	PUNCT
aji-63	68	1	_	_	PUNCT
aji-63	69	1	_	_	PUNCT
aji-63	70	1	_	_	PUNCT
aji-63	71	1	_	_	PUNCT
aji-63	72	1	_	_	PUNCT
aji-63	73	1	_	_	PUNCT
aji-63	74	1	_	_	PUNCT
aji-63	75	1	_	_	PUNCT
aji-63	76	1	_	_	PUNCT
aji-63	77	1	_	_	PUNCT
aji-63	78	1	_	_	PUNCT
aji-63	79	1	_	_	PUNCT
aji-63	80	1	_	_	PUNCT
aji-63	81	1	_	_	PUNCT
aji-63	82	1	_	_	PUNCT
aji-63	83	1	_	_	PUNCT
aji-63	84	1	_	_	PUNCT
aji-63	85	1	_	_	PUNCT
aji-63	86	1	_	_	PUNCT
aji-63	87	1	_	_	PUNCT
aji-63	88	1	_	_	PUNCT
aji-63	89	1	_	_	PUNCT
aji-63	90	1	_	_	PUNCT
aji-63	91	1	_	_	PUNCT
aji-63	92	1	_	_	PUNCT
aji-63	93	1	_	_	PUNCT
aji-63	94	1	_	_	PUNCT
aji-63	95	1	_	_	PUNCT
aji-63	96	1	_	_	PUNCT
aji-63	97	1	_	_	PUNCT
aji-63	98	1	_	_	PUNCT
aji-63	99	1	_	_	PUNCT
aji-63	100	1	_	_	PUNCT
aji-63	101	1	_	_	PUNCT
aji-63	102	1	#	#	NOUN
aji-63	102	2	professor	professor	NOUN
aji-63	102	3	;	;	PUNCT
aji-63	102	4	≡	≡	PROPN
aji-63	102	5	director	director	NOUN
aji-63	102	6	;	;	PUNCT
aji-63	102	7	*	*	PUNCT
aji-63	102	8	corresponding	correspond	VERB
aji-63	102	9	author	author	NOUN
aji-63	102	10	:	:	PUNCT
aji-63	102	11	e	e	NOUN
aji-63	102	12	-	-	NOUN
aji-63	102	13	mail	mail	NOUN
aji-63	102	14	:	:	PUNCT
aji-63	103	1	bawazir56@gmail.com	bawazir56@gmail.com	NOUN
aji-63	103	2	;	;	PUNCT
aji-63	103	3	asian	asian	ADJ
aji-63	103	4	journal	journal	NOUN
aji-63	103	5	of	of	ADP
aji-63	103	6	immunology	immunology	NOUN
aji-63	103	7	4(1	4(1	NOUN
aji-63	103	8	):	):	PUNCT
aji-63	103	9	146	146	NUM
aji-63	103	10	-	-	SYM
aji-63	103	11	153	153	NUM
aji-63	103	12	,	,	PUNCT
aji-63	103	13	2021	2021	NUM
aji-63	103	14	;	;	PUNCT
aji-63	103	15	article	article	NOUN
aji-63	103	16	no.aji.83681	no.aji.83681	PROPN
aji-63	103	17	prevalence	prevalence	NOUN
aji-63	103	18	and	and	CCONJ
aji-63	103	19	classes	class	NOUN
aji-63	103	20	of	of	ADP
aji-63	103	21	sars	sar	NOUN
aji-63	103	22	-	-	PUNCT
aji-63	103	23	cov-2	cov-2	NOUN
aji-63	103	24	antibodies	antibodie	VERB
aji-63	103	25	among	among	ADP
aji-63	103	26	covid-19	covid-19	PROPN
aji-63	103	27	suspected	suspect	VERB
aji-63	103	28	patients	patient	NOUN
aji-63	103	29	who	who	PRON
aji-63	103	30	attended	attend	VERB
aji-63	103	31	a	a	DET
aji-63	103	32	health	health	NOUN
aji-63	103	33	care	care	NOUN
aji-63	103	34	setting	setting	NOUN
aji-63	103	35	in	in	ADP
aji-63	103	36	sana’a	sana’a	NOUN
aji-63	103	37	,	,	PUNCT
aji-63	104	1	yemen	yemen	PROPN
aji-63	104	2	talal	talal	PROPN
aji-63	104	3	a.	a.	PROPN
aji-63	104	4	sallam	sallam	PROPN
aji-63	104	5	a	a	DET
aji-63	104	6	#	#	NOUN
aji-63	104	7	,	,	PUNCT
aji-63	104	8	mokhtar	mokhtar	PROPN
aji-63	104	9	al	al	PROPN
aji-63	104	10	-	-	PUNCT
aji-63	104	11	youssefi	youssefi	NOUN
aji-63	104	12	b≡	b≡	NOUN
aji-63	104	13	and	and	CCONJ
aji-63	104	14	amen	amen	INTJ
aji-63	104	15	a	a	DET
aji-63	104	16	bawazir	bawazir	NOUN
aji-63	104	17	c	c	NOUN
aji-63	104	18	*	*	NOUN
aji-63	104	19	#	#	NOUN
aji-63	104	20	a	a	DET
aji-63	104	21	department	department	NOUN
aji-63	104	22	of	of	ADP
aji-63	104	23	medical	medical	ADJ
aji-63	104	24	microbiology	microbiology	NOUN
aji-63	104	25	,	,	PUNCT
aji-63	104	26	faculty	faculty	NOUN
aji-63	104	27	of	of	ADP
aji-63	104	28	medicine	medicine	NOUN
aji-63	104	29	and	and	CCONJ
aji-63	104	30	health	health	NOUN
aji-63	104	31	sciences	science	NOUN
aji-63	104	32	,	,	PUNCT
aji-63	104	33	sana`a	sana`a	NUM
aji-63	104	34	university	university	PROPN
aji-63	104	35	,	,	PUNCT
aji-63	104	36	yemen	yemen	PROPN
aji-63	104	37	.	.	PUNCT
aji-63	105	1	b	b	X
aji-63	105	2	alyoussefi	alyoussefi	VERB
aji-63	105	3	specialized	specialized	ADJ
aji-63	105	4	laboratories	laboratory	NOUN
aji-63	105	5	,	,	PUNCT
aji-63	105	6	sana’a	sana’a	NOUN
aji-63	105	7	,	,	PUNCT
aji-63	105	8	yemen	yemen	PROPN
aji-63	105	9	.	.	PUNCT
aji-63	106	1	c	c	PROPN
aji-63	106	2	department	department	PROPN
aji-63	106	3	of	of	ADP
aji-63	106	4	public	public	ADJ
aji-63	106	5	health	health	NOUN
aji-63	106	6	and	and	CCONJ
aji-63	106	7	epidemiology	epidemiology	NOUN
aji-63	106	8	,	,	PUNCT
aji-63	106	9	faculty	faculty	NOUN
aji-63	106	10	of	of	ADP
aji-63	106	11	medicine	medicine	NOUN
aji-63	106	12	and	and	CCONJ
aji-63	106	13	health	health	NOUN
aji-63	106	14	sciences	sciences	PROPN
aji-63	106	15	,	,	PUNCT
aji-63	106	16	aden	aden	PROPN
aji-63	106	17	university	university	PROPN
aji-63	106	18	,	,	PUNCT
aji-63	106	19	yemen	yemen	PROPN
aji-63	106	20	.	.	PUNCT
aji-63	107	1	authors	author	NOUN
aji-63	107	2	’	'	PUNCT
aji-63	107	3	contributions	contribution	NOUN
aji-63	107	4	this	this	DET
aji-63	107	5	work	work	NOUN
aji-63	107	6	was	be	AUX
aji-63	107	7	carried	carry	VERB
aji-63	107	8	out	out	ADP
aji-63	107	9	in	in	ADP
aji-63	107	10	collaboration	collaboration	NOUN
aji-63	107	11	among	among	ADP
aji-63	107	12	all	all	DET
aji-63	107	13	authors	author	NOUN
aji-63	107	14	.	.	PUNCT
aji-63	108	1	authors	author	NOUN
aji-63	108	2	tas	tas	PROPN
aji-63	108	3	and	and	CCONJ
aji-63	108	4	may	may	AUX
aji-63	108	5	designed	design	VERB
aji-63	108	6	the	the	DET
aji-63	108	7	study	study	NOUN
aji-63	108	8	and	and	CCONJ
aji-63	108	9	author	author	NOUN
aji-63	108	10	may	may	AUX
aji-63	108	11	carried	carry	VERB
aji-63	108	12	out	out	ADP
aji-63	108	13	the	the	DET
aji-63	108	14	data	datum	NOUN
aji-63	108	15	collection	collection	NOUN
aji-63	108	16	.	.	PUNCT
aji-63	109	1	authors	author	NOUN
aji-63	109	2	tas	tas	PROPN
aji-63	109	3	and	and	CCONJ
aji-63	109	4	aab	aab	PROPN
aji-63	109	5	analysed	analyse	VERB
aji-63	109	6	and	and	CCONJ
aji-63	109	7	interpreted	interpret	VERB
aji-63	109	8	the	the	DET
aji-63	109	9	data	datum	NOUN
aji-63	109	10	.	.	PUNCT
aji-63	110	1	all	all	DET
aji-63	110	2	authors	author	NOUN
aji-63	110	3	read	read	VERB
aji-63	110	4	and	and	CCONJ
aji-63	110	5	approved	approve	VERB
aji-63	110	6	the	the	DET
aji-63	110	7	final	final	ADJ
aji-63	110	8	manuscript	manuscript	NOUN
aji-63	110	9	.	.	PUNCT
aji-63	111	1	article	article	NOUN
aji-63	111	2	information	information	PROPN
aji-63	111	3	editor(s	editor(s	PROPN
aji-63	111	4	):	):	PUNCT
aji-63	111	5	(	(	PUNCT
aji-63	111	6	1	1	X
aji-63	111	7	)	)	PUNCT
aji-63	111	8	prof	prof	NOUN
aji-63	111	9	.	.	PUNCT
aji-63	112	1	cynthia	cynthia	PROPN
aji-63	112	2	aracely	aracely	ADV
aji-63	112	3	alvizo	alvizo	VERB
aji-63	112	4	báez	báez	ADJ
aji-63	112	5	,	,	PUNCT
aji-63	112	6	autonomous	autonomous	ADJ
aji-63	112	7	university	university	PROPN
aji-63	112	8	of	of	ADP
aji-63	112	9	nuevo	nuevo	PROPN
aji-63	112	10	leon	leon	PROPN
aji-63	112	11	,	,	PUNCT
aji-63	112	12	mexico	mexico	PROPN
aji-63	112	13	.	.	PUNCT
aji-63	113	1	(	(	PUNCT
aji-63	113	2	2	2	X
aji-63	113	3	)	)	PUNCT
aji-63	113	4	dr	dr	PROPN
aji-63	113	5	.	.	PROPN
aji-63	113	6	wagner	wagner	PROPN
aji-63	113	7	loyola	loyola	PROPN
aji-63	113	8	,	,	PUNCT
aji-63	113	9	brazilian	brazilian	ADJ
aji-63	113	10	agricultural	agricultural	ADJ
aji-63	113	11	research	research	NOUN
aji-63	113	12	corporation	corporation	NOUN
aji-63	113	13	,	,	PUNCT
aji-63	113	14	brazil	brazil	PROPN
aji-63	113	15	.	.	PUNCT
aji-63	114	1	reviewers	reviewer	NOUN
aji-63	114	2	:	:	PUNCT
aji-63	114	3	(	(	PUNCT
aji-63	114	4	1	1	X
aji-63	114	5	)	)	PUNCT
aji-63	114	6	sadeeq	sadeeq	NOUN
aji-63	114	7	sheshe	sheshe	PROPN
aji-63	114	8	,	,	PUNCT
aji-63	114	9	kano	kano	PROPN
aji-63	114	10	university	university	PROPN
aji-63	114	11	of	of	ADP
aji-63	114	12	science	science	PROPN
aji-63	114	13	&	&	CCONJ
aji-63	114	14	technology	technology	PROPN
aji-63	114	15	,	,	PUNCT
aji-63	114	16	nigeria	nigeria	PROPN
aji-63	114	17	.	.	PUNCT
aji-63	115	1	(	(	PUNCT
aji-63	115	2	2	2	X
aji-63	115	3	)	)	PUNCT
aji-63	115	4	ji	ji	NOUN
aji-63	115	5	dejun	dejun	PROPN
aji-63	115	6	,	,	PUNCT
aji-63	115	7	yangzhou	yangzhou	PROPN
aji-63	115	8	university	university	PROPN
aji-63	115	9	,	,	PUNCT
aji-63	115	10	china	china	PROPN
aji-63	115	11	.	.	PUNCT
aji-63	116	1	complete	complete	ADJ
aji-63	116	2	peer	peer	NOUN
aji-63	116	3	review	review	NOUN
aji-63	116	4	history	history	NOUN
aji-63	116	5	,	,	PUNCT
aji-63	116	6	details	detail	NOUN
aji-63	116	7	of	of	ADP
aji-63	116	8	the	the	DET
aji-63	116	9	editor(s	editor(s	NOUN
aji-63	116	10	)	)	PUNCT
aji-63	116	11	,	,	PUNCT
aji-63	116	12	reviewers	reviewer	NOUN
aji-63	116	13	and	and	CCONJ
aji-63	116	14	additional	additional	ADJ
aji-63	116	15	reviewers	reviewer	NOUN
aji-63	116	16	are	be	AUX
aji-63	116	17	available	available	ADJ
aji-63	116	18	here	here	ADV
aji-63	116	19	:	:	PUNCT
aji-63	116	20	https://www.sdiarticle5.com/review-history/83681	https://www.sdiarticle5.com/review-history/83681	PROPN
aji-63	116	21	received	receive	VERB
aji-63	116	22	19	19	NUM
aji-63	116	23	november	november	PROPN
aji-63	116	24	2021	2021	NUM
aji-63	116	25	accepted	accept	VERB
aji-63	116	26	28	28	NUM
aji-63	116	27	december	december	PROPN
aji-63	116	28	2021	2021	NUM
aji-63	116	29	published	publish	VERB
aji-63	116	30	29	29	NUM
aji-63	116	31	december	december	PROPN
aji-63	116	32	2021	2021	NUM
aji-63	116	33	abstract	abstract	ADJ
aji-63	116	34	aims	aim	NOUN
aji-63	116	35	:	:	PUNCT
aji-63	116	36	this	this	DET
aji-63	116	37	study	study	NOUN
aji-63	116	38	investigates	investigate	VERB
aji-63	116	39	sarscov-2	sarscov-2	NUM
aji-63	116	40	antibody	antibody	NOUN
aji-63	116	41	prevalence	prevalence	NOUN
aji-63	116	42	and	and	CCONJ
aji-63	116	43	classes	class	NOUN
aji-63	116	44	among	among	ADP
aji-63	116	45	covid-19	covid-19	PROPN
aji-63	116	46	suspected	suspect	VERB
aji-63	116	47	patients	patient	NOUN
aji-63	116	48	in	in	ADP
aji-63	116	49	sana’a	sana’a	PROPN
aji-63	116	50	,	,	PUNCT
aji-63	116	51	yemen	yemen	PROPN
aji-63	116	52	.	.	PUNCT
aji-63	117	1	antibody	antibody	NOUN
aji-63	117	2	response	response	NOUN
aji-63	117	3	to	to	ADP
aji-63	117	4	sars	sar	NOUN
aji-63	117	5	-	-	PUNCT
aji-63	117	6	cov-2	cov-2	PART
aji-63	117	7	infection	infection	NOUN
aji-63	117	8	remains	remain	VERB
aji-63	117	9	to	to	PART
aji-63	117	10	be	be	AUX
aji-63	117	11	fully	fully	ADV
aji-63	117	12	elucidated	elucidated	ADJ
aji-63	117	13	.	.	PUNCT
aji-63	118	1	currently	currently	ADV
aji-63	118	2	,	,	PUNCT
aji-63	118	3	no	no	DET
aji-63	118	4	reports	report	NOUN
aji-63	118	5	on	on	ADP
aji-63	118	6	sars	sar	NOUN
aji-63	118	7	-	-	PUNCT
aji-63	118	8	cov-2	cov-2	NOUN
aji-63	118	9	antibody	antibody	NOUN
aji-63	118	10	response	response	NOUN
aji-63	118	11	from	from	ADP
aji-63	118	12	yemen	yemen	PROPN
aji-63	118	13	are	be	AUX
aji-63	118	14	available	available	ADJ
aji-63	118	15	.	.	PUNCT
aji-63	119	1	study	study	NOUN
aji-63	119	2	design	design	NOUN
aji-63	119	3	:	:	PUNCT
aji-63	119	4	this	this	DET
aji-63	119	5	cross	cross	ADJ
aji-63	119	6	-	-	ADJ
aji-63	119	7	sectional	sectional	ADJ
aji-63	119	8	study	study	NOUN
aji-63	119	9	investigates	investigate	VERB
aji-63	119	10	sars	sar	NOUN
aji-63	119	11	-	-	PUNCT
aji-63	119	12	cov-2	cov-2	NOUN
aji-63	119	13	antibody	antibody	NOUN
aji-63	119	14	prevalence	prevalence	NOUN
aji-63	119	15	and	and	CCONJ
aji-63	119	16	classes	class	NOUN
aji-63	119	17	among	among	ADP
aji-63	119	18	covid-19	covid-19	PROPN
aji-63	119	19	suspected	suspect	VERB
aji-63	119	20	patients	patient	NOUN
aji-63	119	21	.	.	PUNCT
aji-63	120	1	place	place	NOUN
aji-63	120	2	and	and	CCONJ
aji-63	120	3	duration	duration	NOUN
aji-63	120	4	of	of	ADP
aji-63	120	5	study	study	NOUN
aji-63	120	6	:	:	PUNCT
aji-63	120	7	this	this	DET
aji-63	120	8	study	study	NOUN
aji-63	120	9	was	be	AUX
aji-63	120	10	conducted	conduct	VERB
aji-63	120	11	in	in	ADP
aji-63	120	12	sana’a	sana’a	NOUN
aji-63	120	13	the	the	DET
aji-63	120	14	capital	capital	NOUN
aji-63	120	15	of	of	ADP
aji-63	120	16	the	the	DET
aji-63	120	17	republic	republic	NOUN
aji-63	120	18	of	of	ADP
aji-63	120	19	yemen	yemen	PROPN
aji-63	120	20	from	from	ADP
aji-63	120	21	june	june	PROPN
aji-63	120	22	2020	2020	NUM
aji-63	120	23	through	through	ADP
aji-63	120	24	january	january	PROPN
aji-63	120	25	2021	2021	NUM
aji-63	120	26	.	.	PUNCT
aji-63	121	1	methodology	methodology	NOUN
aji-63	121	2	:	:	PUNCT
aji-63	121	3	serological	serological	ADJ
aji-63	121	4	investigation	investigation	NOUN
aji-63	121	5	for	for	ADP
aji-63	121	6	anti	anti	ADJ
aji-63	121	7	-	-	ADJ
aji-63	121	8	sars	sars	ADJ
aji-63	121	9	-	-	PUNCT
aji-63	121	10	cov-2	cov-2	NOUN
aji-63	121	11	antibody	antibody	NOUN
aji-63	121	12	tests	test	NOUN
aji-63	121	13	was	be	AUX
aji-63	121	14	conducted	conduct	VERB
aji-63	121	15	for	for	ADP
aji-63	121	16	259	259	NUM
aji-63	121	17	original	original	ADJ
aji-63	121	18	research	research	NOUN
aji-63	121	19	article	article	NOUN
aji-63	121	20	sallam	sallam	NOUN
aji-63	121	21	et	et	PROPN
aji-63	121	22	al	al	PROPN
aji-63	121	23	.	.	PROPN
aji-63	121	24	;	;	PUNCT
aji-63	121	25	aji	aji	PROPN
aji-63	121	26	,	,	PUNCT
aji-63	121	27	4(1	4(1	NOUN
aji-63	121	28	):	):	PUNCT
aji-63	121	29	146	146	NUM
aji-63	121	30	-	-	SYM
aji-63	121	31	153	153	NUM
aji-63	121	32	,	,	PUNCT
aji-63	121	33	2021	2021	NUM
aji-63	121	34	;	;	PUNCT
aji-63	121	35	article	article	NOUN
aji-63	121	36	no.aji.83681	no.aji.83681	VERB
aji-63	121	37	147	147	NUM
aji-63	121	38	suspected	suspect	VERB
aji-63	121	39	covid-19	covid-19	PROPN
aji-63	121	40	patients	patient	NOUN
aji-63	121	41	who	who	PRON
aji-63	121	42	attended	attend	VERB
aji-63	121	43	a	a	DET
aji-63	121	44	health	health	NOUN
aji-63	121	45	care	care	NOUN
aji-63	121	46	facility	facility	NOUN
aji-63	121	47	for	for	ADP
aji-63	121	48	antibody	antibody	NOUN
aji-63	121	49	testing	testing	NOUN
aji-63	121	50	to	to	PART
aji-63	121	51	confirm	confirm	VERB
aji-63	121	52	the	the	DET
aji-63	121	53	diagnosis	diagnosis	NOUN
aji-63	121	54	on	on	ADP
aji-63	121	55	c.	c.	NOUN
aji-63	121	56	results	result	NOUN
aji-63	121	57	:	:	PUNCT
aji-63	121	58	the	the	DET
aji-63	121	59	mean	mean	ADJ
aji-63	121	60	age	age	NOUN
aji-63	121	61	was	be	AUX
aji-63	121	62	40.8	40.8	NUM
aji-63	121	63	±16.6	±16.6	NUM
aji-63	121	64	years	year	NOUN
aji-63	121	65	.	.	PUNCT
aji-63	122	1	of	of	ADP
aji-63	122	2	all	all	DET
aji-63	122	3	subjects	subject	NOUN
aji-63	122	4	,	,	PUNCT
aji-63	122	5	180	180	NUM
aji-63	122	6	(	(	PUNCT
aji-63	122	7	69.5	69.5	NUM
aji-63	122	8	%	%	NOUN
aji-63	122	9	)	)	PUNCT
aji-63	122	10	were	be	AUX
aji-63	122	11	males	male	NOUN
aji-63	122	12	and	and	CCONJ
aji-63	122	13	79	79	NUM
aji-63	122	14	(	(	PUNCT
aji-63	122	15	30.5	30.5	NUM
aji-63	122	16	%	%	NOUN
aji-63	122	17	)	)	PUNCT
aji-63	122	18	were	be	AUX
aji-63	122	19	females	female	NOUN
aji-63	122	20	,	,	PUNCT
aji-63	122	21	73	73	NUM
aji-63	122	22	%	%	NOUN
aji-63	122	23	were	be	AUX
aji-63	122	24	<	<	X
aji-63	122	25	50	50	NUM
aji-63	122	26	years	year	NOUN
aji-63	122	27	of	of	ADP
aji-63	122	28	age	age	NOUN
aji-63	122	29	.	.	PUNCT
aji-63	123	1	a	a	DET
aji-63	123	2	total	total	NOUN
aji-63	123	3	of	of	ADP
aji-63	123	4	133	133	NUM
aji-63	123	5	(	(	PUNCT
aji-63	123	6	51.4	51.4	NUM
aji-63	123	7	%	%	NOUN
aji-63	123	8	)	)	PUNCT
aji-63	123	9	had	have	VERB
aji-63	123	10	at	at	ADV
aji-63	123	11	least	least	ADV
aji-63	123	12	one	one	NUM
aji-63	123	13	antisars	antisar	NOUN
aji-63	123	14	-	-	PUNCT
aji-63	123	15	cov-2	cov-2	NOUN
aji-63	123	16	antibody	antibody	NOUN
aji-63	123	17	class	class	NOUN
aji-63	123	18	,	,	PUNCT
aji-63	123	19	6	6	NUM
aji-63	123	20	(	(	PUNCT
aji-63	123	21	2.3	2.3	NUM
aji-63	123	22	%	%	NOUN
aji-63	123	23	)	)	PUNCT
aji-63	123	24	had	have	AUX
aji-63	123	25	isolated	isolate	VERB
aji-63	123	26	igm	igm	PROPN
aji-63	123	27	,	,	PUNCT
aji-63	123	28	80	80	NUM
aji-63	123	29	(	(	PUNCT
aji-63	123	30	30.9	30.9	NUM
aji-63	123	31	%	%	NOUN
aji-63	123	32	)	)	PUNCT
aji-63	123	33	had	have	VERB
aji-63	123	34	concomitant	concomitant	ADJ
aji-63	123	35	igm	igm	NOUN
aji-63	123	36	and	and	CCONJ
aji-63	123	37	igg	igg	PROPN
aji-63	123	38	and	and	CCONJ
aji-63	123	39	49	49	NUM
aji-63	123	40	(	(	PUNCT
aji-63	123	41	18.9	18.9	NUM
aji-63	123	42	%	%	NOUN
aji-63	123	43	)	)	PUNCT
aji-63	123	44	had	have	AUX
aji-63	123	45	isolated	isolate	VERB
aji-63	123	46	igg	igg	PROPN
aji-63	123	47	.	.	PUNCT
aji-63	124	1	only	only	ADV
aji-63	124	2	the	the	DET
aji-63	124	3	seropositivity	seropositivity	NOUN
aji-63	124	4	of	of	ADP
aji-63	124	5	isolated	isolated	ADJ
aji-63	124	6	anti	anti	ADJ
aji-63	124	7	-	-	ADJ
aji-63	124	8	sars	sar	NOUN
aji-63	124	9	-	-	PUNCT
aji-63	124	10	cov-2	cov-2	NOUN
aji-63	124	11	igg	igg	PROPN
aji-63	124	12	significantly	significantly	ADV
aji-63	124	13	(	(	PUNCT
aji-63	124	14	p=0.002	p=0.002	X
aji-63	124	15	)	)	PUNCT
aji-63	124	16	differs	differ	VERB
aji-63	124	17	among	among	ADP
aji-63	124	18	various	various	ADJ
aji-63	124	19	age	age	NOUN
aji-63	124	20	groups	group	NOUN
aji-63	124	21	.	.	PUNCT
aji-63	125	1	there	there	PRON
aji-63	125	2	was	be	VERB
aji-63	125	3	a	a	DET
aji-63	125	4	significantly	significantly	ADV
aji-63	125	5	higher	high	ADJ
aji-63	125	6	(	(	PUNCT
aji-63	125	7	p=0.017	p=0.017	NUM
aji-63	125	8	)	)	PUNCT
aji-63	125	9	igm	igm	NOUN
aji-63	125	10	seropositivity	seropositivity	NOUN
aji-63	125	11	among	among	ADP
aji-63	125	12	females	female	NOUN
aji-63	125	13	than	than	ADP
aji-63	125	14	among	among	ADP
aji-63	125	15	males	male	NOUN
aji-63	125	16	.	.	PUNCT
aji-63	126	1	conclusions	conclusion	NOUN
aji-63	126	2	:	:	PUNCT
aji-63	126	3	among	among	ADP
aji-63	126	4	subjects	subject	NOUN
aji-63	126	5	with	with	ADP
aji-63	126	6	suspected	suspect	VERB
aji-63	126	7	covid-19	covid-19	PROPN
aji-63	126	8	,	,	PUNCT
aji-63	126	9	>	>	X
aji-63	126	10	30	30	NUM
aji-63	126	11	%	%	NOUN
aji-63	126	12	had	have	VERB
aji-63	126	13	concomitant	concomitant	ADJ
aji-63	126	14	igm	igm	NOUN
aji-63	126	15	and	and	CCONJ
aji-63	126	16	igg	igg	PROPN
aji-63	126	17	with	with	ADP
aji-63	126	18	a	a	DET
aji-63	126	19	minority	minority	NOUN
aji-63	126	20	having	having	AUX
aji-63	126	21	isolated	isolate	VERB
aji-63	126	22	igm	igm	NOUN
aji-63	126	23	or	or	CCONJ
aji-63	126	24	igg	igg	PROPN
aji-63	126	25	suggesting	suggest	VERB
aji-63	126	26	concurrent	concurrent	ADJ
aji-63	126	27	or	or	CCONJ
aji-63	126	28	close	close	ADJ
aji-63	126	29	seroconversion	seroconversion	NOUN
aji-63	126	30	time	time	NOUN
aji-63	126	31	of	of	ADP
aji-63	126	32	both	both	DET
aji-63	126	33	antibody	antibody	NOUN
aji-63	126	34	classes	class	NOUN
aji-63	126	35	.	.	PUNCT
aji-63	127	1	in	in	ADP
aji-63	127	2	addition	addition	NOUN
aji-63	127	3	,	,	PUNCT
aji-63	127	4	around	around	ADP
aji-63	127	5	50	50	NUM
aji-63	127	6	%	%	NOUN
aji-63	127	7	of	of	ADP
aji-63	127	8	subjects	subject	NOUN
aji-63	127	9	were	be	AUX
aji-63	127	10	sars	sar	NOUN
aji-63	127	11	-	-	PUNCT
aji-63	127	12	cov-2	cov-2	PART
aji-63	127	13	seropositive	seropositive	ADJ
aji-63	127	14	suggestion	suggestion	NOUN
aji-63	127	15	low	low	ADJ
aji-63	127	16	sars	sar	NOUN
aji-63	127	17	-	-	PUNCT
aji-63	127	18	cov-2	cov-2	NOUN
aji-63	127	19	seroconversion	seroconversion	NOUN
aji-63	127	20	and	and	CCONJ
aji-63	127	21	consequently	consequently	ADV
aji-63	127	22	low	low	ADJ
aji-63	127	23	community	community	NOUN
aji-63	127	24	seroprevalence	seroprevalence	NOUN
aji-63	127	25	.	.	PUNCT
aji-63	128	1	an	an	DET
aji-63	128	2	antibody	antibody	NOUN
aji-63	128	3	dynamic	dynamic	ADJ
aji-63	128	4	study	study	NOUN
aji-63	128	5	based	base	VERB
aji-63	128	6	on	on	ADP
aji-63	128	7	will	will	AUX
aji-63	128	8	characteristics	characteristic	NOUN
aji-63	128	9	of	of	ADP
aji-63	128	10	covid-19	covid-19	PROPN
aji-63	128	11	patients	patient	NOUN
aji-63	128	12	is	be	AUX
aji-63	128	13	required	require	VERB
aji-63	128	14	.	.	PUNCT
aji-63	129	1	also	also	ADV
aji-63	129	2	,	,	PUNCT
aji-63	129	3	a	a	DET
aji-63	129	4	community	community	NOUN
aji-63	129	5	-	-	PUNCT
aji-63	129	6	based	base	VERB
aji-63	129	7	seroprevalence	seroprevalence	NOUN
aji-63	129	8	study	study	NOUN
aji-63	129	9	based	base	VERB
aji-63	129	10	on	on	ADP
aji-63	129	11	the	the	DET
aji-63	129	12	detection	detection	NOUN
aji-63	129	13	of	of	ADP
aji-63	129	14	a	a	DET
aji-63	129	15	combination	combination	NOUN
aji-63	129	16	of	of	ADP
aji-63	129	17	igm	igm	PROPN
aji-63	129	18	,	,	PUNCT
aji-63	129	19	igg	igg	PROPN
aji-63	129	20	,	,	PUNCT
aji-63	129	21	and	and	CCONJ
aji-63	129	22	iga	iga	PROPN
aji-63	129	23	remains	remain	VERB
aji-63	129	24	essential	essential	ADJ
aji-63	129	25	to	to	PART
aji-63	129	26	determine	determine	VERB
aji-63	129	27	the	the	DET
aji-63	129	28	prevalence	prevalence	NOUN
aji-63	129	29	of	of	ADP
aji-63	129	30	sars	sar	NOUN
aji-63	129	31	-	-	PUNCT
aji-63	129	32	cov-2	cov-2	NOUN
aji-63	129	33	infection	infection	NOUN
aji-63	129	34	in	in	ADP
aji-63	129	35	yemen	yemen	PROPN
aji-63	129	36	.	.	PUNCT
aji-63	130	1	keywords	keyword	NOUN
aji-63	130	2	:	:	PUNCT
aji-63	130	3	covid-19	covid-19	PROPN
aji-63	130	4	;	;	PUNCT
aji-63	130	5	igg	igg	PROPN
aji-63	130	6	;	;	PUNCT
aji-63	130	7	igm	igm	PROPN
aji-63	130	8	;	;	PUNCT
aji-63	130	9	sarscov-2	sarscov-2	NUM
aji-63	130	10	;	;	PUNCT
aji-63	130	11	seroprevalence	seroprevalence	NOUN
aji-63	130	12	;	;	PUNCT
aji-63	130	13	yemen	yemen	PROPN
aji-63	130	14	.	.	PUNCT
aji-63	131	1	1	1	X
aji-63	131	2	.	.	X
aji-63	131	3	introduction	introduction	NOUN
aji-63	131	4	immune	immune	ADJ
aji-63	131	5	response	response	NOUN
aji-63	131	6	to	to	ADP
aji-63	131	7	sars	sar	NOUN
aji-63	131	8	-	-	PUNCT
aji-63	131	9	cov-2	cov-2	PART
aji-63	131	10	infection	infection	NOUN
aji-63	131	11	remains	remain	VERB
aji-63	131	12	to	to	PART
aji-63	131	13	be	be	AUX
aji-63	131	14	fully	fully	ADV
aji-63	131	15	elucidated	elucidated	ADJ
aji-63	131	16	.	.	PUNCT
aji-63	132	1	however	however	ADV
aji-63	132	2	,	,	PUNCT
aji-63	132	3	the	the	DET
aji-63	132	4	available	available	ADJ
aji-63	132	5	data	datum	NOUN
aji-63	132	6	,	,	PUNCT
aji-63	132	7	although	although	SCONJ
aji-63	132	8	inconsistent	inconsistent	ADJ
aji-63	132	9	,	,	PUNCT
aji-63	132	10	have	have	AUX
aji-63	132	11	shown	show	VERB
aji-63	132	12	that	that	SCONJ
aji-63	132	13	sars	sar	NOUN
aji-63	132	14	-	-	PUNCT
aji-63	132	15	cov-2	cov-2	PART
aji-63	132	16	infection	infection	NOUN
aji-63	132	17	induces	induce	VERB
aji-63	132	18	antibody	antibody	NOUN
aji-63	132	19	response	response	NOUN
aji-63	132	20	4	4	NUM
aji-63	132	21	to	to	PART
aji-63	132	22	15	15	NUM
aji-63	132	23	days	day	NOUN
aji-63	132	24	post	post	X
aji-63	132	25	infection[16	infection[16	NOUN
aji-63	132	26	]	]	PUNCT
aji-63	132	27	with	with	ADP
aji-63	132	28	rising	rise	VERB
aji-63	132	29	levels	level	NOUN
aji-63	132	30	in	in	ADP
aji-63	132	31	severe	severe	ADJ
aji-63	132	32	disease	disease	NOUN
aji-63	132	33	[	[	X
aji-63	132	34	7,8	7,8	X
aji-63	132	35	]	]	PUNCT
aji-63	132	36	and	and	CCONJ
aji-63	132	37	increasing	increase	VERB
aji-63	132	38	seroconversion	seroconversion	NOUN
aji-63	132	39	rates	rate	NOUN
aji-63	132	40	with	with	ADP
aji-63	132	41	progress	progress	NOUN
aji-63	132	42	of	of	ADP
aji-63	132	43	time	time	NOUN
aji-63	132	44	[	[	X
aji-63	132	45	2,9,10	2,9,10	NUM
aji-63	132	46	]	]	X
aji-63	132	47	.	.	PUNCT
aji-63	133	1	although	although	SCONJ
aji-63	133	2	anti	anti	ADJ
aji-63	133	3	-	-	ADJ
aji-63	133	4	sars	sar	NOUN
aji-63	133	5	-	-	PUNCT
aji-63	133	6	cov-2	cov-2	NOUN
aji-63	133	7	antibodies	antibodie	VERB
aji-63	133	8	response	response	NOUN
aji-63	133	9	apparently	apparently	ADV
aji-63	133	10	follows	follow	VERB
aji-63	133	11	conventical	conventical	ADJ
aji-63	133	12	serological	serological	ADJ
aji-63	133	13	dynamic	dynamic	NOUN
aji-63	133	14	with	with	ADP
aji-63	133	15	sequential	sequential	ADJ
aji-63	133	16	igm	igm	NOUN
aji-63	133	17	and	and	CCONJ
aji-63	133	18	igg	igg	PROPN
aji-63	133	19	,	,	PUNCT
aji-63	133	20	the	the	DET
aji-63	133	21	concomitant	concomitant	ADJ
aji-63	133	22	appearance	appearance	NOUN
aji-63	133	23	of	of	ADP
aji-63	133	24	both	both	DET
aji-63	133	25	antibody	antibody	NOUN
aji-63	133	26	isotypes	isotype	NOUN
aji-63	133	27	has	have	AUX
aji-63	133	28	been	be	AUX
aji-63	133	29	reported	report	VERB
aji-63	133	30	[	[	X
aji-63	133	31	11,12	11,12	NUM
aji-63	133	32	]	]	X
aji-63	133	33	immunoglobulin	immunoglobulin	NOUN
aji-63	133	34	m	m	VERB
aji-63	133	35	first	first	ADV
aji-63	133	36	appears	appear	VERB
aji-63	133	37	5	5	NUM
aji-63	133	38	-	-	SYM
aji-63	133	39	10	10	NUM
aji-63	133	40	days	day	NOUN
aji-63	133	41	post	post	NOUN
aji-63	133	42	onset	onset	NOUN
aji-63	133	43	of	of	ADP
aji-63	133	44	symptoms	symptom	NOUN
aji-63	133	45	in	in	ADP
aji-63	133	46	most	most	ADJ
aji-63	133	47	patients	patient	NOUN
aji-63	133	48	,	,	PUNCT
aji-63	133	49	rising	rise	VERB
aji-63	133	50	about	about	ADP
aji-63	133	51	2	2	NUM
aji-63	133	52	to	to	PART
aji-63	133	53	3	3	NUM
aji-63	133	54	weeks	week	NOUN
aji-63	133	55	rapidly	rapidly	ADV
aji-63	133	56	to	to	PART
aji-63	133	57	reach	reach	VERB
aji-63	133	58	a	a	DET
aji-63	133	59	level	level	NOUN
aji-63	133	60	maintained	maintain	VERB
aji-63	133	61	for	for	ADP
aji-63	133	62	1	1	NUM
aji-63	133	63	to	to	PART
aji-63	133	64	4	4	NUM
aji-63	133	65	weeks	week	NOUN
aji-63	133	66	and	and	CCONJ
aji-63	133	67	begin	begin	VERB
aji-63	133	68	to	to	PART
aji-63	133	69	decline	decline	VERB
aji-63	133	70	thereafter	thereafter	ADV
aji-63	133	71	[	[	X
aji-63	133	72	8,13	8,13	NUM
aji-63	133	73	]	]	PUNCT
aji-63	133	74	.	.	PUNCT
aji-63	134	1	however	however	ADV
aji-63	134	2	,	,	PUNCT
aji-63	134	3	igg	igg	NOUN
aji-63	134	4	antibody	antibody	NOUN
aji-63	134	5	has	have	AUX
aji-63	134	6	been	be	AUX
aji-63	134	7	reported	report	VERB
aji-63	134	8	to	to	PART
aji-63	134	9	appear	appear	VERB
aji-63	134	10	10	10	NUM
aji-63	134	11	days	day	NOUN
aji-63	134	12	after	after	ADP
aji-63	134	13	infection	infection	NOUN
aji-63	134	14	[	[	X
aji-63	134	15	13	13	NUM
aji-63	134	16	]	]	PUNCT
aji-63	134	17	,	,	PUNCT
aji-63	134	18	and	and	CCONJ
aji-63	134	19	remains	remain	VERB
aji-63	134	20	detectable	detectable	ADJ
aji-63	134	21	up	up	ADP
aji-63	134	22	to	to	PART
aji-63	134	23	6	6	NUM
aji-63	134	24	months	month	NOUN
aji-63	134	25	after	after	ADP
aji-63	134	26	infection	infection	NOUN
aji-63	134	27	[	[	X
aji-63	134	28	14	14	NUM
aji-63	134	29	]	]	PUNCT
aji-63	134	30	.	.	PUNCT
aji-63	135	1	reports	report	NOUN
aji-63	135	2	on	on	ADP
aji-63	135	3	decline	decline	NOUN
aji-63	135	4	time	time	NOUN
aji-63	135	5	frame	frame	NOUN
aji-63	135	6	of	of	ADP
aji-63	135	7	antisars	antisar	NOUN
aji-63	135	8	-	-	PUNCT
aji-63	135	9	cov-2	cov-2	NOUN
aji-63	135	10	antibody	antibody	NOUN
aji-63	135	11	levels	level	NOUN
aji-63	135	12	are	be	AUX
aji-63	135	13	inconsistent	inconsistent	ADJ
aji-63	135	14	as	as	SCONJ
aji-63	135	15	they	they	PRON
aji-63	135	16	vary	vary	VERB
aji-63	135	17	from	from	ADP
aji-63	135	18	20	20	NUM
aji-63	136	1	[	[	X
aji-63	136	2	11,12	11,12	NUM
aji-63	136	3	]	]	PUNCT
aji-63	136	4	to	to	ADP
aji-63	136	5	63	63	NUM
aji-63	136	6	days	day	NOUN
aji-63	136	7	[	[	X
aji-63	136	8	15	15	NUM
aji-63	136	9	-	-	SYM
aji-63	136	10	17	17	NUM
aji-63	136	11	]	]	PUNCT
aji-63	136	12	for	for	ADP
aji-63	136	13	igm	igm	NOUN
aji-63	136	14	and	and	CCONJ
aji-63	136	15	35	35	NUM
aji-63	136	16	to	to	ADP
aji-63	136	17	>	>	X
aji-63	136	18	49	49	NUM
aji-63	136	19	days.[8,11,18,19	days.[8,11,18,19	NOUN
aji-63	136	20	]	]	PUNCT
aji-63	136	21	and	and	CCONJ
aji-63	136	22	even	even	ADV
aji-63	136	23	to	to	ADP
aji-63	136	24	as	as	ADV
aji-63	136	25	long	long	ADJ
aji-63	136	26	as	as	ADP
aji-63	136	27	199	199	NUM
aji-63	136	28	days	day	NOUN
aji-63	137	1	[	[	X
aji-63	137	2	18	18	NUM
aji-63	137	3	]	]	PUNCT
aji-63	137	4	in	in	ADP
aji-63	137	5	the	the	DET
aji-63	137	6	case	case	NOUN
aji-63	137	7	of	of	ADP
aji-63	137	8	igg	igg	PROPN
aji-63	137	9	.	.	PUNCT
aji-63	138	1	this	this	DET
aji-63	138	2	variation	variation	NOUN
aji-63	138	3	in	in	ADP
aji-63	138	4	seroconversion	seroconversion	NOUN
aji-63	138	5	time	time	NOUN
aji-63	138	6	and	and	CCONJ
aji-63	138	7	duration	duration	NOUN
aji-63	138	8	of	of	ADP
aji-63	138	9	antibodies	antibody	NOUN
aji-63	138	10	reflects	reflect	VERB
aji-63	138	11	variations	variation	NOUN
aji-63	138	12	in	in	ADP
aji-63	138	13	different	different	ADJ
aji-63	138	14	studies	study	NOUN
aji-63	138	15	,	,	PUNCT
aji-63	138	16	in	in	ADP
aji-63	138	17	patients	patient	NOUN
aji-63	138	18	’	'	PUNCT
aji-63	138	19	populations	population	NOUN
aji-63	138	20	,	,	PUNCT
aji-63	138	21	in	in	ADP
aji-63	138	22	age	age	NOUN
aji-63	138	23	and	and	CCONJ
aji-63	138	24	gender	gender	NOUN
aji-63	138	25	of	of	ADP
aji-63	138	26	the	the	DET
aji-63	138	27	population	population	NOUN
aji-63	138	28	enrolled	enrol	VERB
aji-63	138	29	,	,	PUNCT
aji-63	138	30	in	in	ADP
aji-63	138	31	disease	disease	NOUN
aji-63	138	32	severity	severity	NOUN
aji-63	138	33	,	,	PUNCT
aji-63	138	34	in	in	ADP
aji-63	138	35	clinical	clinical	ADJ
aji-63	138	36	course	course	NOUN
aji-63	138	37	,	,	PUNCT
aji-63	138	38	and	and	CCONJ
aji-63	138	39	in	in	ADP
aji-63	138	40	the	the	DET
aji-63	138	41	serological	serological	ADJ
aji-63	138	42	assays	assay	NOUN
aji-63	138	43	used	use	VERB
aji-63	138	44	.	.	PUNCT
aji-63	139	1	these	these	DET
aji-63	139	2	together	together	ADV
aji-63	139	3	seem	seem	VERB
aji-63	139	4	to	to	PART
aji-63	139	5	negatively	negatively	ADV
aji-63	139	6	impact	impact	VERB
aji-63	139	7	the	the	DET
aji-63	139	8	attempt	attempt	NOUN
aji-63	139	9	to	to	PART
aji-63	139	10	reliably	reliably	ADV
aji-63	139	11	establish	establish	VERB
aji-63	139	12	the	the	DET
aji-63	139	13	dynamic	dynamic	NOUN
aji-63	139	14	of	of	ADP
aji-63	139	15	the	the	DET
aji-63	139	16	antibody	antibody	NOUN
aji-63	139	17	response	response	NOUN
aji-63	139	18	and	and	CCONJ
aji-63	139	19	hinder	hinder	VERB
aji-63	139	20	a	a	DET
aji-63	139	21	genuine	genuine	ADJ
aji-63	139	22	estimate	estimate	NOUN
aji-63	139	23	of	of	ADP
aji-63	139	24	seroprevalence	seroprevalence	NOUN
aji-63	139	25	and	and	CCONJ
aji-63	139	26	the	the	DET
aji-63	139	27	herd	herd	NOUN
aji-63	139	28	immunity	immunity	NOUN
aji-63	139	29	level	level	NOUN
aji-63	139	30	.	.	PUNCT
aji-63	140	1	so	so	ADV
aji-63	140	2	far	far	ADV
aji-63	140	3	epidemiological	epidemiological	ADJ
aji-63	140	4	studies	study	NOUN
aji-63	140	5	have	have	AUX
aji-63	140	6	shown	show	VERB
aji-63	140	7	conflicting	conflicting	ADJ
aji-63	140	8	low	low	ADJ
aji-63	140	9	seroprevalence	seroprevalence	NOUN
aji-63	140	10	rates	rate	NOUN
aji-63	140	11	of	of	ADP
aji-63	140	12	sarscov-2	sarscov-2	NUM
aji-63	140	13	antibodies	antibodie	VERB
aji-63	140	14	,	,	PUNCT
aji-63	140	15	in	in	ADP
aji-63	140	16	different	different	ADJ
aji-63	140	17	parts	part	NOUN
aji-63	140	18	of	of	ADP
aji-63	140	19	the	the	DET
aji-63	140	20	world	world	NOUN
aji-63	140	21	.	.	PUNCT
aji-63	141	1	various	various	ADJ
aji-63	141	2	reports	report	NOUN
aji-63	141	3	have	have	AUX
aji-63	141	4	shown	show	VERB
aji-63	141	5	seroprevalence	seroprevalence	NOUN
aji-63	141	6	rates	rate	NOUN
aji-63	141	7	of	of	ADP
aji-63	141	8	4	4	NUM
aji-63	141	9	to	to	PART
aji-63	141	10	7.3	7.3	NUM
aji-63	141	11	%	%	NOUN
aji-63	141	12	in	in	ADP
aji-63	141	13	several	several	ADJ
aji-63	141	14	part	part	NOUN
aji-63	141	15	of	of	ADP
aji-63	141	16	europe	europe	PROPN
aji-63	141	17	,	,	PUNCT
aji-63	141	18	4.2	4.2	NUM
aji-63	141	19	%	%	NOUN
aji-63	141	20	in	in	ADP
aji-63	141	21	northern	northern	PROPN
aji-63	141	22	america	america	PROPN
aji-63	141	23	,	,	PUNCT
aji-63	141	24	22	22	NUM
aji-63	141	25	%	%	NOUN
aji-63	141	26	in	in	ADP
aji-63	141	27	central	central	ADJ
aji-63	141	28	and	and	CCONJ
aji-63	141	29	southern	southern	ADJ
aji-63	141	30	asia	asia	PROPN
aji-63	142	1	[	[	X
aji-63	142	2	17	17	NUM
aji-63	142	3	]	]	PUNCT
aji-63	142	4	,	,	PUNCT
aji-63	142	5	0.07	0.07	NUM
aji-63	142	6	%	%	NOUN
aji-63	142	7	in	in	ADP
aji-63	142	8	south	south	PROPN
aji-63	142	9	korea	korea	PROPN
aji-63	143	1	[	[	X
aji-63	143	2	16	16	NUM
aji-63	143	3	]	]	X
aji-63	143	4	,	,	PUNCT
aji-63	143	5	3.8	3.8	NUM
aji-63	143	6	%	%	NOUN
aji-63	143	7	in	in	ADP
aji-63	143	8	wuhan	wuhan	PROPN
aji-63	143	9	geographic	geographic	ADJ
aji-63	143	10	regions	region	NOUN
aji-63	143	11	[	[	X
aji-63	143	12	19	19	NUM
aji-63	143	13	]	]	PUNCT
aji-63	143	14	and	and	CCONJ
aji-63	143	15	7.8	7.8	NUM
aji-63	143	16	%	%	NOUN
aji-63	143	17	in	in	ADP
aji-63	143	18	malaysia	malaysia	PROPN
aji-63	144	1	[	[	X
aji-63	144	2	20	20	NUM
aji-63	144	3	]	]	PUNCT
aji-63	144	4	.	.	PUNCT
aji-63	145	1	this	this	DET
aji-63	145	2	variation	variation	NOUN
aji-63	145	3	suggests	suggest	VERB
aji-63	145	4	varying	vary	VERB
aji-63	145	5	time	time	NOUN
aji-63	145	6	of	of	ADP
aji-63	145	7	testing	testing	NOUN
aji-63	145	8	through	through	ADP
aji-63	145	9	the	the	DET
aji-63	145	10	pandemic	pandemic	ADJ
aji-63	145	11	,	,	PUNCT
aji-63	145	12	demographic	demographic	ADJ
aji-63	145	13	and	and	CCONJ
aji-63	145	14	geographic	geographic	ADJ
aji-63	145	15	variations	variation	NOUN
aji-63	145	16	and	and	CCONJ
aji-63	145	17	variation	variation	NOUN
aji-63	145	18	of	of	ADP
aji-63	145	19	serological	serological	ADJ
aji-63	145	20	assays	assay	NOUN
aji-63	145	21	used	use	VERB
aji-63	145	22	.	.	PUNCT
aji-63	146	1	the	the	DET
aji-63	146	2	low	low	ADJ
aji-63	146	3	seroprevalence	seroprevalence	NOUN
aji-63	146	4	rates	rate	NOUN
aji-63	146	5	is	be	AUX
aji-63	146	6	attributable	attributable	ADJ
aji-63	146	7	to	to	ADP
aji-63	146	8	the	the	DET
aji-63	146	9	fact	fact	NOUN
aji-63	146	10	that	that	SCONJ
aji-63	146	11	majority	majority	NOUN
aji-63	146	12	of	of	ADP
aji-63	146	13	the	the	DET
aji-63	146	14	studies	study	NOUN
aji-63	146	15	were	be	AUX
aji-63	146	16	mainly	mainly	ADV
aji-63	146	17	based	base	VERB
aji-63	146	18	on	on	ADP
aji-63	146	19	detection	detection	NOUN
aji-63	146	20	of	of	ADP
aji-63	146	21	igg	igg	PROPN
aji-63	146	22	and	and	CCONJ
aji-63	146	23	igm	igm	PROPN
aji-63	146	24	whereas	whereas	SCONJ
aji-63	146	25	iga	iga	PROPN
aji-63	146	26	was	be	AUX
aji-63	146	27	found	find	VERB
aji-63	146	28	in	in	ADP
aji-63	146	29	covid-19	covid-19	PROPN
aji-63	146	30	patients	patient	NOUN
aji-63	146	31	in	in	ADP
aji-63	146	32	isolation	isolation	NOUN
aji-63	146	33	of	of	ADP
aji-63	146	34	igm	igm	PROPN
aji-63	146	35	and	and	CCONJ
aji-63	146	36	igg	igg	PROPN
aji-63	147	1	[	[	X
aji-63	147	2	20,21	20,21	NUM
aji-63	147	3	]	]	PUNCT
aji-63	147	4	.	.	PUNCT
aji-63	148	1	thus	thus	ADV
aji-63	148	2	inclusion	inclusion	NOUN
aji-63	148	3	of	of	ADP
aji-63	148	4	iga	iga	PROPN
aji-63	148	5	detection	detection	NOUN
aji-63	148	6	in	in	ADP
aji-63	148	7	seroprevalence	seroprevalence	NOUN
aji-63	148	8	studies	study	NOUN
aji-63	148	9	detects	detect	VERB
aji-63	148	10	more	more	ADJ
aji-63	148	11	covid-19	covid-19	PROPN
aji-63	148	12	infections	infection	NOUN
aji-63	148	13	.	.	PUNCT
aji-63	149	1	yemen	yemen	PROPN
aji-63	149	2	is	be	AUX
aji-63	149	3	one	one	NUM
aji-63	149	4	of	of	ADP
aji-63	149	5	the	the	DET
aji-63	149	6	countries	country	NOUN
aji-63	149	7	where	where	SCONJ
aji-63	149	8	confinements	confinement	NOUN
aji-63	149	9	were	be	AUX
aji-63	149	10	inadequately	inadequately	ADV
aji-63	149	11	implemented	implement	VERB
aji-63	149	12	during	during	ADP
aji-63	149	13	spread	spread	NOUN
aji-63	149	14	of	of	ADP
aji-63	149	15	covid-19	covid-19	PROPN
aji-63	149	16	because	because	SCONJ
aji-63	149	17	of	of	ADP
aji-63	149	18	the	the	DET
aji-63	149	19	current	current	ADJ
aji-63	149	20	political	political	ADJ
aji-63	149	21	turmoil	turmoil	NOUN
aji-63	149	22	and	and	CCONJ
aji-63	149	23	the	the	DET
aji-63	149	24	collapse	collapse	NOUN
aji-63	149	25	of	of	ADP
aji-63	149	26	the	the	DET
aji-63	149	27	health	health	NOUN
aji-63	149	28	care	care	NOUN
aji-63	149	29	system	system	NOUN
aji-63	149	30	.	.	PUNCT
aji-63	150	1	based	base	VERB
aji-63	150	2	on	on	ADP
aji-63	150	3	latest	late	ADJ
aji-63	150	4	estimate	estimate	NOUN
aji-63	150	5	of	of	ADP
aji-63	150	6	the	the	DET
aji-63	150	7	ministry	ministry	PROPN
aji-63	150	8	of	of	ADP
aji-63	150	9	public	public	ADJ
aji-63	150	10	health	health	NOUN
aji-63	150	11	and	and	CCONJ
aji-63	150	12	population	population	NOUN
aji-63	150	13	in	in	ADP
aji-63	150	14	yemen	yemen	PROPN
aji-63	150	15	,	,	PUNCT
aji-63	150	16	covid-19	covid-19	PROPN
aji-63	150	17	might	might	AUX
aji-63	150	18	expand	expand	VERB
aji-63	150	19	and	and	CCONJ
aji-63	150	20	potentially	potentially	ADV
aji-63	150	21	infect	infect	VERB
aji-63	150	22	90	90	NUM
aji-63	150	23	%	%	NOUN
aji-63	150	24	of	of	ADP
aji-63	150	25	the	the	DET
aji-63	150	26	population	population	NOUN
aji-63	151	1	[	[	X
aji-63	151	2	2,22	2,22	X
aji-63	151	3	]	]	PUNCT
aji-63	151	4	.	.	PUNCT
aji-63	152	1	despite	despite	SCONJ
aji-63	152	2	this	this	DET
aji-63	152	3	gloomy	gloomy	ADJ
aji-63	152	4	scenario	scenario	NOUN
aji-63	152	5	the	the	DET
aji-63	152	6	other	other	ADJ
aji-63	152	7	side	side	NOUN
aji-63	152	8	of	of	ADP
aji-63	152	9	the	the	DET
aji-63	152	10	story	story	NOUN
aji-63	152	11	is	be	AUX
aji-63	152	12	vowing	vow	VERB
aji-63	152	13	as	as	SCONJ
aji-63	152	14	the	the	DET
aji-63	152	15	absence	absence	NOUN
aji-63	152	16	of	of	ADP
aji-63	152	17	containment	containment	NOUN
aji-63	152	18	measures	measure	NOUN
aji-63	152	19	will	will	AUX
aji-63	152	20	promote	promote	VERB
aji-63	152	21	the	the	DET
aji-63	152	22	development	development	NOUN
aji-63	152	23	of	of	ADP
aji-63	152	24	natural	natural	ADJ
aji-63	152	25	herd	herd	NOUN
aji-63	152	26	immunity	immunity	NOUN
aji-63	152	27	.	.	PUNCT
aji-63	153	1	despite	despite	SCONJ
aji-63	153	2	the	the	DET
aji-63	153	3	frequent	frequent	ADJ
aji-63	153	4	reports	report	NOUN
aji-63	153	5	of	of	ADP
aji-63	153	6	sarscov-2	sarscov-2	NUM
aji-63	153	7	antibody	antibody	NOUN
aji-63	153	8	prevalence	prevalence	NOUN
aji-63	153	9	and	and	CCONJ
aji-63	153	10	insights	insight	NOUN
aji-63	153	11	on	on	ADP
aji-63	153	12	antibody	antibody	NOUN
aji-63	153	13	response	response	NOUN
aji-63	153	14	from	from	ADP
aji-63	153	15	a	a	DET
aji-63	153	16	number	number	NOUN
aji-63	153	17	of	of	ADP
aji-63	153	18	countries	country	NOUN
aji-63	153	19	around	around	ADP
aji-63	153	20	the	the	DET
aji-63	153	21	globe	globe	NOUN
aji-63	153	22	but	but	CCONJ
aji-63	153	23	not	not	PART
aji-63	153	24	from	from	ADP
aji-63	153	25	sana’a	sana’a	NOUN
aji-63	153	26	,	,	PUNCT
aji-63	153	27	yemen	yemen	PROPN
aji-63	153	28	.	.	PUNCT
aji-63	153	29	yemen	yemen	PROPN
aji-63	153	30	as	as	ADP
aji-63	153	31	one	one	NUM
aji-63	153	32	of	of	ADP
aji-63	153	33	the	the	DET
aji-63	153	34	countries	country	NOUN
aji-63	153	35	where	where	SCONJ
aji-63	153	36	confinement	confinement	NOUN
aji-63	153	37	of	of	ADP
aji-63	153	38	covid-19	covid-19	PROPN
aji-63	153	39	was	be	AUX
aji-63	153	40	ineffectively	ineffectively	ADV
aji-63	153	41	implemented	implement	VERB
aji-63	153	42	since	since	SCONJ
aji-63	153	43	the	the	DET
aji-63	153	44	emergence	emergence	NOUN
aji-63	153	45	of	of	ADP
aji-63	153	46	the	the	DET
aji-63	153	47	disease	disease	NOUN
aji-63	153	48	because	because	SCONJ
aji-63	153	49	of	of	ADP
aji-63	153	50	the	the	DET
aji-63	153	51	current	current	ADJ
aji-63	153	52	political	political	ADJ
aji-63	153	53	turmoil	turmoil	NOUN
aji-63	153	54	and	and	CCONJ
aji-63	153	55	the	the	DET
aji-63	153	56	collapse	collapse	NOUN
aji-63	153	57	of	of	ADP
aji-63	153	58	the	the	DET
aji-63	153	59	health	health	NOUN
aji-63	153	60	care	care	NOUN
aji-63	153	61	system	system	NOUN
aji-63	153	62	.	.	PUNCT
aji-63	154	1	this	this	PRON
aji-63	154	2	is	be	AUX
aji-63	154	3	one	one	NUM
aji-63	154	4	of	of	ADP
aji-63	154	5	the	the	DET
aji-63	154	6	very	very	ADV
aji-63	154	7	few	few	ADJ
aji-63	154	8	studies	study	NOUN
aji-63	154	9	if	if	SCONJ
aji-63	154	10	not	not	PART
aji-63	154	11	the	the	DET
aji-63	154	12	first	first	ADJ
aji-63	154	13	on	on	ADP
aji-63	154	14	antibody	antibody	NOUN
aji-63	154	15	response	response	NOUN
aji-63	154	16	and	and	CCONJ
aji-63	154	17	sallam	sallam	NOUN
aji-63	154	18	et	et	PROPN
aji-63	154	19	al	al	PROPN
aji-63	154	20	.	.	PROPN
aji-63	154	21	;	;	PUNCT
aji-63	154	22	aji	aji	PROPN
aji-63	154	23	,	,	PUNCT
aji-63	154	24	4(1	4(1	NOUN
aji-63	154	25	):	):	PUNCT
aji-63	154	26	146	146	NUM
aji-63	154	27	-	-	SYM
aji-63	154	28	153	153	NUM
aji-63	154	29	,	,	PUNCT
aji-63	154	30	2021	2021	NUM
aji-63	154	31	;	;	PUNCT
aji-63	154	32	article	article	NOUN
aji-63	154	33	no.aji.83681	no.aji.83681	VERB
aji-63	154	34	148	148	NUM
aji-63	154	35	seroprevalence	seroprevalence	NOUN
aji-63	154	36	of	of	ADP
aji-63	154	37	sars	sar	NOUN
aji-63	154	38	-	-	PUNCT
aji-63	154	39	cov-2	cov-2	NOUN
aji-63	154	40	in	in	ADP
aji-63	154	41	the	the	DET
aji-63	154	42	major	major	ADJ
aji-63	154	43	city	city	NOUN
aji-63	154	44	of	of	ADP
aji-63	154	45	sana`a	sana`a	NUM
aji-63	154	46	,	,	PUNCT
aji-63	154	47	northern	northern	ADJ
aji-63	154	48	part	part	NOUN
aji-63	154	49	of	of	ADP
aji-63	154	50	yemen	yemen	PROPN
aji-63	154	51	.	.	PUNCT
aji-63	155	1	moreover	moreover	ADV
aji-63	155	2	,	,	PUNCT
aji-63	155	3	this	this	DET
aji-63	155	4	study	study	NOUN
aji-63	155	5	will	will	AUX
aji-63	155	6	provide	provide	VERB
aji-63	155	7	insights	insight	NOUN
aji-63	155	8	on	on	ADP
aji-63	155	9	the	the	DET
aji-63	155	10	antibody	antibody	NOUN
aji-63	155	11	response	response	NOUN
aji-63	155	12	to	to	ADP
aji-63	155	13	sars	sar	NOUN
aji-63	155	14	-	-	PUNCT
aji-63	155	15	cov-2	cov-2	NOUN
aji-63	155	16	in	in	ADP
aji-63	155	17	yemen	yemen	PROPN
aji-63	155	18	where	where	SCONJ
aji-63	155	19	the	the	DET
aji-63	155	20	study	study	NOUN
aji-63	155	21	was	be	AUX
aji-63	155	22	conducted	conduct	VERB
aji-63	155	23	relatively	relatively	ADV
aji-63	155	24	early	early	ADV
aji-63	155	25	during	during	ADP
aji-63	155	26	sars	sar	NOUN
aji-63	155	27	-	-	PUNCT
aji-63	155	28	cov-2	cov-2	NOUN
aji-63	155	29	pandemic	pandemic	NOUN
aji-63	155	30	as	as	ADV
aji-63	155	31	well	well	ADV
aji-63	155	32	as	as	SCONJ
aji-63	155	33	it	it	PRON
aji-63	155	34	could	could	AUX
aji-63	155	35	work	work	VERB
aji-63	155	36	as	as	ADP
aji-63	155	37	a	a	DET
aji-63	155	38	baseline	baseline	NOUN
aji-63	155	39	to	to	ADP
aji-63	155	40	further	further	ADJ
aji-63	155	41	studies	study	NOUN
aji-63	155	42	that	that	PRON
aji-63	155	43	measure	measure	VERB
aji-63	155	44	the	the	DET
aji-63	155	45	level	level	NOUN
aji-63	155	46	of	of	ADP
aji-63	155	47	herd	herd	NOUN
aji-63	155	48	immunity	immunity	NOUN
aji-63	155	49	to	to	ADP
aji-63	155	50	covid-19	covid-19	PROPN
aji-63	155	51	in	in	ADP
aji-63	155	52	the	the	DET
aji-63	155	53	country	country	NOUN
aji-63	155	54	.	.	PUNCT
aji-63	156	1	therefore	therefore	ADV
aji-63	156	2	,	,	PUNCT
aji-63	156	3	the	the	DET
aji-63	156	4	aim	aim	NOUN
aji-63	156	5	of	of	ADP
aji-63	156	6	this	this	DET
aji-63	156	7	study	study	NOUN
aji-63	156	8	was	be	AUX
aji-63	156	9	to	to	PART
aji-63	156	10	investigate	investigate	VERB
aji-63	156	11	the	the	DET
aji-63	156	12	antibody	antibody	NOUN
aji-63	156	13	response	response	NOUN
aji-63	156	14	and	and	CCONJ
aji-63	156	15	to	to	PART
aji-63	156	16	estimate	estimate	VERB
aji-63	156	17	the	the	DET
aji-63	156	18	seroprevalence	seroprevalence	NOUN
aji-63	156	19	of	of	ADP
aji-63	156	20	sars	sar	NOUN
aji-63	156	21	-	-	PUNCT
aji-63	156	22	cov-2	cov-2	PART
aji-63	156	23	among	among	ADP
aji-63	156	24	covid-19suspected	covid-19suspecte	VERB
aji-63	156	25	patients	patient	NOUN
aji-63	156	26	who	who	PRON
aji-63	156	27	attended	attend	VERB
aji-63	156	28	a	a	DET
aji-63	156	29	health	health	NOUN
aji-63	156	30	care	care	NOUN
aji-63	156	31	setting	set	VERB
aji-63	156	32	for	for	ADP
aji-63	156	33	covid-19	covid-19	PROPN
aji-63	156	34	testing	testing	NOUN
aji-63	156	35	in	in	ADP
aji-63	156	36	sana`a	sana`a	NUM
aji-63	156	37	,	,	PUNCT
aji-63	156	38	yemen	yemen	PROPN
aji-63	156	39	.	.	PUNCT
aji-63	157	1	2	2	X
aji-63	157	2	.	.	X
aji-63	157	3	materials	material	NOUN
aji-63	157	4	and	and	CCONJ
aji-63	157	5	methods	method	NOUN
aji-63	157	6	2.1	2.1	NUM
aji-63	157	7	study	study	NOUN
aji-63	157	8	design	design	NOUN
aji-63	157	9	and	and	CCONJ
aji-63	157	10	settings	setting	NOUN
aji-63	157	11	this	this	DET
aji-63	157	12	crosssectional	crosssectional	ADJ
aji-63	157	13	study	study	NOUN
aji-63	157	14	was	be	AUX
aji-63	157	15	conducted	conduct	VERB
aji-63	157	16	retrospectively	retrospectively	ADV
aji-63	157	17	in	in	ADP
aji-63	157	18	the	the	DET
aji-63	157	19	sana`a	sana`a	NUM
aji-63	157	20	region	region	NOUN
aji-63	157	21	in	in	ADP
aji-63	157	22	yemen	yemen	PROPN
aji-63	157	23	during	during	ADP
aji-63	157	24	the	the	DET
aji-63	157	25	second	second	ADJ
aji-63	157	26	week	week	NOUN
aji-63	157	27	of	of	ADP
aji-63	157	28	june	june	PROPN
aji-63	157	29	2020	2020	NUM
aji-63	157	30	through	through	ADP
aji-63	157	31	january	january	PROPN
aji-63	157	32	2021	2021	NUM
aji-63	157	33	.	.	PUNCT
aji-63	158	1	on	on	ADP
aji-63	158	2	an	an	DET
aji-63	158	3	informed	informed	ADJ
aji-63	158	4	consent	consent	NOUN
aji-63	158	5	the	the	DET
aji-63	158	6	antisars	antisar	NOUN
aji-63	158	7	-	-	PUNCT
aji-63	158	8	cov-2	cov-2	NOUN
aji-63	158	9	antibody	antibody	NOUN
aji-63	158	10	tests	test	NOUN
aji-63	158	11	results	result	NOUN
aji-63	158	12	and	and	CCONJ
aji-63	158	13	the	the	DET
aji-63	158	14	demographic	demographic	ADJ
aji-63	158	15	data	datum	NOUN
aji-63	158	16	that	that	PRON
aji-63	158	17	included	include	VERB
aji-63	158	18	age	age	NOUN
aji-63	158	19	and	and	CCONJ
aji-63	158	20	gender	gender	NOUN
aji-63	158	21	of	of	ADP
aji-63	158	22	259	259	NUM
aji-63	158	23	covid-19	covid-19	PROPN
aji-63	158	24	suspected	suspect	VERB
aji-63	158	25	patients	patient	NOUN
aji-63	158	26	who	who	PRON
aji-63	158	27	were	be	AUX
aji-63	158	28	referred	refer	VERB
aji-63	158	29	to	to	ADP
aji-63	158	30	a	a	DET
aji-63	158	31	health	health	NOUN
aji-63	158	32	care	care	NOUN
aji-63	158	33	facility	facility	NOUN
aji-63	158	34	for	for	ADP
aji-63	158	35	antibody	antibody	NOUN
aji-63	158	36	testing	testing	NOUN
aji-63	158	37	to	to	PART
aji-63	158	38	confirm	confirm	VERB
aji-63	158	39	the	the	DET
aji-63	158	40	diagnosis	diagnosis	NOUN
aji-63	158	41	were	be	AUX
aji-63	158	42	anonymously	anonymously	ADV
aji-63	158	43	enrolled	enrol	VERB
aji-63	158	44	in	in	ADP
aji-63	158	45	this	this	DET
aji-63	158	46	study	study	NOUN
aji-63	158	47	.	.	PUNCT
aji-63	159	1	2.2	2.2	NUM
aji-63	159	2	antibody	antibody	NOUN
aji-63	159	3	testing	test	VERB
aji-63	159	4	the	the	DET
aji-63	159	5	sera	sera	NOUN
aji-63	159	6	were	be	AUX
aji-63	159	7	tested	test	VERB
aji-63	159	8	for	for	ADP
aji-63	159	9	anti	anti	ADJ
aji-63	159	10	-	-	ADJ
aji-63	159	11	sars	sar	NOUN
aji-63	159	12	-	-	PUNCT
aji-63	159	13	cov-2	cov-2	NOUN
aji-63	159	14	igm	igm	NOUN
aji-63	159	15	and	and	CCONJ
aji-63	159	16	igg	igg	PROPN
aji-63	159	17	antibodies	antibodie	VERB
aji-63	159	18	using	use	VERB
aji-63	159	19	iflash	iflash	NOUN
aji-63	159	20	–	–	PUNCT
aji-63	159	21	sars	sar	NOUN
aji-63	159	22	-	-	PUNCT
aji-63	159	23	cov-2	cov-2	NOUN
aji-63	159	24	igm	igm	NOUN
aji-63	159	25	and	and	CCONJ
aji-63	159	26	igg	igg	PROPN
aji-63	159	27	paramagnetic	paramagnetic	PROPN
aji-63	159	28	particle	particle	PROPN
aji-63	159	29	chemiluminescent	chemiluminescent	PROPN
aji-63	159	30	(	(	PUNCT
aji-63	159	31	clia	clia	PROPN
aji-63	159	32	)	)	PUNCT
aji-63	159	33	(	(	PUNCT
aji-63	159	34	shenzhen	shenzhen	PROPN
aji-63	159	35	yhlo	yhlo	PROPN
aji-63	159	36	biotech	biotech	PROPN
aji-63	159	37	co.	co.	PROPN
aji-63	159	38	,	,	PUNCT
aji-63	159	39	ltd	ltd	PROPN
aji-63	159	40	.	.	PROPN
aji-63	159	41	china	china	PROPN
aji-63	159	42	)	)	PUNCT
aji-63	159	43	for	for	ADP
aji-63	159	44	qualitative	qualitative	ADJ
aji-63	159	45	determination	determination	NOUN
aji-63	159	46	of	of	ADP
aji-63	159	47	igm	igm	PROPN
aji-63	159	48	and	and	CCONJ
aji-63	159	49	igg	igg	PROPN
aji-63	159	50	according	accord	VERB
aji-63	159	51	to	to	ADP
aji-63	159	52	the	the	DET
aji-63	159	53	manufacture	manufacture	NOUN
aji-63	159	54	instructions	instruction	NOUN
aji-63	159	55	.	.	PUNCT
aji-63	160	1	in	in	ADP
aji-63	160	2	summary	summary	NOUN
aji-63	160	3	prediluted	predilute	VERB
aji-63	160	4	serum	serum	NOUN
aji-63	160	5	samples	sample	NOUN
aji-63	160	6	were	be	AUX
aji-63	160	7	incubated	incubate	VERB
aji-63	160	8	with	with	ADP
aji-63	160	9	a	a	DET
aji-63	160	10	recombinant	recombinant	ADJ
aji-63	160	11	sars	sar	NOUN
aji-63	160	12	-	-	PUNCT
aji-63	160	13	cov-2	cov-2	NOUN
aji-63	160	14	antigen	antigen	NOUN
aji-63	160	15	that	that	PRON
aji-63	160	16	was	be	AUX
aji-63	160	17	coated	coat	VERB
aji-63	160	18	to	to	ADP
aji-63	160	19	paramagnetic	paramagnetic	ADJ
aji-63	160	20	microparticles	microparticle	NOUN
aji-63	160	21	to	to	PART
aji-63	160	22	allow	allow	VERB
aji-63	160	23	the	the	DET
aji-63	160	24	formation	formation	NOUN
aji-63	160	25	of	of	ADP
aji-63	160	26	antigenantibody	antigenantibody	ADJ
aji-63	160	27	complex	complex	NOUN
aji-63	160	28	.	.	PUNCT
aji-63	161	1	then	then	ADV
aji-63	161	2	complex	complex	ADJ
aji-63	161	3	was	be	AUX
aji-63	161	4	washed	wash	VERB
aji-63	161	5	under	under	ADP
aji-63	161	6	magnetic	magnetic	ADJ
aji-63	161	7	field	field	NOUN
aji-63	161	8	during	during	ADP
aji-63	161	9	which	which	PRON
aji-63	161	10	magnetic	magnetic	ADJ
aji-63	161	11	particles	particle	NOUN
aji-63	161	12	were	be	AUX
aji-63	161	13	absorbed	absorb	VERB
aji-63	161	14	into	into	ADP
aji-63	161	15	the	the	DET
aji-63	161	16	inner	inner	ADJ
aji-63	161	17	wall	wall	NOUN
aji-63	161	18	of	of	ADP
aji-63	161	19	the	the	DET
aji-63	161	20	reaction	reaction	NOUN
aji-63	161	21	tubes	tube	NOUN
aji-63	161	22	while	while	SCONJ
aji-63	161	23	the	the	DET
aji-63	161	24	unbound	unbound	NOUN
aji-63	161	25	materials	material	NOUN
aji-63	161	26	were	be	AUX
aji-63	161	27	washed	wash	VERB
aji-63	161	28	away	away	ADV
aji-63	161	29	from	from	ADP
aji-63	161	30	the	the	DET
aji-63	161	31	solid	solid	ADJ
aji-63	161	32	phase	phase	NOUN
aji-63	161	33	of	of	ADP
aji-63	161	34	the	the	DET
aji-63	161	35	magnetic	magnetic	ADJ
aji-63	161	36	field	field	NOUN
aji-63	161	37	.	.	PUNCT
aji-63	162	1	then	then	ADV
aji-63	162	2	the	the	DET
aji-63	162	3	complex	complex	NOUN
aji-63	162	4	was	be	AUX
aji-63	162	5	incubated	incubate	VERB
aji-63	162	6	with	with	ADP
aji-63	162	7	acridinium	acridinium	NOUN
aji-63	162	8	-	-	PUNCT
aji-63	162	9	labeled	label	VERB
aji-63	162	10	anti	anti	ADJ
aji-63	162	11	-	-	ADJ
aji-63	162	12	human	human	ADJ
aji-63	162	13	antibody	antibody	NOUN
aji-63	162	14	conjugate	conjugate	VERB
aji-63	162	15	.	.	PUNCT
aji-63	163	1	the	the	DET
aji-63	163	2	newly	newly	ADV
aji-63	163	3	formed	form	VERB
aji-63	163	4	complex	complex	NOUN
aji-63	163	5	that	that	PRON
aji-63	163	6	consisted	consist	VERB
aji-63	163	7	of	of	ADP
aji-63	163	8	sars	sar	NOUN
aji-63	163	9	-	-	PUNCT
aji-63	163	10	cov-2	cov-2	NOUN
aji-63	163	11	antigenantibody	antigenantibody	ADJ
aji-63	163	12	and	and	CCONJ
aji-63	163	13	acridinium	acridinium	NOUN
aji-63	163	14	-	-	PUNCT
aji-63	163	15	labeled	label	VERB
aji-63	163	16	antihuman	antihuman	NOUN
aji-63	163	17	antibody	antibody	NOUN
aji-63	163	18	was	be	AUX
aji-63	163	19	washed	wash	VERB
aji-63	163	20	.	.	PUNCT
aji-63	164	1	then	then	ADV
aji-63	164	2	a	a	DET
aji-63	164	3	pre	pre	NOUN
aji-63	164	4	-	-	NOUN
aji-63	164	5	trigger	trigger	NOUN
aji-63	164	6	and	and	CCONJ
aji-63	164	7	a	a	DET
aji-63	164	8	trigger	trigger	NOUN
aji-63	164	9	solution	solution	NOUN
aji-63	164	10	were	be	AUX
aji-63	164	11	added	add	VERB
aji-63	164	12	to	to	PART
aji-63	164	13	trigger	trigger	VERB
aji-63	164	14	the	the	DET
aji-63	164	15	signal	signal	NOUN
aji-63	164	16	and	and	CCONJ
aji-63	164	17	the	the	DET
aji-63	164	18	resulting	result	VERB
aji-63	164	19	chemiluminescent	chemiluminescent	NOUN
aji-63	164	20	reaction	reaction	NOUN
aji-63	164	21	was	be	AUX
aji-63	164	22	measured	measure	VERB
aji-63	164	23	as	as	ADP
aji-63	164	24	relative	relative	ADJ
aji-63	164	25	light	light	ADJ
aji-63	164	26	units	unit	NOUN
aji-63	164	27	(	(	PUNCT
aji-63	164	28	rlus	rlus	ADJ
aji-63	164	29	)	)	PUNCT
aji-63	164	30	the	the	DET
aji-63	164	31	detection	detection	NOUN
aji-63	164	32	of	of	ADP
aji-63	164	33	which	which	PRON
aji-63	164	34	by	by	ADP
aji-63	164	35	the	the	DET
aji-63	164	36	iflash	iflash	ADJ
aji-63	164	37	optical	optical	ADJ
aji-63	164	38	system	system	NOUN
aji-63	164	39	was	be	AUX
aji-63	164	40	proportional	proportional	ADJ
aji-63	164	41	to	to	ADP
aji-63	164	42	the	the	DET
aji-63	164	43	antibody	antibody	NOUN
aji-63	164	44	concentration	concentration	NOUN
aji-63	164	45	present	present	ADJ
aji-63	164	46	in	in	ADP
aji-63	164	47	the	the	DET
aji-63	164	48	sample	sample	NOUN
aji-63	164	49	.	.	PUNCT
aji-63	165	1	the	the	DET
aji-63	165	2	results	result	NOUN
aji-63	165	3	are	be	AUX
aji-63	165	4	determined	determine	VERB
aji-63	165	5	through	through	ADP
aji-63	165	6	a	a	DET
aji-63	165	7	calibration	calibration	NOUN
aji-63	165	8	curve	curve	NOUN
aji-63	165	9	by	by	ADP
aji-63	165	10	2point	2point	NUM
aji-63	165	11	calibration	calibration	NOUN
aji-63	165	12	.	.	PUNCT
aji-63	166	1	antibody	antibody	NOUN
aji-63	166	2	level	level	NOUN
aji-63	166	3	≥	≥	NOUN
aji-63	166	4	10	10	NUM
aji-63	166	5	absorbance	absorbance	NOUN
aji-63	166	6	units	unit	NOUN
aji-63	166	7	per	per	ADP
aji-63	166	8	milliliter	milliliter	NOUN
aji-63	166	9	(	(	PUNCT
aji-63	166	10	au	au	PROPN
aji-63	166	11	/	/	SYM
aji-63	166	12	ml	ml	VERB
aji-63	166	13	)	)	PUNCT
aji-63	166	14	was	be	AUX
aji-63	166	15	considered	consider	VERB
aji-63	166	16	positive	positive	ADJ
aji-63	166	17	.	.	PUNCT
aji-63	167	1	2.3	2.3	NUM
aji-63	167	2	statistical	statistical	ADJ
aji-63	167	3	analysis	analysis	NOUN
aji-63	167	4	data	datum	NOUN
aji-63	167	5	entered	enter	VERB
aji-63	167	6	in	in	ADP
aji-63	167	7	a	a	DET
aji-63	167	8	statistical	statistical	ADJ
aji-63	167	9	package	package	NOUN
aji-63	167	10	(	(	PUNCT
aji-63	167	11	spss	spss	PROPN
aji-63	167	12	version	version	NOUN
aji-63	167	13	22	22	NUM
aji-63	167	14	)	)	PUNCT
aji-63	167	15	for	for	ADP
aji-63	167	16	analysis	analysis	NOUN
aji-63	167	17	.	.	PUNCT
aji-63	168	1	categorical	categorical	ADJ
aji-63	168	2	variables	variable	NOUN
aji-63	168	3	were	be	AUX
aji-63	168	4	used	use	VERB
aji-63	168	5	for	for	ADP
aji-63	168	6	the	the	DET
aji-63	168	7	description	description	NOUN
aji-63	168	8	of	of	ADP
aji-63	168	9	the	the	DET
aji-63	168	10	demographic	demographic	ADJ
aji-63	168	11	characteristics	characteristic	NOUN
aji-63	168	12	of	of	ADP
aji-63	168	13	the	the	DET
aji-63	168	14	participants	participant	NOUN
aji-63	168	15	(	(	PUNCT
aji-63	168	16	age	age	NOUN
aji-63	168	17	and	and	CCONJ
aji-63	168	18	sex	sex	NOUN
aji-63	168	19	)	)	PUNCT
aji-63	168	20	.	.	PUNCT
aji-63	169	1	association	association	NOUN
aji-63	169	2	between	between	ADP
aji-63	169	3	the	the	DET
aji-63	169	4	seroprevalence	seroprevalence	NOUN
aji-63	169	5	findings	finding	NOUN
aji-63	169	6	of	of	ADP
aji-63	169	7	the	the	DET
aji-63	169	8	igm	igm	NOUN
aji-63	169	9	and	and	CCONJ
aji-63	169	10	igg	igg	PROPN
aji-63	169	11	with	with	ADP
aji-63	169	12	the	the	DET
aji-63	169	13	characteristics	characteristic	NOUN
aji-63	169	14	of	of	ADP
aji-63	169	15	the	the	DET
aji-63	169	16	participants	participant	NOUN
aji-63	169	17	were	be	AUX
aji-63	169	18	undertaken	undertake	VERB
aji-63	169	19	using	use	VERB
aji-63	169	20	a	a	DET
aji-63	169	21	chi	chi	ADJ
aji-63	169	22	-	-	PUNCT
aji-63	169	23	square	square	ADJ
aji-63	169	24	test	test	NOUN
aji-63	169	25	,	,	PUNCT
aji-63	169	26	where	where	SCONJ
aji-63	169	27	p	p	NOUN
aji-63	169	28	value	value	NOUN
aji-63	169	29	findings	finding	NOUN
aji-63	169	30	of	of	ADP
aji-63	169	31	<	<	X
aji-63	169	32	0.05	0.05	NUM
aji-63	169	33	was	be	AUX
aji-63	169	34	considered	consider	VERB
aji-63	169	35	significant	significant	ADJ
aji-63	169	36	.	.	PUNCT
aji-63	170	1	3	3	X
aji-63	170	2	.	.	X
aji-63	170	3	results	result	VERB
aji-63	170	4	the	the	DET
aji-63	170	5	mean	mean	ADJ
aji-63	170	6	age	age	NOUN
aji-63	170	7	of	of	ADP
aji-63	170	8	the	the	DET
aji-63	170	9	259	259	NUM
aji-63	170	10	subjects	subject	NOUN
aji-63	170	11	was	be	AUX
aji-63	170	12	40.8	40.8	NUM
aji-63	170	13	±16.6	±16.6	NUM
aji-63	170	14	years	year	NOUN
aji-63	170	15	,	,	PUNCT
aji-63	170	16	ranging	range	VERB
aji-63	170	17	between	between	ADP
aji-63	170	18	3	3	NUM
aji-63	170	19	-	-	SYM
aji-63	170	20	85	85	NUM
aji-63	170	21	years	year	NOUN
aji-63	170	22	.	.	PUNCT
aji-63	171	1	most	most	ADJ
aji-63	171	2	of	of	ADP
aji-63	171	3	the	the	DET
aji-63	171	4	participants	participant	NOUN
aji-63	171	5	180	180	NUM
aji-63	171	6	(	(	PUNCT
aji-63	171	7	69.5	69.5	NUM
aji-63	171	8	%	%	NOUN
aji-63	171	9	)	)	PUNCT
aji-63	171	10	were	be	AUX
aji-63	171	11	males	male	NOUN
aji-63	171	12	and	and	CCONJ
aji-63	171	13	79	79	NUM
aji-63	171	14	(	(	PUNCT
aji-63	171	15	30.5	30.5	NUM
aji-63	171	16	%	%	NOUN
aji-63	171	17	)	)	PUNCT
aji-63	171	18	were	be	AUX
aji-63	171	19	females	female	NOUN
aji-63	171	20	,	,	PUNCT
aji-63	171	21	young	young	ADJ
aji-63	171	22	adults	adult	NOUN
aji-63	171	23	(	(	PUNCT
aji-63	171	24	≤18	≤18	NOUN
aji-63	171	25	-49	-49	NUM
aji-63	171	26	years	year	NOUN
aji-63	171	27	)	)	PUNCT
aji-63	171	28	,	,	PUNCT
aji-63	171	29	who	who	PRON
aji-63	171	30	were	be	AUX
aji-63	171	31	mostly	mostly	ADV
aji-63	171	32	infected	infect	VERB
aji-63	171	33	in	in	ADP
aji-63	171	34	week	week	NOUN
aji-63	171	35	2	2	NUM
aji-63	171	36	of	of	ADP
aji-63	171	37	june	june	PROPN
aji-63	171	38	2020	2020	NUM
aji-63	171	39	(	(	PUNCT
aji-63	171	40	fig	fig	NOUN
aji-63	171	41	.	.	PUNCT
aji-63	172	1	1	1	NUM
aji-63	172	2	)	)	PUNCT
aji-63	172	3	.	.	PUNCT
aji-63	173	1	a	a	DET
aji-63	173	2	total	total	NOUN
aji-63	173	3	of	of	ADP
aji-63	173	4	133	133	NUM
aji-63	173	5	(	(	PUNCT
aji-63	173	6	51.4	51.4	NUM
aji-63	173	7	%	%	NOUN
aji-63	173	8	)	)	PUNCT
aji-63	173	9	were	be	AUX
aji-63	173	10	positive	positive	ADJ
aji-63	173	11	for	for	ADP
aji-63	173	12	at	at	ADV
aji-63	173	13	least	least	ADV
aji-63	173	14	one	one	NUM
aji-63	173	15	anti	anti	ADJ
aji-63	173	16	-	-	ADJ
aji-63	173	17	sars	sars	ADJ
aji-63	173	18	-	-	PUNCT
aji-63	173	19	cov-2	cov-2	NOUN
aji-63	173	20	antibody	antibody	NOUN
aji-63	173	21	class	class	NOUN
aji-63	173	22	,	,	PUNCT
aji-63	173	23	and	and	CCONJ
aji-63	173	24	of	of	ADP
aji-63	173	25	these	these	DET
aji-63	173	26	6	6	NUM
aji-63	173	27	(	(	PUNCT
aji-63	173	28	2.3	2.3	NUM
aji-63	173	29	%	%	NOUN
aji-63	173	30	)	)	PUNCT
aji-63	173	31	had	have	AUX
aji-63	173	32	isolated	isolate	VERB
aji-63	173	33	igm	igm	PROPN
aji-63	173	34	,	,	PUNCT
aji-63	173	35	80	80	NUM
aji-63	173	36	(	(	PUNCT
aji-63	173	37	30.9	30.9	NUM
aji-63	173	38	%	%	NOUN
aji-63	173	39	)	)	PUNCT
aji-63	173	40	had	have	VERB
aji-63	173	41	concomitant	concomitant	ADJ
aji-63	173	42	igm	igm	NOUN
aji-63	173	43	and	and	CCONJ
aji-63	173	44	igg	igg	PROPN
aji-63	173	45	,	,	PUNCT
aji-63	173	46	49	49	NUM
aji-63	173	47	(	(	PUNCT
aji-63	173	48	18.9	18.9	NUM
aji-63	173	49	%	%	NOUN
aji-63	173	50	)	)	PUNCT
aji-63	173	51	had	have	AUX
aji-63	173	52	isolated	isolate	VERB
aji-63	173	53	igg	igg	PROPN
aji-63	173	54	,	,	PUNCT
aji-63	173	55	and	and	CCONJ
aji-63	173	56	128	128	NUM
aji-63	173	57	(	(	PUNCT
aji-63	173	58	49.4	49.4	NUM
aji-63	173	59	%	%	NOUN
aji-63	173	60	)	)	PUNCT
aji-63	173	61	had	have	VERB
aji-63	173	62	igg	igg	PROPN
aji-63	173	63	with	with	ADP
aji-63	173	64	or	or	CCONJ
aji-63	173	65	without	without	ADP
aji-63	173	66	igm	igm	PROPN
aji-63	173	67	(	(	PUNCT
aji-63	173	68	table	table	NOUN
aji-63	173	69	1	1	NUM
aji-63	173	70	)	)	PUNCT
aji-63	173	71	.	.	PUNCT
aji-63	174	1	table	table	NOUN
aji-63	174	2	1	1	NUM
aji-63	174	3	.	.	PUNCT
aji-63	174	4	seropositivity	seropositivity	NOUN
aji-63	174	5	rate	rate	NOUN
aji-63	174	6	of	of	ADP
aji-63	174	7	various	various	ADJ
aji-63	174	8	anti	anti	ADJ
aji-63	174	9	-	-	ADJ
aji-63	174	10	sars	sars	ADJ
aji-63	174	11	-	-	PUNCT
aji-63	174	12	cov-2	cov-2	NOUN
aji-63	174	13	antibody	antibody	NOUN
aji-63	174	14	classes	class	NOUN
aji-63	174	15	among	among	ADP
aji-63	174	16	covid-19	covid-19	PROPN
aji-63	174	17	suspected	suspect	VERB
aji-63	174	18	subjects	subject	NOUN
aji-63	174	19	who	who	PRON
aji-63	174	20	attended	attend	VERB
aji-63	174	21	a	a	DET
aji-63	174	22	health	health	NOUN
aji-63	174	23	care	care	NOUN
aji-63	174	24	facility	facility	NOUN
aji-63	174	25	in	in	ADP
aji-63	174	26	in	in	ADP
aji-63	174	27	sana`a	sana`a	NUM
aji-63	174	28	,	,	PUNCT
aji-63	174	29	yemen	yemen	PROPN
aji-63	174	30	variable	variable	ADJ
aji-63	174	31	category	category	NOUN
aji-63	174	32	n	n	CCONJ
aji-63	174	33	%	%	NOUN
aji-63	174	34	antibody	antibody	NOUN
aji-63	174	35	response	response	NOUN
aji-63	174	36	at	at	ADP
aji-63	174	37	least	least	ADV
aji-63	174	38	one	one	NUM
aji-63	174	39	antibodies	antibodie	VERB
aji-63	174	40	133	133	NUM
aji-63	174	41	51.4	51.4	NUM
aji-63	174	42	absence	absence	NOUN
aji-63	174	43	of	of	ADP
aji-63	174	44	antibodies	antibody	NOUN
aji-63	174	45	126	126	NUM
aji-63	174	46	48.6	48.6	NUM
aji-63	174	47	isolated	isolate	VERB
aji-63	174	48	igm	igm	NOUN
aji-63	174	49	6	6	NUM
aji-63	174	50	2.3	2.3	NUM
aji-63	174	51	concomitant	concomitant	ADJ
aji-63	174	52	igg	igg	PROPN
aji-63	174	53	/	/	SYM
aji-63	174	54	igm	igm	PROPN
aji-63	174	55	80	80	NUM
aji-63	174	56	30.9	30.9	NUM
aji-63	174	57	isolated	isolate	VERB
aji-63	174	58	igg	igg	PROPN
aji-63	174	59	49	49	NUM
aji-63	174	60	18.9	18.9	NUM
aji-63	174	61	igg	igg	NOUN
aji-63	174	62	with	with	ADP
aji-63	174	63	/	/	SYM
aji-63	174	64	without	without	ADP
aji-63	174	65	igm	igm	PROPN
aji-63	174	66	128	128	NUM
aji-63	174	67	49.4	49.4	NUM
aji-63	174	68	sallam	sallam	NOUN
aji-63	174	69	et	et	PROPN
aji-63	174	70	al	al	PROPN
aji-63	174	71	.	.	PROPN
aji-63	174	72	;	;	PUNCT
aji-63	174	73	aji	aji	PROPN
aji-63	174	74	,	,	PUNCT
aji-63	174	75	4(1	4(1	NOUN
aji-63	174	76	):	):	PUNCT
aji-63	174	77	146	146	NUM
aji-63	174	78	-	-	SYM
aji-63	174	79	153	153	NUM
aji-63	174	80	,	,	PUNCT
aji-63	174	81	2021	2021	NUM
aji-63	174	82	;	;	PUNCT
aji-63	174	83	article	article	NOUN
aji-63	174	84	no.aji.83681	no.aji.83681	VERB
aji-63	174	85	149	149	NUM
aji-63	174	86	table	table	NOUN
aji-63	174	87	2	2	NUM
aji-63	174	88	.	.	PUNCT
aji-63	174	89	seropositivity	seropositivity	NOUN
aji-63	174	90	rate	rate	NOUN
aji-63	174	91	of	of	ADP
aji-63	174	92	anti	anti	ADJ
aji-63	174	93	-	-	ADJ
aji-63	174	94	sars	sars	ADJ
aji-63	174	95	-	-	PUNCT
aji-63	174	96	cov-2	cov-2	NOUN
aji-63	174	97	antibody	antibody	NOUN
aji-63	174	98	classes	class	NOUN
aji-63	174	99	among	among	ADP
aji-63	174	100	males	male	NOUN
aji-63	174	101	and	and	CCONJ
aji-63	174	102	females	female	NOUN
aji-63	174	103	and	and	CCONJ
aji-63	174	104	different	different	ADJ
aji-63	174	105	age	age	NOUN
aji-63	174	106	groups	group	NOUN
aji-63	174	107	of	of	ADP
aji-63	174	108	covid-19suspected	covid-19suspecte	VERB
aji-63	174	109	subjects	subject	NOUN
aji-63	174	110	who	who	PRON
aji-63	174	111	attended	attend	VERB
aji-63	174	112	a	a	DET
aji-63	174	113	health	health	NOUN
aji-63	174	114	care	care	NOUN
aji-63	174	115	facility	facility	NOUN
aji-63	174	116	in	in	ADP
aji-63	174	117	in	in	ADP
aji-63	174	118	sana`a	sana`a	NUM
aji-63	174	119	,	,	PUNCT
aji-63	174	120	yemen(n=259	yemen(n=259	NUM
aji-63	174	121	)	)	PUNCT
aji-63	174	122	variable	variable	NOUN
aji-63	174	123	at	at	ADV
aji-63	174	124	least	least	ADV
aji-63	174	125	1	1	NUM
aji-63	174	126	antibody	antibody	NOUN
aji-63	174	127	class	class	NOUN
aji-63	174	128	n=	n=	ADJ
aji-63	174	129	133	133	NUM
aji-63	174	130	isolated	isolated	ADJ
aji-63	174	131	igm	igm	NOUN
aji-63	174	132	(	(	PUNCT
aji-63	174	133	n=	n=	ADJ
aji-63	174	134	6	6	NUM
aji-63	174	135	)	)	PUNCT
aji-63	174	136	isolated	isolated	ADJ
aji-63	174	137	igg	igg	PROPN
aji-63	174	138	(	(	PUNCT
aji-63	174	139	n=	n=	ADJ
aji-63	174	140	49	49	NUM
aji-63	174	141	)	)	PUNCT
aji-63	174	142	igg	igg	NOUN
aji-63	174	143	with	with	ADP
aji-63	174	144	/	/	SYM
aji-63	174	145	without	without	ADP
aji-63	174	146	igm	igm	PROPN
aji-63	174	147	(	(	PUNCT
aji-63	174	148	n=128	n=128	PROPN
aji-63	174	149	)	)	PUNCT
aji-63	174	150	concomitant	concomitant	PROPN
aji-63	174	151	igm	igm	PROPN
aji-63	174	152	&	&	CCONJ
aji-63	174	153	igg	igg	PROPN
aji-63	174	154	(	(	PUNCT
aji-63	174	155	n=	n=	ADJ
aji-63	174	156	80	80	NUM
aji-63	174	157	)	)	PUNCT
aji-63	174	158	n	n	PROPN
aji-63	174	159	(	(	PUNCT
aji-63	174	160	%	%	NOUN
aji-63	174	161	)	)	PUNCT
aji-63	174	162	p	p	NOUN
aji-63	174	163	n	n	PROPN
aji-63	174	164	(	(	PUNCT
aji-63	174	165	%	%	NOUN
aji-63	174	166	)	)	PUNCT
aji-63	174	167	p	p	NOUN
aji-63	174	168	n	n	PROPN
aji-63	174	169	(	(	PUNCT
aji-63	174	170	%	%	NOUN
aji-63	174	171	)	)	PUNCT
aji-63	174	172	p	p	NOUN
aji-63	174	173	n	n	PROPN
aji-63	174	174	(	(	PUNCT
aji-63	174	175	%	%	NOUN
aji-63	174	176	)	)	PUNCT
aji-63	174	177	p	p	NOUN
aji-63	174	178	n	n	PROPN
aji-63	174	179	(	(	PUNCT
aji-63	174	180	%	%	INTJ
aji-63	174	181	)	)	PUNCT
aji-63	174	182	p	p	NOUN
aji-63	174	183	sex	sex	NOUN
aji-63	174	184	male	male	NOUN
aji-63	174	185	88	88	NUM
aji-63	174	186	(	(	PUNCT
aji-63	174	187	69.8	69.8	NUM
aji-63	174	188	)	)	PUNCT
aji-63	174	189	0.907	0.907	NUM
aji-63	174	190	1	1	NUM
aji-63	174	191	(	(	PUNCT
aji-63	174	192	17.0	17.0	NUM
aji-63	174	193	)	)	PUNCT
aji-63	174	194	0.017	0.017	NUM
aji-63	174	195	144	144	NUM
aji-63	174	196	(	(	PUNCT
aji-63	174	197	68.6	68.6	NUM
aji-63	174	198	)	)	PUNCT
aji-63	174	199	0.503	0.503	NUM
aji-63	174	200	89	89	NUM
aji-63	174	201	(	(	PUNCT
aji-63	174	202	67.9	67.9	NUM
aji-63	174	203	)	)	PUNCT
aji-63	174	204	0.581	0.581	NUM
aji-63	174	205	125	125	NUM
aji-63	174	206	(	(	PUNCT
aji-63	174	207	69.8	69.8	NUM
aji-63	174	208	)	)	PUNCT
aji-63	174	209	0.861	0.861	NUM
aji-63	174	210	female	female	NOUN
aji-63	174	211	38	38	NUM
aji-63	174	212	(	(	PUNCT
aji-63	174	213	30.2	30.2	NUM
aji-63	174	214	)	)	SYM
aji-63	174	215	5	5	NUM
aji-63	174	216	(	(	PUNCT
aji-63	174	217	83.0	83.0	NUM
aji-63	174	218	)	)	PUNCT
aji-63	174	219	66	66	NUM
aji-63	174	220	(	(	PUNCT
aji-63	174	221	31.4	31.4	NUM
aji-63	174	222	)	)	PUNCT
aji-63	174	223	42	42	NUM
aji-63	174	224	(	(	PUNCT
aji-63	174	225	32.1	32.1	NUM
aji-63	174	226	)	)	PUNCT
aji-63	174	227	54	54	NUM
aji-63	174	228	(	(	PUNCT
aji-63	174	229	30.2	30.2	NUM
aji-63	174	230	)	)	PUNCT
aji-63	174	231	age	age	NOUN
aji-63	174	232	(	(	PUNCT
aji-63	174	233	years	year	NOUN
aji-63	174	234	)	)	PUNCT
aji-63	174	235	3	3	NUM
aji-63	174	236	-	-	SYM
aji-63	174	237	18	18	NUM
aji-63	174	238	8	8	NUM
aji-63	174	239	(	(	PUNCT
aji-63	174	240	6.3	6.3	NUM
aji-63	174	241	)	)	PUNCT
aji-63	174	242	0.069	0.069	NUM
aji-63	174	243	0	0	NUM
aji-63	174	244	(	(	PUNCT
aji-63	174	245	0.0	0.0	NUM
aji-63	174	246	)	)	PUNCT
aji-63	174	247	0.721	0.721	NUM
aji-63	174	248	16	16	NUM
aji-63	174	249	(	(	PUNCT
aji-63	174	250	7.6	7.6	NUM
aji-63	174	251	)	)	PUNCT
aji-63	174	252	0.002	0.002	NUM
aji-63	174	253	8	8	NUM
aji-63	174	254	(	(	PUNCT
aji-63	174	255	6.1	6.1	NUM
aji-63	174	256	)	)	PUNCT
aji-63	174	257	0.112	0.112	NUM
aji-63	174	258	8	8	NUM
aji-63	174	259	(	(	PUNCT
aji-63	174	260	4.5	4.5	NUM
aji-63	174	261	)	)	PUNCT
aji-63	174	262	0.074	0.074	NUM
aji-63	174	263	19	19	NUM
aji-63	174	264	-	-	SYM
aji-63	174	265	49	49	NUM
aji-63	174	266	85	85	NUM
aji-63	174	267	(	(	PUNCT
aji-63	174	268	67.5	67.5	NUM
aji-63	174	269	)	)	SYM
aji-63	174	270	5	5	NUM
aji-63	174	271	(	(	PUNCT
aji-63	174	272	83.3	83.3	NUM
aji-63	174	273	)	)	PUNCT
aji-63	174	274	147	147	NUM
aji-63	174	275	(	(	PUNCT
aji-63	174	276	70.0	70.0	NUM
aji-63	174	277	)	)	SYM
aji-63	174	278	89	89	NUM
aji-63	174	279	(	(	PUNCT
aji-63	174	280	67.9	67.9	NUM
aji-63	174	281	)	)	PUNCT
aji-63	174	282	117	117	NUM
aji-63	174	283	(	(	PUNCT
aji-63	174	284	65.4	65.4	NUM
aji-63	174	285	)	)	PUNCT
aji-63	174	286	50	50	NUM
aji-63	174	287	-	-	SYM
aji-63	174	288	64	64	NUM
aji-63	174	289	13	13	NUM
aji-63	174	290	(	(	PUNCT
aji-63	174	291	10.3	10.3	NUM
aji-63	174	292	)	)	PUNCT
aji-63	174	293	1	1	NUM
aji-63	174	294	(	(	PUNCT
aji-63	174	295	16.7	16.7	NUM
aji-63	174	296	)	)	PUNCT
aji-63	174	297	23	23	NUM
aji-63	174	298	(	(	PUNCT
aji-63	174	299	11.0	11.0	NUM
aji-63	174	300	)	)	SYM
aji-63	174	301	14	14	NUM
aji-63	174	302	(	(	PUNCT
aji-63	174	303	10.7	10.7	NUM
aji-63	174	304	)	)	PUNCT
aji-63	174	305	29	29	NUM
aji-63	174	306	(	(	PUNCT
aji-63	174	307	16.2	16.2	NUM
aji-63	174	308	)	)	PUNCT
aji-63	174	309	≥	≥	NOUN
aji-63	174	310	65	65	NUM
aji-63	174	311	20	20	NUM
aji-63	174	312	(	(	PUNCT
aji-63	174	313	15.9	15.9	NUM
aji-63	174	314	)	)	PUNCT
aji-63	174	315	0	0	NUM
aji-63	175	1	(	(	PUNCT
aji-63	175	2	0.0	0.0	NUM
aji-63	175	3	)	)	PUNCT
aji-63	175	4	24	24	NUM
aji-63	175	5	(	(	PUNCT
aji-63	175	6	11.4	11.4	NUM
aji-63	175	7	)	)	PUNCT
aji-63	175	8	20	20	NUM
aji-63	175	9	(	(	PUNCT
aji-63	175	10	15.3	15.3	NUM
aji-63	175	11	)	)	PUNCT
aji-63	175	12	25	25	NUM
aji-63	175	13	(	(	PUNCT
aji-63	175	14	14.0	14.0	NUM
aji-63	175	15	)	)	PUNCT
aji-63	175	16	fig	fig	NOUN
aji-63	175	17	.	.	PUNCT
aji-63	176	1	1	1	X
aji-63	176	2	.	.	X
aji-63	176	3	demographic	demographic	ADJ
aji-63	176	4	characteristics	characteristic	NOUN
aji-63	176	5	of	of	ADP
aji-63	176	6	subjects	subject	NOUN
aji-63	176	7	covid-19	covid-19	PROPN
aji-63	176	8	-suspected	-suspected	PROPN
aji-63	176	9	who	who	PRON
aji-63	176	10	attended	attend	VERB
aji-63	176	11	a	a	DET
aji-63	176	12	health	health	NOUN
aji-63	176	13	care	care	NOUN
aji-63	176	14	facility	facility	NOUN
aji-63	176	15	in	in	ADP
aji-63	176	16	in	in	ADP
aji-63	176	17	sana`a	sana`a	NUM
aji-63	176	18	,	,	PUNCT
aji-63	176	19	yemen	yemen	PROPN
aji-63	176	20	(	(	PUNCT
aji-63	176	21	n=259	n=259	NOUN
aji-63	176	22	)	)	PUNCT
aji-63	176	23	69.5	69.5	NUM
aji-63	176	24	30.5	30.5	NUM
aji-63	176	25	6.2	6.2	NUM
aji-63	176	26	67.2	67.2	NUM
aji-63	176	27	14.7	14.7	NUM
aji-63	176	28	11.9	11.9	NUM
aji-63	176	29	0	0	NUM
aji-63	176	30	10	10	NUM
aji-63	176	31	20	20	NUM
aji-63	176	32	30	30	NUM
aji-63	176	33	40	40	NUM
aji-63	176	34	50	50	NUM
aji-63	176	35	60	60	NUM
aji-63	176	36	70	70	NUM
aji-63	176	37	80	80	NUM
aji-63	176	38	male	male	ADJ
aji-63	176	39	female	female	ADJ
aji-63	176	40	18	18	NUM
aji-63	176	41	-	-	PUNCT
aji-63	176	42	mar	mar	PROPN
aji-63	176	43	19	19	NUM
aji-63	176	44	-	-	SYM
aji-63	176	45	49	49	NUM
aji-63	176	46	50	50	NUM
aji-63	176	47	-	-	SYM
aji-63	176	48	64	64	NUM
aji-63	176	49	≥	≥	NOUN
aji-63	176	50	65	65	NUM
aji-63	176	51	sex	sex	NOUN
aji-63	176	52	age	age	NOUN
aji-63	176	53	(	(	PUNCT
aji-63	176	54	years	year	NOUN
aji-63	176	55	)	)	PUNCT
aji-63	176	56	p	p	X
aji-63	176	57	er	er	INTJ
aji-63	176	58	ce	ce	PROPN
aji-63	176	59	n	n	X
aji-63	176	60	ta	ta	X
aji-63	176	61	g	g	PROPN
aji-63	176	62	es	es	ADP
aji-63	176	63	sallam	sallam	PROPN
aji-63	176	64	et	et	PROPN
aji-63	176	65	al	al	PROPN
aji-63	176	66	.	.	PROPN
aji-63	176	67	;	;	PUNCT
aji-63	176	68	aji	aji	PROPN
aji-63	176	69	,	,	PUNCT
aji-63	176	70	4(1	4(1	NOUN
aji-63	176	71	):	):	PUNCT
aji-63	176	72	146	146	NUM
aji-63	176	73	-	-	SYM
aji-63	176	74	153	153	NUM
aji-63	176	75	,	,	PUNCT
aji-63	176	76	2021	2021	NUM
aji-63	176	77	;	;	PUNCT
aji-63	176	78	article	article	NOUN
aji-63	176	79	no.aji.83681	no.aji.83681	VERB
aji-63	176	80	150	150	NUM
aji-63	176	81	3.1	3.1	NUM
aji-63	176	82	seropositivity	seropositivity	NOUN
aji-63	176	83	rate	rate	NOUN
aji-63	176	84	according	accord	VERB
aji-63	176	85	to	to	ADP
aji-63	176	86	antibody	antibody	NOUN
aji-63	176	87	classes	class	NOUN
aji-63	176	88	by	by	ADP
aji-63	176	89	age	age	NOUN
aji-63	176	90	and	and	CCONJ
aji-63	176	91	sex	sex	NOUN
aji-63	176	92	although	although	ADV
aji-63	176	93	,	,	PUNCT
aji-63	176	94	the	the	DET
aji-63	176	95	seropositivity	seropositivity	NOUN
aji-63	176	96	rate	rate	NOUN
aji-63	176	97	of	of	ADP
aji-63	176	98	the	the	DET
aji-63	176	99	isolated	isolated	ADJ
aji-63	176	100	anti	anti	ADJ
aji-63	176	101	-	-	ADJ
aji-63	176	102	sars	sar	NOUN
aji-63	176	103	-	-	PUNCT
aji-63	176	104	cov-2	cov-2	NOUN
aji-63	176	105	igg	igg	PROPN
aji-63	176	106	significantly	significantly	ADV
aji-63	176	107	(	(	PUNCT
aji-63	176	108	p=0.002	p=0.002	X
aji-63	176	109	)	)	PUNCT
aji-63	176	110	differs	differ	VERB
aji-63	176	111	among	among	ADP
aji-63	176	112	various	various	ADJ
aji-63	176	113	age	age	NOUN
aji-63	176	114	groups	group	NOUN
aji-63	176	115	,	,	PUNCT
aji-63	176	116	the	the	DET
aji-63	176	117	seropositivity	seropositivity	NOUN
aji-63	176	118	of	of	ADP
aji-63	176	119	the	the	DET
aji-63	176	120	igg	igg	PROPN
aji-63	176	121	and	and	CCONJ
aji-63	176	122	the	the	DET
aji-63	176	123	igm	igm	NOUN
aji-63	176	124	in	in	ADP
aji-63	176	125	combination	combination	NOUN
aji-63	176	126	or	or	CCONJ
aji-63	176	127	in	in	ADP
aji-63	176	128	isolation	isolation	NOUN
aji-63	176	129	did	do	AUX
aji-63	176	130	not	not	PART
aji-63	176	131	differ	differ	VERB
aji-63	176	132	significantly	significantly	ADV
aji-63	176	133	(	(	PUNCT
aji-63	176	134	p>0.05	p>0.05	PROPN
aji-63	176	135	)	)	PUNCT
aji-63	176	136	between	between	ADP
aji-63	176	137	males	male	NOUN
aji-63	176	138	and	and	CCONJ
aji-63	176	139	females	female	NOUN
aji-63	176	140	or	or	CCONJ
aji-63	176	141	between	between	ADP
aji-63	176	142	various	various	ADJ
aji-63	176	143	age	age	NOUN
aji-63	176	144	groups	group	NOUN
aji-63	176	145	with	with	ADP
aji-63	176	146	the	the	DET
aji-63	176	147	highest	high	ADJ
aji-63	176	148	seropositivity	seropositivity	NOUN
aji-63	176	149	rate	rate	NOUN
aji-63	176	150	detected	detect	VERB
aji-63	176	151	being	be	AUX
aji-63	176	152	among	among	ADP
aji-63	176	153	the	the	DET
aji-63	176	154	19	19	NUM
aji-63	176	155	-	-	SYM
aji-63	176	156	49	49	NUM
aji-63	176	157	years	year	NOUN
aji-63	176	158	age	age	NOUN
aji-63	176	159	group	group	NOUN
aji-63	176	160	and	and	CCONJ
aji-63	176	161	the	the	DET
aji-63	176	162	lowest	low	ADJ
aji-63	176	163	detected	detect	VERB
aji-63	176	164	was	be	AUX
aji-63	176	165	among	among	ADP
aji-63	176	166	≥65	≥65	NUM
aji-63	176	167	years	year	NOUN
aji-63	176	168	age	age	NOUN
aji-63	176	169	group	group	NOUN
aji-63	176	170	(	(	PUNCT
aji-63	176	171	table	table	NOUN
aji-63	176	172	2	2	NUM
aji-63	176	173	)	)	PUNCT
aji-63	176	174	.	.	PUNCT
aji-63	177	1	4	4	X
aji-63	177	2	.	.	X
aji-63	177	3	discussion	discussion	NOUN
aji-63	177	4	to	to	ADP
aji-63	177	5	the	the	DET
aji-63	177	6	best	good	ADJ
aji-63	177	7	of	of	ADP
aji-63	177	8	our	our	PRON
aji-63	177	9	knowledge	knowledge	NOUN
aji-63	177	10	,	,	PUNCT
aji-63	177	11	this	this	PRON
aji-63	177	12	is	be	AUX
aji-63	177	13	one	one	NUM
aji-63	177	14	of	of	ADP
aji-63	177	15	very	very	ADV
aji-63	177	16	few	few	ADJ
aji-63	177	17	studies	study	NOUN
aji-63	177	18	if	if	SCONJ
aji-63	177	19	not	not	PART
aji-63	177	20	the	the	DET
aji-63	177	21	first	first	ADJ
aji-63	177	22	on	on	ADP
aji-63	177	23	seroprevalence	seroprevalence	NOUN
aji-63	177	24	of	of	ADP
aji-63	177	25	sars	sar	NOUN
aji-63	177	26	-	-	PUNCT
aji-63	177	27	cov-2	cov-2	NOUN
aji-63	177	28	in	in	ADP
aji-63	177	29	the	the	DET
aji-63	177	30	major	major	ADJ
aji-63	177	31	city	city	NOUN
aji-63	177	32	of	of	ADP
aji-63	177	33	sana`a	sana`a	NUM
aji-63	177	34	,	,	PUNCT
aji-63	177	35	northern	northern	ADJ
aji-63	177	36	part	part	NOUN
aji-63	177	37	of	of	ADP
aji-63	177	38	yemen	yemen	PROPN
aji-63	177	39	.	.	PUNCT
aji-63	178	1	of	of	ADP
aji-63	178	2	all	all	DET
aji-63	178	3	patients	patient	NOUN
aji-63	178	4	who	who	PRON
aji-63	178	5	were	be	AUX
aji-63	178	6	suspected	suspect	VERB
aji-63	178	7	of	of	ADP
aji-63	178	8	having	have	VERB
aji-63	178	9	covid-19	covid-19	PROPN
aji-63	178	10	around	around	ADP
aji-63	178	11	half	half	NOUN
aji-63	178	12	of	of	ADP
aji-63	178	13	them	they	PRON
aji-63	178	14	had	have	VERB
aji-63	178	15	at	at	ADV
aji-63	178	16	least	least	ADV
aji-63	178	17	one	one	NUM
aji-63	178	18	antibody	antibody	NOUN
aji-63	178	19	marker	marker	NOUN
aji-63	178	20	,	,	PUNCT
aji-63	178	21	either	either	CCONJ
aji-63	178	22	igg	igg	PROPN
aji-63	178	23	or	or	CCONJ
aji-63	178	24	igm	igm	PROPN
aji-63	178	25	or	or	CCONJ
aji-63	178	26	both	both	PRON
aji-63	178	27	,	,	PUNCT
aji-63	178	28	suggesting	suggest	VERB
aji-63	178	29	exposure	exposure	NOUN
aji-63	178	30	to	to	ADP
aji-63	178	31	sars	sar	NOUN
aji-63	178	32	-	-	PUNCT
aji-63	178	33	cov-2	cov-2	PART
aji-63	178	34	infection	infection	NOUN
aji-63	178	35	.	.	PUNCT
aji-63	179	1	this	this	PRON
aji-63	179	2	is	be	AUX
aji-63	179	3	obviously	obviously	ADV
aji-63	179	4	because	because	SCONJ
aji-63	179	5	these	these	DET
aji-63	179	6	patients	patient	NOUN
aji-63	179	7	were	be	AUX
aji-63	179	8	not	not	PART
aji-63	179	9	clinically	clinically	ADV
aji-63	179	10	well	well	ADV
aji-63	179	11	characterized	characterized	ADJ
aji-63	179	12	as	as	ADP
aji-63	179	13	cases	case	NOUN
aji-63	179	14	of	of	ADP
aji-63	179	15	covid-19	covid-19	PROPN
aji-63	179	16	but	but	CCONJ
aji-63	179	17	were	be	AUX
aji-63	179	18	referred	refer	VERB
aji-63	179	19	for	for	ADP
aji-63	179	20	testing	testing	NOUN
aji-63	179	21	on	on	ADP
aji-63	179	22	suspension	suspension	NOUN
aji-63	179	23	of	of	ADP
aji-63	179	24	the	the	DET
aji-63	179	25	disease	disease	NOUN
aji-63	179	26	having	having	AUX
aji-63	179	27	presented	present	VERB
aji-63	179	28	with	with	ADP
aji-63	179	29	suggestive	suggestive	ADJ
aji-63	179	30	signs	sign	NOUN
aji-63	179	31	and	and	CCONJ
aji-63	179	32	symptoms	symptom	NOUN
aji-63	179	33	.	.	PUNCT
aji-63	180	1	this	this	PRON
aji-63	180	2	explain	explain	VERB
aji-63	180	3	the	the	DET
aji-63	180	4	lower	low	ADJ
aji-63	180	5	seroprevalence	seroprevalence	NOUN
aji-63	180	6	than	than	SCONJ
aji-63	180	7	has	have	AUX
aji-63	180	8	been	be	AUX
aji-63	180	9	reported	report	VERB
aji-63	180	10	among	among	ADP
aji-63	180	11	well	well	ADV
aji-63	180	12	characterized	characterize	VERB
aji-63	180	13	patients	patient	NOUN
aji-63	180	14	who	who	PRON
aji-63	180	15	were	be	AUX
aji-63	180	16	clinically	clinically	ADV
aji-63	180	17	diagnosed	diagnose	VERB
aji-63	180	18	with	with	ADP
aji-63	180	19	covid-19	covid-19	PROPN
aji-63	180	20	early	early	ADV
aji-63	180	21	in	in	ADP
aji-63	180	22	epidemic	epidemic	NOUN
aji-63	180	23	where	where	SCONJ
aji-63	180	24	almost	almost	ADV
aji-63	180	25	100	100	NUM
aji-63	180	26	%	%	NOUN
aji-63	180	27	became	become	VERB
aji-63	180	28	antibody	antibody	NOUN
aji-63	180	29	positive	positive	ADJ
aji-63	180	30	2	2	NUM
aji-63	180	31	to	to	PART
aji-63	180	32	3	3	NUM
aji-63	180	33	weeks	week	NOUN
aji-63	180	34	post	post	NOUN
aji-63	180	35	disease	disease	NOUN
aji-63	180	36	onset	onset	VERB
aji-63	181	1	[	[	X
aji-63	181	2	7,12	7,12	NUM
aji-63	181	3	]	]	PUNCT
aji-63	181	4	.	.	PUNCT
aji-63	182	1	however	however	ADV
aji-63	182	2	,	,	PUNCT
aji-63	182	3	owing	owe	VERB
aji-63	182	4	to	to	ADP
aji-63	182	5	the	the	DET
aji-63	182	6	attendance	attendance	NOUN
aji-63	182	7	of	of	ADP
aji-63	182	8	the	the	DET
aji-63	182	9	majority	majority	NOUN
aji-63	182	10	of	of	ADP
aji-63	182	11	the	the	DET
aji-63	182	12	cases	case	NOUN
aji-63	182	13	in	in	ADP
aji-63	182	14	a	a	DET
aji-63	182	15	single	single	ADJ
aji-63	182	16	health	health	NOUN
aji-63	182	17	care	care	NOUN
aji-63	182	18	facility	facility	NOUN
aji-63	182	19	for	for	ADP
aji-63	182	20	testing	testing	NOUN
aji-63	182	21	in	in	ADP
aji-63	182	22	only	only	ADV
aji-63	182	23	two	two	NUM
aji-63	182	24	weeks	week	NOUN
aji-63	182	25	’	'	PUNCT
aji-63	182	26	time	time	NOUN
aji-63	182	27	indicating	indicate	VERB
aji-63	182	28	the	the	DET
aji-63	182	29	peak	peak	NOUN
aji-63	182	30	of	of	ADP
aji-63	182	31	epidemic	epidemic	NOUN
aji-63	182	32	,	,	PUNCT
aji-63	182	33	the	the	DET
aji-63	182	34	contagious	contagious	ADJ
aji-63	182	35	nature	nature	NOUN
aji-63	182	36	of	of	ADP
aji-63	182	37	covid-19	covid-19	PROPN
aji-63	182	38	and	and	CCONJ
aji-63	182	39	the	the	DET
aji-63	182	40	lack	lack	NOUN
aji-63	182	41	of	of	ADP
aji-63	182	42	adequate	adequate	ADJ
aji-63	182	43	confinement	confinement	ADJ
aji-63	182	44	measures	measure	NOUN
aji-63	182	45	,	,	PUNCT
aji-63	182	46	a	a	DET
aji-63	182	47	higher	high	ADJ
aji-63	182	48	seropositive	seropositive	ADJ
aji-63	182	49	can	can	AUX
aji-63	182	50	be	be	AUX
aji-63	182	51	expected	expect	VERB
aji-63	182	52	.	.	PUNCT
aji-63	183	1	one	one	NUM
aji-63	183	2	reason	reason	NOUN
aji-63	183	3	for	for	ADP
aji-63	183	4	the	the	DET
aji-63	183	5	low	low	ADJ
aji-63	183	6	seroprevalence	seroprevalence	NOUN
aji-63	183	7	rate	rate	NOUN
aji-63	183	8	is	be	AUX
aji-63	183	9	that	that	SCONJ
aji-63	183	10	the	the	DET
aji-63	183	11	subjects	subject	NOUN
aji-63	183	12	may	may	AUX
aji-63	183	13	have	have	AUX
aji-63	183	14	produced	produce	VERB
aji-63	183	15	transient	transient	ADJ
aji-63	183	16	systemic	systemic	ADJ
aji-63	183	17	antibodies	antibody	NOUN
aji-63	183	18	because	because	SCONJ
aji-63	183	19	of	of	ADP
aji-63	183	20	less	less	ADV
aji-63	183	21	severe	severe	ADJ
aji-63	183	22	or	or	CCONJ
aji-63	183	23	mild	mild	ADJ
aji-63	183	24	infection	infection	NOUN
aji-63	183	25	.	.	PUNCT
aji-63	184	1	it	it	PRON
aji-63	184	2	has	have	AUX
aji-63	184	3	been	be	AUX
aji-63	184	4	reported	report	VERB
aji-63	184	5	that	that	SCONJ
aji-63	184	6	systemic	systemic	ADJ
aji-63	184	7	antibody	antibody	NOUN
aji-63	184	8	production	production	NOUN
aji-63	184	9	against	against	ADP
aji-63	184	10	sars	sar	NOUN
aji-63	184	11	-	-	PUNCT
aji-63	184	12	cov-2	cov-2	PART
aji-63	184	13	develops	develop	VERB
aji-63	184	14	mainly	mainly	ADV
aji-63	184	15	in	in	ADP
aji-63	184	16	severe	severe	ADJ
aji-63	184	17	covid-19	covid-19	PROPN
aji-63	184	18	,	,	PUNCT
aji-63	184	19	whereas	whereas	SCONJ
aji-63	184	20	mild	mild	ADJ
aji-63	184	21	disease	disease	NOUN
aji-63	184	22	may	may	AUX
aji-63	184	23	be	be	AUX
aji-63	184	24	associated	associate	VERB
aji-63	184	25	with	with	ADP
aji-63	184	26	transient	transient	ADJ
aji-63	184	27	serum	serum	NOUN
aji-63	184	28	antisars	antisar	NOUN
aji-63	184	29	-	-	PUNCT
aji-63	184	30	cov-2specific	cov-2specific	ADJ
aji-63	184	31	antibodies	antibody	NOUN
aji-63	184	32	[	[	X
aji-63	184	33	9	9	NUM
aji-63	184	34	]	]	PUNCT
aji-63	184	35	.	.	PUNCT
aji-63	185	1	additionally	additionally	ADV
aji-63	185	2	,	,	PUNCT
aji-63	185	3	our	our	PRON
aji-63	185	4	subjects	subject	NOUN
aji-63	185	5	may	may	AUX
aji-63	185	6	have	have	AUX
aji-63	185	7	responded	respond	VERB
aji-63	185	8	with	with	ADP
aji-63	185	9	more	more	ADV
aji-63	185	10	localized	localized	ADJ
aji-63	185	11	respiratory	respiratory	ADJ
aji-63	185	12	antibody	antibody	NOUN
aji-63	185	13	response	response	NOUN
aji-63	185	14	.	.	PUNCT
aji-63	186	1	it	it	PRON
aji-63	186	2	has	have	AUX
aji-63	186	3	been	be	AUX
aji-63	186	4	reported	report	VERB
aji-63	186	5	that	that	SCONJ
aji-63	186	6	some	some	DET
aji-63	186	7	sarscov-2	sarscov-2	ADV
aji-63	186	8	-	-	PUNCT
aji-63	186	9	exposed	expose	VERB
aji-63	186	10	cohorts	cohort	NOUN
aji-63	186	11	were	be	AUX
aji-63	186	12	negative	negative	ADJ
aji-63	186	13	for	for	ADP
aji-63	186	14	sarscov-2	sarscov-2	PRON
aji-63	186	15	-	-	PUNCT
aji-63	186	16	specific	specific	ADJ
aji-63	186	17	serum	serum	NOUN
aji-63	186	18	iga	iga	PROPN
aji-63	186	19	and	and	CCONJ
aji-63	186	20	igg	igg	PROPN
aji-63	186	21	but	but	CCONJ
aji-63	186	22	showed	show	VERB
aji-63	186	23	detectable	detectable	ADJ
aji-63	186	24	sars	sar	NOUN
aji-63	186	25	-	-	PUNCT
aji-63	186	26	cov-2	cov-2	NOUN
aji-63	186	27	-	-	PUNCT
aji-63	186	28	specific	specific	ADJ
aji-63	186	29	iga	iga	PROPN
aji-63	186	30	in	in	ADP
aji-63	186	31	nasal	nasal	NOUN
aji-63	186	32	fluids	fluid	NOUN
aji-63	186	33	and	and	CCONJ
aji-63	186	34	tears	tear	NOUN
aji-63	186	35	without	without	ADP
aji-63	186	36	serum	serum	NOUN
aji-63	186	37	antibody	antibody	NOUN
aji-63	186	38	response	response	NOUN
aji-63	187	1	[	[	X
aji-63	187	2	9	9	NUM
aji-63	187	3	]	]	PUNCT
aji-63	187	4	.	.	PUNCT
aji-63	188	1	additionally	additionally	ADV
aji-63	188	2	symptomatic	symptomatic	ADJ
aji-63	188	3	patients	patient	NOUN
aji-63	188	4	who	who	PRON
aji-63	188	5	may	may	AUX
aji-63	188	6	not	not	PART
aji-63	188	7	seroconvert	seroconvert	VERB
aji-63	188	8	despite	despite	SCONJ
aji-63	188	9	developing	develop	VERB
aji-63	188	10	persisting	persist	VERB
aji-63	188	11	t	t	NOUN
aji-63	188	12	cell	cell	NOUN
aji-63	188	13	responses	response	NOUN
aji-63	188	14	have	have	AUX
aji-63	188	15	also	also	ADV
aji-63	188	16	been	be	AUX
aji-63	188	17	reported	report	VERB
aji-63	188	18	[	[	X
aji-63	188	19	7	7	NUM
aji-63	188	20	]	]	PUNCT
aji-63	188	21	.	.	PUNCT
aji-63	189	1	several	several	ADJ
aji-63	189	2	reports	report	NOUN
aji-63	189	3	have	have	AUX
aji-63	189	4	shown	show	VERB
aji-63	189	5	underestimated	underestimated	ADJ
aji-63	189	6	seroprevalence	seroprevalence	NOUN
aji-63	189	7	when	when	SCONJ
aji-63	189	8	investigation	investigation	NOUN
aji-63	189	9	was	be	AUX
aji-63	189	10	based	base	VERB
aji-63	189	11	on	on	ADP
aji-63	189	12	igm	igm	PROPN
aji-63	189	13	and	and	CCONJ
aji-63	189	14	igg	igg	PROPN
aji-63	189	15	alone	alone	ADV
aji-63	190	1	[	[	X
aji-63	190	2	20	20	NUM
aji-63	190	3	]	]	PUNCT
aji-63	190	4	.	.	PUNCT
aji-63	191	1	over	over	ADP
aji-63	191	2	70	70	NUM
aji-63	191	3	%	%	NOUN
aji-63	191	4	of	of	ADP
aji-63	191	5	our	our	PRON
aji-63	191	6	seropositive	seropositive	ADJ
aji-63	191	7	subjects	subject	NOUN
aji-63	191	8	were	be	AUX
aji-63	191	9	below	below	ADP
aji-63	191	10	the	the	DET
aji-63	191	11	age	age	NOUN
aji-63	191	12	of	of	ADP
aji-63	191	13	50	50	NUM
aji-63	191	14	years	year	NOUN
aji-63	191	15	,	,	PUNCT
aji-63	191	16	which	which	PRON
aji-63	191	17	reflects	reflect	VERB
aji-63	191	18	the	the	DET
aji-63	191	19	main	main	ADJ
aji-63	191	20	age	age	NOUN
aji-63	191	21	stratum	stratum	NOUN
aji-63	191	22	of	of	ADP
aji-63	191	23	the	the	DET
aji-63	191	24	yemeni	yemeni	ADJ
aji-63	191	25	population	population	NOUN
aji-63	191	26	(	(	PUNCT
aji-63	191	27	<	<	X
aji-63	191	28	50	50	NUM
aji-63	191	29	years	year	NOUN
aji-63	191	30	)	)	PUNCT
aji-63	191	31	constituting	constitute	VERB
aji-63	191	32	90	90	NUM
aji-63	191	33	%	%	NOUN
aji-63	191	34	of	of	ADP
aji-63	191	35	the	the	DET
aji-63	191	36	population	population	NOUN
aji-63	192	1	[	[	X
aji-63	192	2	23	23	NUM
aji-63	192	3	]	]	PUNCT
aji-63	192	4	,	,	PUNCT
aji-63	192	5	rather	rather	ADV
aji-63	192	6	than	than	ADP
aji-63	192	7	suggests	suggest	VERB
aji-63	192	8	that	that	SCONJ
aji-63	192	9	this	this	DET
aji-63	192	10	age	age	NOUN
aji-63	192	11	groups	group	NOUN
aji-63	192	12	were	be	AUX
aji-63	192	13	particularly	particularly	ADV
aji-63	192	14	susceptible	susceptible	ADJ
aji-63	192	15	.	.	PUNCT
aji-63	193	1	the	the	DET
aji-63	193	2	low	low	ADJ
aji-63	193	3	seroprevalence	seroprevalence	NOUN
aji-63	193	4	among	among	ADP
aji-63	193	5	those	those	DET
aji-63	193	6	3	3	NUM
aji-63	193	7	-	-	SYM
aji-63	193	8	18	18	NUM
aji-63	193	9	years	year	NOUN
aji-63	193	10	may	may	AUX
aji-63	193	11	reflect	reflect	VERB
aji-63	193	12	the	the	DET
aji-63	193	13	mild	mild	ADJ
aji-63	193	14	or	or	CCONJ
aji-63	193	15	asymptomatic	asymptomatic	ADJ
aji-63	193	16	infection	infection	NOUN
aji-63	193	17	that	that	PRON
aji-63	193	18	usually	usually	ADV
aji-63	193	19	occur	occur	VERB
aji-63	193	20	in	in	ADP
aji-63	193	21	this	this	DET
aji-63	193	22	age	age	NOUN
aji-63	193	23	group	group	NOUN
aji-63	193	24	and	and	CCONJ
aji-63	193	25	thus	thus	ADV
aji-63	193	26	do	do	AUX
aji-63	193	27	not	not	PART
aji-63	193	28	seek	seek	VERB
aji-63	193	29	health	health	NOUN
aji-63	193	30	care	care	NOUN
aji-63	193	31	.	.	PUNCT
aji-63	194	1	various	various	ADJ
aji-63	194	2	reports	report	NOUN
aji-63	194	3	have	have	AUX
aji-63	194	4	shown	show	VERB
aji-63	194	5	that	that	SCONJ
aji-63	194	6	less	less	ADJ
aji-63	194	7	children	child	NOUN
aji-63	194	8	(	(	PUNCT
aji-63	194	9	<	<	X
aji-63	194	10	18	18	NUM
aji-63	194	11	years	year	NOUN
aji-63	194	12	)	)	PUNCT
aji-63	194	13	than	than	ADP
aji-63	194	14	adults	adult	NOUN
aji-63	194	15	presented	present	VERB
aji-63	194	16	with	with	ADP
aji-63	194	17	mild	mild	ADJ
aji-63	194	18	to	to	ADP
aji-63	194	19	less	less	ADV
aji-63	194	20	severe	severe	ADJ
aji-63	194	21	and	and	CCONJ
aji-63	194	22	lower	low	ADJ
aji-63	194	23	death	death	NOUN
aji-63	194	24	rate	rate	NOUN
aji-63	194	25	[	[	X
aji-63	194	26	24	24	NUM
aji-63	194	27	-	-	SYM
aji-63	194	28	26	26	NUM
aji-63	194	29	]	]	PUNCT
aji-63	194	30	.	.	PUNCT
aji-63	195	1	the	the	DET
aji-63	195	2	attendance	attendance	NOUN
aji-63	195	3	of	of	ADP
aji-63	195	4	small	small	ADJ
aji-63	195	5	proportion	proportion	NOUN
aji-63	195	6	of	of	ADP
aji-63	195	7	our	our	PRON
aji-63	195	8	subjects	subject	NOUN
aji-63	195	9	of	of	ADP
aji-63	195	10	this	this	DET
aji-63	195	11	age	age	NOUN
aji-63	195	12	for	for	ADP
aji-63	195	13	testing	test	VERB
aji-63	195	14	further	far	ADV
aji-63	195	15	supports	support	VERB
aji-63	195	16	this	this	DET
aji-63	195	17	inference	inference	NOUN
aji-63	195	18	.	.	PUNCT
aji-63	196	1	the	the	DET
aji-63	196	2	low	low	ADJ
aji-63	196	3	level	level	NOUN
aji-63	196	4	of	of	ADP
aji-63	196	5	sars	sar	NOUN
aji-63	196	6	-	-	PUNCT
aji-63	196	7	cov-2	cov-2	NOUN
aji-63	196	8	infection	infection	NOUN
aji-63	196	9	among	among	ADP
aji-63	196	10	children	child	NOUN
aji-63	196	11	has	have	AUX
aji-63	196	12	been	be	AUX
aji-63	196	13	explained	explain	VERB
aji-63	196	14	by	by	ADP
aji-63	196	15	the	the	DET
aji-63	196	16	less	less	ADV
aji-63	196	17	expressed	expressed	ADJ
aji-63	196	18	angiotensin	angiotensin	NOUN
aji-63	196	19	-	-	PUNCT
aji-63	196	20	converting	convert	VERB
aji-63	196	21	enzyme	enzyme	NOUN
aji-63	196	22	2	2	NUM
aji-63	196	23	(	(	PUNCT
aji-63	196	24	ace2	ace2	NOUN
aji-63	196	25	)	)	PUNCT
aji-63	196	26	receptor	receptor	NOUN
aji-63	196	27	of	of	ADP
aji-63	196	28	the	the	DET
aji-63	196	29	virus	virus	NOUN
aji-63	196	30	,	,	PUNCT
aji-63	196	31	better	well	ADJ
aji-63	196	32	containment	containment	NOUN
aji-63	196	33	of	of	ADP
aji-63	196	34	the	the	DET
aji-63	196	35	virus	virus	NOUN
aji-63	196	36	in	in	ADP
aji-63	196	37	the	the	DET
aji-63	196	38	upper	upper	ADJ
aji-63	196	39	tract	tract	NOUN
aji-63	196	40	or	or	CCONJ
aji-63	196	41	to	to	ADP
aji-63	196	42	the	the	DET
aji-63	196	43	less	less	ADV
aji-63	196	44	adverse	adverse	ADJ
aji-63	196	45	immune	immune	ADJ
aji-63	196	46	mechanisms	mechanism	NOUN
aji-63	196	47	arising	arise	VERB
aji-63	196	48	from	from	ADP
aji-63	196	49	infection	infection	NOUN
aji-63	196	50	in	in	ADP
aji-63	196	51	<	<	X
aji-63	196	52	18	18	NUM
aji-63	196	53	years	year	NOUN
aji-63	196	54	than	than	ADP
aji-63	196	55	in	in	ADP
aji-63	196	56	adults	adult	NOUN
aji-63	196	57	[	[	X
aji-63	196	58	22	22	NUM
aji-63	196	59	]	]	PUNCT
aji-63	196	60	.	.	PUNCT
aji-63	197	1	among	among	ADP
aji-63	197	2	our	our	PRON
aji-63	197	3	subjects	subject	NOUN
aji-63	197	4	less	less	ADJ
aji-63	197	5	females	female	NOUN
aji-63	197	6	than	than	ADP
aji-63	197	7	males	male	NOUN
aji-63	197	8	presented	present	VERB
aji-63	197	9	for	for	ADP
aji-63	197	10	testing	testing	NOUN
aji-63	197	11	which	which	PRON
aji-63	197	12	could	could	AUX
aji-63	197	13	suggests	suggest	VERB
aji-63	197	14	low	low	ADJ
aji-63	197	15	exposure	exposure	NOUN
aji-63	197	16	among	among	ADP
aji-63	197	17	females	female	NOUN
aji-63	197	18	.	.	PUNCT
aji-63	198	1	however	however	ADV
aji-63	198	2	this	this	PRON
aji-63	198	3	possibly	possibly	ADV
aji-63	198	4	because	because	SCONJ
aji-63	198	5	of	of	ADP
aji-63	198	6	stay	stay	VERB
aji-63	198	7	-	-	PUNCT
aji-63	198	8	at	at	ADP
aji-63	198	9	-	-	PUNCT
aji-63	198	10	home	home	NOUN
aji-63	198	11	custom	custom	NOUN
aji-63	198	12	of	of	ADP
aji-63	198	13	yemeni	yemeni	ADJ
aji-63	198	14	women	woman	NOUN
aji-63	198	15	rather	rather	ADV
aji-63	198	16	than	than	ADP
aji-63	198	17	due	due	ADJ
aji-63	198	18	to	to	ADP
aji-63	198	19	low	low	ADJ
aji-63	198	20	susceptibility	susceptibility	NOUN
aji-63	198	21	to	to	ADP
aji-63	198	22	infection	infection	NOUN
aji-63	198	23	among	among	ADP
aji-63	198	24	females	female	NOUN
aji-63	198	25	.	.	PUNCT
aji-63	199	1	supporting	support	VERB
aji-63	199	2	this	this	PRON
aji-63	199	3	is	be	AUX
aji-63	199	4	the	the	DET
aji-63	199	5	seroprevalence	seroprevalence	NOUN
aji-63	199	6	rate	rate	NOUN
aji-63	199	7	among	among	ADP
aji-63	199	8	females	female	NOUN
aji-63	199	9	which	which	PRON
aji-63	199	10	did	do	AUX
aji-63	199	11	not	not	PART
aji-63	199	12	significantly	significantly	ADV
aji-63	199	13	differ	differ	VERB
aji-63	199	14	from	from	ADP
aji-63	199	15	that	that	PRON
aji-63	199	16	among	among	ADP
aji-63	199	17	males	male	NOUN
aji-63	199	18	indicating	indicate	VERB
aji-63	199	19	equal	equal	ADJ
aji-63	199	20	risk	risk	NOUN
aji-63	199	21	of	of	ADP
aji-63	199	22	infection	infection	NOUN
aji-63	199	23	.	.	PUNCT
aji-63	200	1	small	small	ADJ
aji-63	200	2	minority	minority	NOUN
aji-63	200	3	of	of	ADP
aji-63	200	4	seropositive	seropositive	ADJ
aji-63	200	5	subjects	subject	NOUN
aji-63	200	6	(	(	PUNCT
aji-63	200	7	2.3	2.3	NUM
aji-63	200	8	%	%	NOUN
aji-63	200	9	)	)	PUNCT
aji-63	200	10	had	have	VERB
aji-63	200	11	an	an	DET
aji-63	200	12	isolated	isolate	VERB
aji-63	200	13	igm	igm	NOUN
aji-63	200	14	and	and	CCONJ
aji-63	200	15	18.9	18.9	NUM
aji-63	200	16	%	%	NOUN
aji-63	200	17	had	have	AUX
aji-63	200	18	isolated	isolate	VERB
aji-63	200	19	igg	igg	NOUN
aji-63	200	20	while	while	SCONJ
aji-63	200	21	over	over	ADP
aji-63	200	22	30	30	NUM
aji-63	200	23	%	%	NOUN
aji-63	200	24	had	have	VERB
aji-63	200	25	concurrent	concurrent	ADJ
aji-63	200	26	igm	igm	NOUN
aji-63	200	27	and	and	CCONJ
aji-63	200	28	igg	igg	PROPN
aji-63	200	29	.	.	PUNCT
aji-63	201	1	this	this	PRON
aji-63	201	2	could	could	AUX
aji-63	201	3	suggest	suggest	VERB
aji-63	201	4	the	the	DET
aji-63	201	5	narrow	narrow	ADJ
aji-63	201	6	window	window	NOUN
aji-63	201	7	period	period	NOUN
aji-63	201	8	of	of	ADP
aji-63	201	9	the	the	DET
aji-63	201	10	antibody	antibody	NOUN
aji-63	201	11	class	class	NOUN
aji-63	201	12	switching	switch	VERB
aji-63	201	13	from	from	ADP
aji-63	201	14	igm	igm	PROPN
aji-63	201	15	to	to	ADP
aji-63	201	16	igg	igg	NOUN
aji-63	201	17	making	make	VERB
aji-63	201	18	it	it	PRON
aji-63	201	19	difficult	difficult	ADJ
aji-63	201	20	to	to	PART
aji-63	201	21	detect	detect	VERB
aji-63	201	22	patients	patient	NOUN
aji-63	201	23	with	with	ADP
aji-63	201	24	isolated	isolated	ADJ
aji-63	201	25	igm	igm	NOUN
aji-63	201	26	and	and	CCONJ
aji-63	201	27	to	to	ADP
aji-63	201	28	less	less	ADJ
aji-63	201	29	extent	extent	NOUN
aji-63	201	30	isolated	isolate	VERB
aji-63	201	31	igg	igg	PROPN
aji-63	201	32	.	.	PUNCT
aji-63	202	1	the	the	DET
aji-63	202	2	possibility	possibility	NOUN
aji-63	202	3	of	of	ADP
aji-63	202	4	simultaneous	simultaneous	ADJ
aji-63	202	5	occurrence	occurrence	NOUN
aji-63	202	6	of	of	ADP
aji-63	202	7	both	both	DET
aji-63	202	8	antibody	antibody	NOUN
aji-63	202	9	classes	class	NOUN
aji-63	202	10	can	can	AUX
aji-63	202	11	not	not	PART
aji-63	202	12	be	be	AUX
aji-63	202	13	excluded	exclude	VERB
aji-63	202	14	as	as	ADP
aji-63	202	15	simultaneous	simultaneous	ADJ
aji-63	202	16	appearance	appearance	NOUN
aji-63	202	17	of	of	ADP
aji-63	202	18	both	both	DET
aji-63	202	19	antibody	antibody	NOUN
aji-63	202	20	classes	class	NOUN
aji-63	202	21	in	in	ADP
aji-63	202	22	some	some	PRON
aji-63	202	23	of	of	ADP
aji-63	202	24	sars	sar	NOUN
aji-63	202	25	-	-	PUNCT
aji-63	202	26	cov-2	cov-2	PART
aji-63	202	27	infected	infected	ADJ
aji-63	202	28	subjects	subject	NOUN
aji-63	202	29	has	have	AUX
aji-63	202	30	been	be	AUX
aji-63	202	31	reported	report	VERB
aji-63	202	32	elsewhere	elsewhere	ADV
aji-63	202	33	[	[	X
aji-63	202	34	7,9,10,12	7,9,10,12	PROPN
aji-63	202	35	-	-	ADJ
aji-63	202	36	22,25	22,25	NUM
aji-63	202	37	-	-	PUNCT
aji-63	202	38	31	31	NUM
aji-63	202	39	]	]	PUNCT
aji-63	202	40	furthermore	furthermore	ADV
aji-63	202	41	,	,	PUNCT
aji-63	202	42	3	3	NUM
aji-63	202	43	patterns	pattern	NOUN
aji-63	202	44	of	of	ADP
aji-63	202	45	sars	sar	NOUN
aji-63	202	46	-	-	PUNCT
aji-63	202	47	cov-2	cov-2	PART
aji-63	202	48	seroconversion	seroconversion	NOUN
aji-63	202	49	have	have	AUX
aji-63	202	50	been	be	AUX
aji-63	202	51	proposed	propose	VERB
aji-63	202	52	so	so	ADV
aji-63	202	53	far	far	ADV
aji-63	202	54	.	.	PUNCT
aji-63	203	1	these	these	PRON
aji-63	203	2	include	include	VERB
aji-63	203	3	sequential	sequential	ADJ
aji-63	203	4	seroconversion	seroconversion	NOUN
aji-63	203	5	of	of	ADP
aji-63	203	6	igm	igm	PROPN
aji-63	203	7	followed	follow	VERB
aji-63	203	8	by	by	ADP
aji-63	203	9	igg	igg	PROPN
aji-63	203	10	,	,	PUNCT
aji-63	203	11	concurrent	concurrent	ADJ
aji-63	203	12	seroconversion	seroconversion	NOUN
aji-63	203	13	of	of	ADP
aji-63	203	14	both	both	DET
aji-63	203	15	igg	igg	PROPN
aji-63	203	16	and	and	CCONJ
aji-63	203	17	igm	igm	PROPN
aji-63	203	18	,	,	PUNCT
aji-63	203	19	and	and	CCONJ
aji-63	203	20	an	an	DET
aji-63	203	21	unusual	unusual	ADJ
aji-63	203	22	pattern	pattern	NOUN
aji-63	203	23	of	of	ADP
aji-63	203	24	igg	igg	PROPN
aji-63	203	25	preceding	precede	VERB
aji-63	203	26	igm	igm	PROPN
aji-63	203	27	[	[	X
aji-63	203	28	30	30	NUM
aji-63	203	29	]	]	PUNCT
aji-63	203	30	.	.	PUNCT
aji-63	204	1	this	this	PRON
aji-63	204	2	probably	probably	ADV
aji-63	204	3	reflects	reflect	VERB
aji-63	204	4	the	the	DET
aji-63	204	5	variation	variation	NOUN
aji-63	204	6	in	in	ADP
aji-63	204	7	different	different	ADJ
aji-63	204	8	serological	serological	ADJ
aji-63	204	9	assays	assay	NOUN
aji-63	204	10	.	.	PUNCT
aji-63	205	1	therefore	therefore	ADV
aji-63	205	2	,	,	PUNCT
aji-63	205	3	validation	validation	NOUN
aji-63	205	4	and	and	CCONJ
aji-63	205	5	standardization	standardization	NOUN
aji-63	205	6	of	of	ADP
aji-63	205	7	sallam	sallam	PROPN
aji-63	205	8	et	et	PROPN
aji-63	205	9	al	al	PROPN
aji-63	205	10	.	.	PROPN
aji-63	205	11	;	;	PUNCT
aji-63	205	12	aji	aji	PROPN
aji-63	205	13	,	,	PUNCT
aji-63	205	14	4(1	4(1	NOUN
aji-63	205	15	):	):	PUNCT
aji-63	205	16	146	146	NUM
aji-63	205	17	-	-	SYM
aji-63	205	18	153	153	NUM
aji-63	205	19	,	,	PUNCT
aji-63	205	20	2021	2021	NUM
aji-63	205	21	;	;	PUNCT
aji-63	205	22	article	article	NOUN
aji-63	205	23	no.aji.83681	no.aji.83681	VERB
aji-63	205	24	151	151	NUM
aji-63	205	25	sars	sar	NOUN
aji-63	205	26	-	-	PUNCT
aji-63	205	27	cov-2	cov-2	NOUN
aji-63	205	28	serologic	serologic	NOUN
aji-63	205	29	assays	assay	NOUN
aji-63	205	30	in	in	ADP
aji-63	205	31	large	large	ADJ
aji-63	205	32	clinical	clinical	ADJ
aji-63	205	33	cohort	cohort	NOUN
aji-63	205	34	is	be	AUX
aji-63	205	35	required	require	VERB
aji-63	205	36	before	before	ADP
aji-63	205	37	coming	come	VERB
aji-63	205	38	to	to	ADP
aji-63	205	39	a	a	DET
aji-63	205	40	final	final	ADJ
aji-63	205	41	inference	inference	NOUN
aji-63	205	42	of	of	ADP
aji-63	205	43	serological	serological	ADJ
aji-63	205	44	dynamic	dynamic	NOUN
aji-63	205	45	of	of	ADP
aji-63	205	46	sars	sar	NOUN
aji-63	205	47	-	-	PUNCT
aji-63	205	48	cov-2	cov-2	NOUN
aji-63	205	49	.	.	PUNCT
aji-63	206	1	majority	majority	NOUN
aji-63	206	2	of	of	ADP
aji-63	206	3	our	our	PRON
aji-63	206	4	subjects	subject	NOUN
aji-63	206	5	with	with	ADP
aji-63	206	6	isolated	isolated	ADJ
aji-63	206	7	igm	igm	NOUN
aji-63	206	8	were	be	AUX
aji-63	206	9	females	female	NOUN
aji-63	206	10	(	(	PUNCT
aji-63	206	11	83	83	NUM
aji-63	206	12	%	%	NOUN
aji-63	206	13	)	)	PUNCT
aji-63	206	14	.	.	PUNCT
aji-63	207	1	the	the	DET
aji-63	207	2	significance	significance	NOUN
aji-63	207	3	of	of	ADP
aji-63	207	4	this	this	PRON
aji-63	207	5	is	be	AUX
aji-63	207	6	difficult	difficult	ADJ
aji-63	207	7	to	to	PART
aji-63	207	8	point	point	VERB
aji-63	207	9	out	out	ADP
aji-63	207	10	due	due	ADP
aji-63	207	11	to	to	ADP
aji-63	207	12	the	the	DET
aji-63	207	13	small	small	ADJ
aji-63	207	14	sample	sample	NOUN
aji-63	207	15	size	size	NOUN
aji-63	207	16	(	(	PUNCT
aji-63	207	17	6	6	NUM
aji-63	207	18	subjects	subject	NOUN
aji-63	207	19	)	)	PUNCT
aji-63	207	20	.	.	PUNCT
aji-63	208	1	however	however	ADV
aji-63	208	2	,	,	PUNCT
aji-63	208	3	this	this	DET
aji-63	208	4	merit	merit	NOUN
aji-63	208	5	further	further	ADJ
aji-63	208	6	investigation	investigation	NOUN
aji-63	208	7	.	.	PUNCT
aji-63	209	1	5	5	X
aji-63	209	2	.	.	X
aji-63	209	3	conclusions	conclusion	NOUN
aji-63	209	4	among	among	ADP
aji-63	209	5	subjects	subject	NOUN
aji-63	209	6	with	with	ADP
aji-63	209	7	suspected	suspect	VERB
aji-63	209	8	covid-19	covid-19	PROPN
aji-63	209	9	over	over	ADP
aji-63	209	10	30	30	NUM
aji-63	209	11	%	%	NOUN
aji-63	209	12	had	have	VERB
aji-63	209	13	concomitant	concomitant	ADJ
aji-63	209	14	igm	igm	NOUN
aji-63	209	15	and	and	CCONJ
aji-63	209	16	igg	igg	PROPN
aji-63	209	17	with	with	ADP
aji-63	209	18	minority	minority	NOUN
aji-63	209	19	having	have	VERB
aji-63	209	20	isolated	isolate	VERB
aji-63	209	21	igm	igm	NOUN
aji-63	209	22	or	or	CCONJ
aji-63	209	23	igg	igg	PROPN
aji-63	209	24	suggesting	suggest	VERB
aji-63	209	25	concomitant	concomitant	ADJ
aji-63	209	26	or	or	CCONJ
aji-63	209	27	close	close	ADJ
aji-63	209	28	seroconversion	seroconversion	NOUN
aji-63	209	29	time	time	NOUN
aji-63	209	30	point	point	NOUN
aji-63	209	31	of	of	ADP
aji-63	209	32	both	both	DET
aji-63	209	33	antibody	antibody	NOUN
aji-63	209	34	classes	class	NOUN
aji-63	209	35	.	.	PUNCT
aji-63	210	1	in	in	ADP
aji-63	210	2	addition	addition	NOUN
aji-63	210	3	,	,	PUNCT
aji-63	210	4	around	around	ADP
aji-63	210	5	50	50	NUM
aji-63	210	6	%	%	NOUN
aji-63	210	7	of	of	ADP
aji-63	210	8	subjects	subject	NOUN
aji-63	210	9	were	be	AUX
aji-63	210	10	sars	sar	NOUN
aji-63	210	11	-	-	PUNCT
aji-63	210	12	cov-2	cov-2	PART
aji-63	210	13	seropositive	seropositive	ADJ
aji-63	210	14	suggestion	suggestion	NOUN
aji-63	210	15	low	low	ADJ
aji-63	210	16	sars	sar	NOUN
aji-63	210	17	-	-	PUNCT
aji-63	210	18	cov-2	cov-2	NOUN
aji-63	210	19	seroconversion	seroconversion	NOUN
aji-63	210	20	and	and	CCONJ
aji-63	210	21	consequently	consequently	ADV
aji-63	210	22	low	low	ADJ
aji-63	210	23	community	community	NOUN
aji-63	210	24	sars	sar	NOUN
aji-63	210	25	-	-	PUNCT
aji-63	210	26	cov-2	cov-2	NOUN
aji-63	210	27	seroprevalence	seroprevalence	NOUN
aji-63	210	28	in	in	ADP
aji-63	210	29	yemen	yemen	PROPN
aji-63	210	30	.	.	PUNCT
aji-63	211	1	as	as	SCONJ
aji-63	211	2	the	the	DET
aji-63	211	3	systemic	systemic	ADJ
aji-63	211	4	immune	immune	ADJ
aji-63	211	5	response	response	NOUN
aji-63	211	6	to	to	ADP
aji-63	211	7	sars	sar	NOUN
aji-63	211	8	-	-	PUNCT
aji-63	211	9	cov-2	cov-2	PART
aji-63	211	10	currently	currently	ADV
aji-63	211	11	is	be	AUX
aji-63	211	12	not	not	PART
aji-63	211	13	well	well	ADV
aji-63	211	14	established	establish	VERB
aji-63	211	15	,	,	PUNCT
aji-63	211	16	the	the	DET
aji-63	211	17	seroprevalence	seroprevalence	NOUN
aji-63	211	18	of	of	ADP
aji-63	211	19	sars	sar	NOUN
aji-63	211	20	-	-	PUNCT
aji-63	211	21	cov-2	cov-2	NUM
aji-63	211	22	can	can	AUX
aji-63	211	23	not	not	PART
aji-63	211	24	be	be	AUX
aji-63	211	25	reliably	reliably	ADV
aji-63	211	26	determined	determined	ADJ
aji-63	211	27	hence	hence	ADV
aji-63	211	28	herd	herd	ADJ
aji-63	211	29	immunity	immunity	NOUN
aji-63	211	30	seems	seem	VERB
aji-63	211	31	to	to	PART
aji-63	211	32	be	be	AUX
aji-63	211	33	hard	hard	ADJ
aji-63	211	34	to	to	PART
aji-63	211	35	establish	establish	VERB
aji-63	211	36	at	at	ADP
aji-63	211	37	this	this	DET
aji-63	211	38	stage	stage	NOUN
aji-63	211	39	.	.	PUNCT
aji-63	212	1	a	a	DET
aji-63	212	2	large	large	ADJ
aji-63	212	3	-	-	PUNCT
aji-63	212	4	scale	scale	NOUN
aji-63	212	5	community	community	NOUN
aji-63	212	6	based	base	VERB
aji-63	212	7	seroprevalence	seroprevalence	NOUN
aji-63	212	8	study	study	NOUN
aji-63	212	9	based	base	VERB
aji-63	212	10	on	on	ADP
aji-63	212	11	detection	detection	NOUN
aji-63	212	12	of	of	ADP
aji-63	212	13	combination	combination	NOUN
aji-63	212	14	of	of	ADP
aji-63	212	15	igm	igm	PROPN
aji-63	212	16	,	,	PUNCT
aji-63	212	17	igg	igg	PROPN
aji-63	212	18	,	,	PUNCT
aji-63	212	19	and	and	CCONJ
aji-63	212	20	iga	iga	PROPN
aji-63	212	21	seems	seem	VERB
aji-63	212	22	essential	essential	ADJ
aji-63	212	23	to	to	PART
aji-63	212	24	determine	determine	VERB
aji-63	212	25	the	the	DET
aji-63	212	26	magnitude	magnitude	NOUN
aji-63	212	27	of	of	ADP
aji-63	212	28	sarscov-2	sarscov-2	NUM
aji-63	212	29	infection	infection	NOUN
aji-63	212	30	in	in	ADP
aji-63	212	31	yemen	yemen	PROPN
aji-63	212	32	.	.	PUNCT
aji-63	213	1	antibody	antibody	NOUN
aji-63	213	2	response	response	NOUN
aji-63	213	3	study	study	NOUN
aji-63	213	4	based	base	VERB
aji-63	213	5	on	on	ADP
aji-63	213	6	will	will	AUX
aji-63	213	7	characterized	characterize	VERB
aji-63	213	8	covid-19	covid-19	PROPN
aji-63	213	9	patients	patient	NOUN
aji-63	213	10	is	be	AUX
aji-63	213	11	also	also	ADV
aji-63	213	12	required	require	VERB
aji-63	213	13	.	.	PUNCT
aji-63	214	1	consent	consent	NOUN
aji-63	214	2	data	datum	NOUN
aji-63	214	3	presented	present	VERB
aji-63	214	4	in	in	ADP
aji-63	214	5	this	this	DET
aji-63	214	6	study	study	NOUN
aji-63	214	7	were	be	AUX
aji-63	214	8	obtained	obtain	VERB
aji-63	214	9	in	in	ADP
aji-63	214	10	an	an	DET
aji-63	214	11	informed	informed	ADJ
aji-63	214	12	consent	consent	NOUN
aji-63	214	13	with	with	ADP
aji-63	214	14	a	a	DET
aji-63	214	15	clear	clear	ADJ
aji-63	214	16	declaration	declaration	NOUN
aji-63	214	17	on	on	ADP
aji-63	214	18	the	the	DET
aji-63	214	19	confidentiality	confidentiality	NOUN
aji-63	214	20	of	of	ADP
aji-63	214	21	the	the	DET
aji-63	214	22	obtained	obtain	VERB
aji-63	214	23	data	datum	NOUN
aji-63	214	24	and	and	CCONJ
aji-63	214	25	will	will	AUX
aji-63	214	26	not	not	PART
aji-63	214	27	be	be	AUX
aji-63	214	28	used	use	VERB
aji-63	214	29	out	out	ADP
aji-63	214	30	of	of	ADP
aji-63	214	31	the	the	DET
aji-63	214	32	research	research	NOUN
aji-63	214	33	dimension	dimension	NOUN
aji-63	214	34	.	.	PUNCT
aji-63	215	1	ethical	ethical	ADJ
aji-63	215	2	approval	approval	NOUN
aji-63	215	3	this	this	DET
aji-63	215	4	study	study	NOUN
aji-63	215	5	attested	attest	VERB
aji-63	215	6	and	and	CCONJ
aji-63	215	7	approved	approve	VERB
aji-63	215	8	(	(	PUNCT
aji-63	215	9	#	#	NOUN
aji-63	215	10	rec-772020	rec-772020	NOUN
aji-63	215	11	)	)	PUNCT
aji-63	215	12	by	by	ADP
aji-63	215	13	relevant	relevant	ADJ
aji-63	215	14	academic	academic	ADJ
aji-63	215	15	institution	institution	NOUN
aji-63	215	16	.	.	PUNCT
aji-63	216	1	acknowledgments	acknowledgment	NOUN
aji-63	216	2	the	the	DET
aji-63	216	3	authors	author	NOUN
aji-63	216	4	are	be	AUX
aji-63	216	5	grateful	grateful	ADJ
aji-63	216	6	to	to	ADP
aji-63	216	7	mr	mr	PROPN
aji-63	216	8	.	.	PROPN
aji-63	216	9	mohammad	mohammad	PROPN
aji-63	216	10	bamashmoos	bamashmoo	VERB
aji-63	216	11	at	at	ADP
aji-63	216	12	the	the	DET
aji-63	216	13	alyoussefi	alyoussefi	NOUN
aji-63	216	14	specialized	specialized	ADJ
aji-63	216	15	laboratories	laboratory	NOUN
aji-63	216	16	for	for	ADP
aji-63	216	17	his	his	PRON
aji-63	216	18	efforts	effort	NOUN
aji-63	216	19	in	in	ADP
aji-63	216	20	the	the	DET
aji-63	216	21	data	datum	NOUN
aji-63	216	22	collection	collection	NOUN
aji-63	216	23	.	.	PUNCT
aji-63	217	1	competing	compete	VERB
aji-63	217	2	interests	interest	NOUN
aji-63	217	3	authors	author	NOUN
aji-63	217	4	have	have	AUX
aji-63	217	5	declared	declare	VERB
aji-63	217	6	that	that	SCONJ
aji-63	217	7	no	no	DET
aji-63	217	8	competing	compete	VERB
aji-63	217	9	interests	interest	NOUN
aji-63	217	10	exist	exist	VERB
aji-63	217	11	.	.	PUNCT
aji-63	218	1	references	reference	NOUN
aji-63	218	2	1	1	NUM
aji-63	218	3	.	.	PUNCT
aji-63	219	1	xiang	xiang	PROPN
aji-63	219	2	f	f	PROPN
aji-63	219	3	,	,	PUNCT
aji-63	219	4	wang	wang	PROPN
aji-63	219	5	x	x	PROPN
aji-63	219	6	,	,	PUNCT
aji-63	219	7	he	he	PRON
aji-63	219	8	x	x	NOUN
aji-63	219	9	,	,	PUNCT
aji-63	219	10	et	et	PROPN
aji-63	219	11	al	al	PROPN
aji-63	219	12	.	.	PUNCT
aji-63	219	13	antibody	antibody	NOUN
aji-63	219	14	detection	detection	NOUN
aji-63	219	15	and	and	CCONJ
aji-63	219	16	dynamic	dynamic	ADJ
aji-63	219	17	characteristics	characteristic	NOUN
aji-63	219	18	in	in	ADP
aji-63	219	19	patients	patient	NOUN
aji-63	219	20	with	with	ADP
aji-63	219	21	covid-19	covid-19	PROPN
aji-63	219	22	.	.	PUNCT
aji-63	220	1	clinical	clinical	ADJ
aji-63	220	2	infectious	infectious	ADJ
aji-63	220	3	diseases	disease	NOUN
aji-63	220	4	;	;	PUNCT
aji-63	220	5	2020	2020	NUM
aji-63	220	6	.	.	PUNCT
aji-63	221	1	doi	doi	NOUN
aji-63	221	2	:	:	PUNCT
aji-63	221	3	http://doi:10.1093	http://doi:10.1093	PROPN
aji-63	221	4	/	/	SYM
aji-63	221	5	cid	cid	PROPN
aji-63	221	6	/	/	SYM
aji-63	221	7	ciaa461	ciaa461	PROPN
aji-63	221	8	2	2	NUM
aji-63	221	9	.	.	PUNCT
aji-63	222	1	zhao	zhao	PROPN
aji-63	222	2	j	j	PROPN
aji-63	222	3	,	,	PUNCT
aji-63	222	4	yuan	yuan	PROPN
aji-63	222	5	q	q	PROPN
aji-63	222	6	,	,	PUNCT
aji-63	222	7	wang	wang	PROPN
aji-63	222	8	h	h	PROPN
aji-63	222	9	,	,	PUNCT
aji-63	222	10	et	et	PROPN
aji-63	222	11	al	al	PROPN
aji-63	222	12	.	.	PUNCT
aji-63	223	1	antibody	antibody	NOUN
aji-63	223	2	responses	response	NOUN
aji-63	223	3	to	to	ADP
aji-63	223	4	sars	sar	NOUN
aji-63	223	5	-	-	PUNCT
aji-63	223	6	cov-2	cov-2	NOUN
aji-63	223	7	in	in	ADP
aji-63	223	8	patients	patient	NOUN
aji-63	223	9	of	of	ADP
aji-63	223	10	novel	novel	ADJ
aji-63	223	11	coronavirus	coronavirus	NOUN
aji-63	223	12	disease	disease	NOUN
aji-63	223	13	2019	2019	NUM
aji-63	223	14	.	.	PUNCT
aji-63	224	1	clinical	clinical	ADJ
aji-63	224	2	infectious	infectious	ADJ
aji-63	224	3	diseases	disease	NOUN
aji-63	224	4	;	;	PUNCT
aji-63	224	5	2020	2020	NUM
aji-63	224	6	.	.	PUNCT
aji-63	225	1	doi	doi	NOUN
aji-63	225	2	:	:	PUNCT
aji-63	225	3	http://doi:10.1093	http://doi:10.1093	PROPN
aji-63	225	4	/	/	SYM
aji-63	225	5	cid	cid	PROPN
aji-63	225	6	/	/	SYM
aji-63	225	7	ciaa344	ciaa344	PROPN
aji-63	225	8	3	3	NUM
aji-63	225	9	.	.	PUNCT
aji-63	226	1	lou	lou	PROPN
aji-63	226	2	b	b	PROPN
aji-63	226	3	lt	lt	PROPN
aji-63	226	4	,	,	PUNCT
aji-63	226	5	zheng	zheng	PROPN
aji-63	226	6	sf	sf	PROPN
aji-63	226	7	,	,	PUNCT
aji-63	226	8	su	su	PROPN
aji-63	226	9	yy	yy	PROPN
aji-63	226	10	,	,	PUNCT
aji-63	226	11	li	li	PROPN
aji-63	226	12	zy	zy	PROPN
aji-63	226	13	,	,	PUNCT
aji-63	226	14	liu	liu	PROPN
aji-63	226	15	w	w	PROPN
aji-63	226	16	,	,	PUNCT
aji-63	226	17	et	et	PROPN
aji-63	226	18	al	al	PROPN
aji-63	226	19	.	.	PROPN
aji-63	226	20	.	.	PUNCT
aji-63	227	1	serology	serology	NOUN
aji-63	227	2	characteristics	characteristic	NOUN
aji-63	227	3	of	of	ADP
aji-63	227	4	sarscov-2	sarscov-2	NUM
aji-63	227	5	infection	infection	NOUN
aji-63	227	6	after	after	ADP
aji-63	227	7	exposure	exposure	NOUN
aji-63	227	8	and	and	CCONJ
aji-63	227	9	postsymptom	postsymptom	NOUN
aji-63	227	10	onset	onset	NOUN
aji-63	227	11	.	.	PUNCT
aji-63	228	1	eur	eur	PROPN
aji-63	228	2	respir	respir	PROPN
aji-63	228	3	j.	j.	PROPN
aji-63	228	4	2020;56:2000763	2020;56:2000763	PROPN
aji-63	228	5	.	.	PUNCT
aji-63	229	1	doi	doi	NOUN
aji-63	229	2	:	:	PUNCT
aji-63	229	3	http://10.1183/13993003.00763	http://10.1183/13993003.00763	PROPN
aji-63	229	4	-	-	PUNCT
aji-63	229	5	2020	2020	NUM
aji-63	229	6	4	4	NUM
aji-63	229	7	.	.	PUNCT
aji-63	230	1	vabret	vabret	PROPN
aji-63	230	2	n	n	CCONJ
aji-63	230	3	,	,	PUNCT
aji-63	230	4	britton	britton	PROPN
aji-63	230	5	gj	gj	PROPN
aji-63	230	6	,	,	PUNCT
aji-63	230	7	gruber	gruber	PROPN
aji-63	230	8	c	c	PROPN
aji-63	230	9	,	,	PUNCT
aji-63	230	10	et	et	PROPN
aji-63	230	11	al	al	PROPN
aji-63	230	12	.	.	PUNCT
aji-63	230	13	immunology	immunology	NOUN
aji-63	230	14	of	of	ADP
aji-63	230	15	covid-19	covid-19	PROPN
aji-63	230	16	:	:	PUNCT
aji-63	230	17	current	current	ADJ
aji-63	230	18	state	state	NOUN
aji-63	230	19	of	of	ADP
aji-63	230	20	the	the	DET
aji-63	230	21	science	science	NOUN
aji-63	230	22	.	.	PUNCT
aji-63	231	1	immunity	immunity	NOUN
aji-63	231	2	;	;	PUNCT
aji-63	231	3	2020	2020	NUM
aji-63	231	4	.	.	X
aji-63	232	1	5	5	NUM
aji-63	232	2	.	.	PUNCT
aji-63	232	3	grzelak	grzelak	PROPN
aji-63	232	4	l	l	PROPN
aji-63	232	5	,	,	PUNCT
aji-63	232	6	temmam	temmam	NOUN
aji-63	232	7	s	s	NOUN
aji-63	232	8	,	,	PUNCT
aji-63	232	9	planchais	planchais	NOUN
aji-63	232	10	c	c	NOUN
aji-63	232	11	,	,	PUNCT
aji-63	232	12	et	et	PROPN
aji-63	232	13	al	al	PROPN
aji-63	232	14	.	.	PUNCT
aji-63	233	1	a	a	DET
aji-63	233	2	comparison	comparison	NOUN
aji-63	233	3	of	of	ADP
aji-63	233	4	four	four	NUM
aji-63	233	5	serological	serological	ADJ
aji-63	233	6	assays	assay	NOUN
aji-63	233	7	for	for	ADP
aji-63	233	8	detecting	detect	VERB
aji-63	233	9	anti	anti	ADJ
aji-63	233	10	–	–	PUNCT
aji-63	233	11	sars	sar	NOUN
aji-63	233	12	-	-	PUNCT
aji-63	233	13	cov-2	cov-2	NOUN
aji-63	233	14	antibodies	antibody	NOUN
aji-63	233	15	in	in	ADP
aji-63	233	16	human	human	ADJ
aji-63	233	17	serum	serum	NOUN
aji-63	233	18	samples	sample	NOUN
aji-63	233	19	from	from	ADP
aji-63	233	20	different	different	ADJ
aji-63	233	21	populations	population	NOUN
aji-63	233	22	.	.	PUNCT
aji-63	234	1	science	science	NOUN
aji-63	234	2	translational	translational	ADJ
aji-63	234	3	medicine	medicine	NOUN
aji-63	234	4	.	.	PUNCT
aji-63	235	1	2020;12(559	2020;12(559	NUM
aji-63	235	2	)	)	PUNCT
aji-63	235	3	.	.	PUNCT
aji-63	236	1	doi	doi	NOUN
aji-63	236	2	:	:	PUNCT
aji-63	236	3	http://10.1126	http://10.1126	NOUN
aji-63	236	4	/	/	SYM
aji-63	236	5	scitranslmed.abc3103	scitranslmed.abc3103	X
aji-63	236	6	6	6	NUM
aji-63	236	7	.	.	PUNCT
aji-63	237	1	hartog	hartog	PROPN
aji-63	237	2	g	g	PROPN
aji-63	237	3	sr	sr	PROPN
aji-63	237	4	,	,	PUNCT
aji-63	237	5	kuijer	kuijer	PROPN
aji-63	237	6	m	m	PROPN
aji-63	237	7	,	,	PUNCT
aji-63	237	8	geurtsvankessel	geurtsvankessel	PROPN
aji-63	237	9	c	c	NOUN
aji-63	237	10	,	,	PUNCT
aji-63	237	11	beek	beek	PROPN
aji-63	237	12	jv	jv	PROPN
aji-63	237	13	,	,	PUNCT
aji-63	237	14	rots	rot	VERB
aji-63	237	15	n	n	CCONJ
aji-63	237	16	,	,	PUNCT
aji-63	237	17	et	et	PROPN
aji-63	237	18	al	al	PROPN
aji-63	237	19	.	.	PUNCT
aji-63	238	1	sars	sars	PROPN
aji-63	238	2	-	-	PUNCT
aji-63	238	3	cov-2	cov-2	NOUN
aji-63	238	4	–	–	PUNCT
aji-63	238	5	specific	specific	ADJ
aji-63	238	6	antibody	antibody	NOUN
aji-63	238	7	detection	detection	NOUN
aji-63	238	8	for	for	ADP
aji-63	238	9	seroepidemiology	seroepidemiology	NOUN
aji-63	238	10	:	:	PUNCT
aji-63	238	11	a	a	DET
aji-63	238	12	multiplex	multiplex	NOUN
aji-63	238	13	analysis	analysis	NOUN
aji-63	238	14	approach	approach	NOUN
aji-63	238	15	accounting	account	VERB
aji-63	238	16	for	for	ADP
aji-63	238	17	accurate	accurate	ADJ
aji-63	238	18	seroprevalence	seroprevalence	NOUN
aji-63	238	19	.	.	PUNCT
aji-63	239	1	j	j	PROPN
aji-63	239	2	infect	infect	PROPN
aji-63	239	3	dis	dis	PROPN
aji-63	239	4	.	.	PUNCT
aji-63	240	1	2020;222:1452	2020;222:1452	NUM
aji-63	240	2	-	-	SYM
aji-63	240	3	61	61	NUM
aji-63	240	4	.	.	PUNCT
aji-63	241	1	doi	doi	NOUN
aji-63	241	2	:	:	PUNCT
aji-63	241	3	https://doi.org/10.1093/infdis/jiaa479	https://doi.org/10.1093/infdis/jiaa479	PROPN
aji-63	241	4	7	7	X
aji-63	241	5	.	.	X
aji-63	241	6	gallais	gallais	PROPN
aji-63	241	7	f	f	PROPN
aji-63	241	8	,	,	PUNCT
aji-63	241	9	velay	velay	VERB
aji-63	241	10	a	a	PRON
aji-63	241	11	,	,	PUNCT
aji-63	241	12	wendling	wendle	VERB
aji-63	241	13	m	m	PROPN
aji-63	241	14	-	-	PROPN
aji-63	241	15	j	j	PROPN
aji-63	241	16	,	,	PUNCT
aji-63	241	17	et	et	PROPN
aji-63	241	18	al	al	PROPN
aji-63	241	19	.	.	PROPN
aji-63	241	20	intrafamilial	intrafamilial	ADJ
aji-63	241	21	exposure	exposure	NOUN
aji-63	241	22	to	to	ADP
aji-63	241	23	sars	sar	NOUN
aji-63	241	24	-	-	PUNCT
aji-63	241	25	cov-2	cov-2	NOUN
aji-63	241	26	induces	induce	VERB
aji-63	241	27	cellular	cellular	ADJ
aji-63	241	28	immune	immune	ADJ
aji-63	241	29	response	response	NOUN
aji-63	241	30	without	without	ADP
aji-63	241	31	seroconversion	seroconversion	NOUN
aji-63	241	32	.	.	PUNCT
aji-63	242	1	medrxiv	medrxiv	PROPN
aji-63	242	2	;	;	PUNCT
aji-63	242	3	2020	2020	NUM
aji-63	242	4	.	.	PUNCT
aji-63	243	1	doi	doi	NOUN
aji-63	243	2	:	:	PUNCT
aji-63	243	3	https://doi.org/10.1101/2020.06.21.20	https://doi.org/10.1101/2020.06.21.20	PROPN
aji-63	243	4	132449	132449	NUM
aji-63	243	5	8	8	NUM
aji-63	243	6	.	.	PUNCT
aji-63	244	1	ou	ou	PROPN
aji-63	244	2	j	j	PROPN
aji-63	244	3	tm	tm	PROPN
aji-63	244	4	,	,	PUNCT
aji-63	244	5	he	he	PRON
aji-63	244	6	h	h	VERB
aji-63	244	7	,	,	PUNCT
aji-63	244	8	tan	tan	PROPN
aji-63	244	9	h	h	NOUN
aji-63	244	10	,	,	PUNCT
aji-63	244	11	mai	mai	PROPN
aji-63	244	12	j	j	PROPN
aji-63	244	13	,	,	PUNCT
aji-63	244	14	long	long	PROPN
aji-63	244	15	y	y	PROPN
aji-63	244	16	,	,	PUNCT
aji-63	244	17	et	et	PROPN
aji-63	244	18	al	al	PROPN
aji-63	244	19	.	.	PROPN
aji-63	244	20	.	.	PUNCT
aji-63	245	1	study	study	NOUN
aji-63	245	2	on	on	ADP
aji-63	245	3	the	the	DET
aji-63	245	4	expression	expression	NOUN
aji-63	245	5	levels	level	NOUN
aji-63	245	6	of	of	ADP
aji-63	245	7	antibodies	antibody	NOUN
aji-63	245	8	against	against	ADP
aji-63	245	9	sars	sar	NOUN
aji-63	245	10	-	-	PUNCT
aji-63	245	11	cov-2	cov-2	NOUN
aji-63	245	12	at	at	ADP
aji-63	245	13	different	different	ADJ
aji-63	245	14	period	period	NOUN
aji-63	245	15	of	of	ADP
aji-63	245	16	disease	disease	NOUN
aji-63	245	17	and	and	CCONJ
aji-63	245	18	its	its	PRON
aji-63	245	19	related	related	ADJ
aji-63	245	20	factors	factor	NOUN
aji-63	245	21	in	in	ADP
aji-63	245	22	192	192	NUM
aji-63	245	23	cases	case	NOUN
aji-63	245	24	of	of	ADP
aji-63	245	25	covid-19	covid-19	PROPN
aji-63	245	26	patients	patient	NOUN
aji-63	245	27	.	.	PUNCT
aji-63	246	1	medrxiv	medrxiv	X
aji-63	246	2	;	;	PUNCT
aji-63	246	3	2020	2020	NUM
aji-63	246	4	.	.	PUNCT
aji-63	247	1	doi	doi	NOUN
aji-63	247	2	:	:	PUNCT
aji-63	247	3	https://doi.org/10.1101/2020.05.22.20	https://doi.org/10.1101/2020.05.22.20	PROPN
aji-63	247	4	102525	102525	NUM
aji-63	247	5	9	9	NUM
aji-63	247	6	.	.	PUNCT
aji-63	248	1	cervia	cervia	PROPN
aji-63	248	2	c	c	PROPN
aji-63	248	3	,	,	PUNCT
aji-63	248	4	nilsson	nilsson	PROPN
aji-63	248	5	j	j	PROPN
aji-63	248	6	,	,	PUNCT
aji-63	248	7	zurbuchen	zurbuchen	PROPN
aji-63	248	8	y	y	PROPN
aji-63	248	9	,	,	PUNCT
aji-63	248	10	et	et	PROPN
aji-63	248	11	al	al	PROPN
aji-63	248	12	.	.	PROPN
aji-63	249	1	systemic	systemic	ADJ
aji-63	249	2	and	and	CCONJ
aji-63	249	3	mucosal	mucosal	ADJ
aji-63	249	4	antibody	antibody	NOUN
aji-63	249	5	secretion	secretion	NOUN
aji-63	249	6	specific	specific	ADJ
aji-63	249	7	to	to	ADP
aji-63	249	8	sars	sar	NOUN
aji-63	249	9	-	-	PUNCT
aji-63	249	10	cov-2	cov-2	NOUN
aji-63	249	11	during	during	ADP
aji-63	249	12	mild	mild	ADJ
aji-63	249	13	versus	versus	ADP
aji-63	249	14	severe	severe	ADJ
aji-63	249	15	covid-19	covid-19	PROPN
aji-63	249	16	.	.	PUNCT
aji-63	249	17	biorxiv	biorxiv	PROPN
aji-63	249	18	;	;	PUNCT
aji-63	249	19	2020	2020	NUM
aji-63	249	20	.	.	PUNCT
aji-63	250	1	doi	doi	NOUN
aji-63	250	2	:	:	PUNCT
aji-63	250	3	https://doi.org/10.1101/2020.05.21.10	https://doi.org/10.1101/2020.05.21.10	PROPN
aji-63	250	4	8308	8308	NUM
aji-63	250	5	10	10	NUM
aji-63	250	6	.	.	PUNCT
aji-63	251	1	perera	perera	PROPN
aji-63	251	2	ra	ra	PROPN
aji-63	251	3	,	,	PUNCT
aji-63	251	4	mok	mok	PROPN
aji-63	251	5	ck	ck	PROPN
aji-63	251	6	,	,	PUNCT
aji-63	251	7	tsang	tsang	PROPN
aji-63	251	8	ot	ot	PROPN
aji-63	251	9	,	,	PUNCT
aji-63	251	10	et	et	PROPN
aji-63	251	11	al	al	PROPN
aji-63	251	12	.	.	PROPN
aji-63	251	13	serological	serological	ADJ
aji-63	251	14	assays	assay	NOUN
aji-63	251	15	for	for	ADP
aji-63	251	16	severe	severe	ADJ
aji-63	251	17	acute	acute	ADJ
aji-63	251	18	respiratory	respiratory	ADJ
aji-63	251	19	syndrome	syndrome	NOUN
aji-63	251	20	coronavirus	coronavirus	NOUN
aji-63	251	21	2	2	NUM
aji-63	251	22	(	(	PUNCT
aji-63	251	23	sars	sar	NOUN
aji-63	251	24	-	-	PUNCT
aji-63	251	25	cov-2	cov-2	NOUN
aji-63	251	26	)	)	PUNCT
aji-63	251	27	,	,	PUNCT
aji-63	251	28	march	march	PROPN
aji-63	251	29	2020	2020	NUM
aji-63	251	30	.	.	PUNCT
aji-63	252	1	eurosurveillance	eurosurveillance	NOUN
aji-63	252	2	.	.	PUNCT
aji-63	253	1	2020;25(16):2000421	2020;25(16):2000421	NUM
aji-63	253	2	.	.	PUNCT
aji-63	254	1	sallam	sallam	PROPN
aji-63	254	2	et	et	PROPN
aji-63	254	3	al	al	PROPN
aji-63	254	4	.	.	PROPN
aji-63	254	5	;	;	PUNCT
aji-63	254	6	aji	aji	PROPN
aji-63	254	7	,	,	PUNCT
aji-63	254	8	4(1	4(1	NOUN
aji-63	254	9	):	):	PUNCT
aji-63	254	10	146	146	NUM
aji-63	254	11	-	-	SYM
aji-63	254	12	153	153	NUM
aji-63	254	13	,	,	PUNCT
aji-63	254	14	2021	2021	NUM
aji-63	254	15	;	;	PUNCT
aji-63	254	16	article	article	NOUN
aji-63	254	17	no.aji.83681	no.aji.83681	VERB
aji-63	254	18	152	152	NUM
aji-63	254	19	doi	doi	NOUN
aji-63	254	20	:	:	PUNCT
aji-63	254	21	https://doi.org/10.2807/15607917.es.2020.25.16.2000421	https://doi.org/10.2807/15607917.es.2020.25.16.2000421	PROPN
aji-63	254	22	11	11	NUM
aji-63	254	23	.	.	PUNCT
aji-63	255	1	hou	hou	PROPN
aji-63	255	2	h	h	PROPN
aji-63	255	3	wt	wt	PROPN
aji-63	255	4	,	,	PUNCT
aji-63	255	5	zhang	zhang	PROPN
aji-63	255	6	b	b	PROPN
aji-63	255	7	,	,	PUNCT
aji-63	255	8	luo	luo	PROPN
aji-63	255	9	y	y	PROPN
aji-63	255	10	,	,	PUNCT
aji-63	255	11	mao	mao	X
aji-63	256	1	l	l	NOUN
aji-63	256	2	,	,	PUNCT
aji-63	256	3	wang	wang	PROPN
aji-63	256	4	f	f	PROPN
aji-63	256	5	,	,	PUNCT
aji-63	256	6	et	et	PROPN
aji-63	256	7	al	al	PROPN
aji-63	256	8	.	.	PUNCT
aji-63	256	9	detection	detection	NOUN
aji-63	256	10	of	of	ADP
aji-63	256	11	igm	igm	PROPN
aji-63	256	12	and	and	CCONJ
aji-63	256	13	igg	igg	PROPN
aji-63	256	14	antibodies	antibodie	VERB
aji-63	256	15	in	in	ADP
aji-63	256	16	patients	patient	NOUN
aji-63	256	17	with	with	ADP
aji-63	256	18	coronavirus	coronavirus	NOUN
aji-63	256	19	disease	disease	NOUN
aji-63	256	20	2019	2019	NUM
aji-63	256	21	.	.	PUNCT
aji-63	257	1	clin	clin	PROPN
aji-63	257	2	transl	transl	PROPN
aji-63	257	3	immunology	immunology	NOUN
aji-63	257	4	.	.	PUNCT
aji-63	258	1	2020;9(5):e01136	2020;9(5):e01136	ADJ
aji-63	258	2	.	.	PUNCT
aji-63	259	1	doi	doi	NOUN
aji-63	259	2	:	:	PUNCT
aji-63	259	3	http://10.1002	http://10.1002	X
aji-63	259	4	/	/	SYM
aji-63	259	5	cti2.1136.pmid:323824	cti2.1136.pmid:323824	NOUN
aji-63	259	6	18;pmcid	18;pmcid	NUM
aji-63	259	7	:	:	PUNCT
aji-63	259	8	pmc7202656	pmc7202656	VERB
aji-63	259	9	12	12	NUM
aji-63	259	10	.	.	PUNCT
aji-63	260	1	u	u	PROPN
aji-63	260	2	j	j	PROPN
aji-63	260	3	wc	wc	PROPN
aji-63	260	4	,	,	PUNCT
aji-63	260	5	li	li	PROPN
aji-63	260	6	x	x	PROPN
aji-63	260	7	,	,	PUNCT
aji-63	260	8	zhang	zhang	PROPN
aji-63	260	9	g	g	PROPN
aji-63	260	10	,	,	PUNCT
aji-63	260	11	jiang	jiang	PROPN
aji-63	260	12	z	z	PROPN
aji-63	260	13	,	,	PUNCT
aji-63	260	14	li	li	PROPN
aji-63	260	15	x	x	PROPN
aji-63	260	16	,	,	PUNCT
aji-63	260	17	zhu	zhu	PROPN
aji-63	260	18	q	q	X
aji-63	260	19	,	,	PUNCT
aji-63	260	20	liu	liu	PROPN
aji-63	260	21	l.	l.	PROPN
aji-63	260	22	profile	profile	PROPN
aji-63	260	23	of	of	ADP
aji-63	260	24	immunoglobulin	immunoglobulin	NOUN
aji-63	260	25	g	g	PROPN
aji-63	260	26	and	and	CCONJ
aji-63	260	27	igm	igm	PROPN
aji-63	260	28	antibodies	antibody	NOUN
aji-63	260	29	against	against	ADP
aji-63	260	30	severe	severe	ADJ
aji-63	260	31	acute	acute	ADJ
aji-63	260	32	respiratory	respiratory	ADJ
aji-63	260	33	syndrome	syndrome	NOUN
aji-63	260	34	coronavirus	coronavirus	NOUN
aji-63	260	35	2	2	NUM
aji-63	260	36	(	(	PUNCT
aji-63	260	37	sars	sar	NOUN
aji-63	260	38	-	-	PUNCT
aji-63	260	39	cov-2	cov-2	NOUN
aji-63	260	40	)	)	PUNCT
aji-63	260	41	.	.	PUNCT
aji-63	261	1	2020	2020	NUM
aji-63	261	2	;	;	PUNCT
aji-63	261	3	.	.	PUNCT
aji-63	262	1	clin	clin	PROPN
aji-63	262	2	infect	infect	PROPN
aji-63	262	3	dis	dis	PROPN
aji-63	262	4	.	.	PUNCT
aji-63	263	1	2020;71:2255	2020;71:2255	NUM
aji-63	263	2	-	-	SYM
aji-63	263	3	58	58	NUM
aji-63	263	4	.	.	PUNCT
aji-63	264	1	doi	doi	NOUN
aji-63	264	2	:	:	PUNCT
aji-63	264	3	http://10.1093	http://10.1093	NUM
aji-63	264	4	/	/	SYM
aji-63	264	5	cid	cid	ADJ
aji-63	264	6	/	/	SYM
aji-63	264	7	ciaa489.pmid:3233	ciaa489.pmid:3233	PROPN
aji-63	264	8	7590;pmcid	7590;pmcid	NUM
aji-63	264	9	:	:	PUNCT
aji-63	264	10	pmc7197626	pmc7197626	NOUN
aji-63	264	11	13	13	NUM
aji-63	264	12	.	.	PUNCT
aji-63	265	1	zhang	zhang	PROPN
aji-63	265	2	g	g	PROPN
aji-63	265	3	,	,	PUNCT
aji-63	265	4	nie	nie	PROPN
aji-63	265	5	s	s	PROPN
aji-63	265	6	,	,	PUNCT
aji-63	265	7	zhang	zhang	PROPN
aji-63	265	8	z	z	PROPN
aji-63	265	9	,	,	PUNCT
aji-63	265	10	et	et	PROPN
aji-63	265	11	al	al	PROPN
aji-63	265	12	.	.	PUNCT
aji-63	265	13	longitudinal	longitudinal	ADJ
aji-63	265	14	change	change	NOUN
aji-63	265	15	of	of	ADP
aji-63	265	16	severe	severe	ADJ
aji-63	265	17	acute	acute	ADJ
aji-63	265	18	respiratory	respiratory	ADJ
aji-63	265	19	syndrome	syndrome	NOUN
aji-63	265	20	coronavirus	coronavirus	NOUN
aji-63	265	21	2	2	NUM
aji-63	265	22	antibodies	antibody	NOUN
aji-63	265	23	in	in	ADP
aji-63	265	24	patients	patient	NOUN
aji-63	265	25	with	with	ADP
aji-63	265	26	coronavirus	coronavirus	NOUN
aji-63	265	27	disease	disease	NOUN
aji-63	265	28	2019	2019	NUM
aji-63	265	29	.	.	PUNCT
aji-63	266	1	the	the	DET
aji-63	266	2	journal	journal	NOUN
aji-63	266	3	of	of	ADP
aji-63	266	4	infectious	infectious	ADJ
aji-63	266	5	diseases	disease	NOUN
aji-63	266	6	;	;	PUNCT
aji-63	266	7	2020	2020	NUM
aji-63	266	8	.	.	PUNCT
aji-63	267	1	doi	doi	NOUN
aji-63	267	2	:	:	PUNCT
aji-63	267	3	https://doi.org/10.1093/infdis/jiaa229	https://doi.org/10.1093/infdis/jiaa229	NOUN
aji-63	267	4	.	.	PUNCT
aji-63	268	1	14	14	NUM
aji-63	268	2	.	.	PUNCT
aji-63	269	1	figueiredo‐campos	figueiredo‐campos	NUM
aji-63	269	2	p	p	NOUN
aji-63	269	3	,	,	PUNCT
aji-63	269	4	blankenhaus	blankenhaus	NOUN
aji-63	269	5	b	b	PROPN
aji-63	269	6	,	,	PUNCT
aji-63	269	7	mota	mota	PROPN
aji-63	269	8	c	c	NOUN
aji-63	269	9	,	,	PUNCT
aji-63	269	10	et	et	PROPN
aji-63	269	11	al	al	PROPN
aji-63	269	12	.	.	PROPN
aji-63	269	13	seroprevalence	seroprevalence	NOUN
aji-63	269	14	of	of	ADP
aji-63	269	15	anti‐sars‐cov‐2	anti‐sars‐cov‐2	PROPN
aji-63	269	16	antibodies	antibody	NOUN
aji-63	269	17	in	in	ADP
aji-63	269	18	covid‐19	covid‐19	PROPN
aji-63	269	19	patients	patient	NOUN
aji-63	269	20	and	and	CCONJ
aji-63	269	21	healthy	healthy	ADJ
aji-63	269	22	volunteers	volunteer	NOUN
aji-63	269	23	up	up	ADV
aji-63	269	24	to	to	PART
aji-63	269	25	6	6	NUM
aji-63	269	26	months	month	NOUN
aji-63	269	27	post	post	NOUN
aji-63	269	28	disease	disease	NOUN
aji-63	269	29	onset	onset	VERB
aji-63	269	30	.	.	PUNCT
aji-63	270	1	european	european	ADJ
aji-63	270	2	journal	journal	PROPN
aji-63	270	3	of	of	ADP
aji-63	270	4	immunology	immunology	NOUN
aji-63	270	5	.	.	PUNCT
aji-63	271	1	2020;50(12):202540	2020;50(12):202540	X
aji-63	271	2	.	.	X
aji-63	271	3	doi	doi	NOUN
aji-63	271	4	:	:	PUNCT
aji-63	271	5	http://doi:10.1002	http://doi:10.1002	PROPN
aji-63	271	6	/	/	SYM
aji-63	271	7	eji.202048970	eji.202048970	PROPN
aji-63	271	8	15	15	NUM
aji-63	271	9	.	.	PUNCT
aji-63	272	1	long	long	ADJ
aji-63	272	2	q	q	NOUN
aji-63	272	3	-	-	PUNCT
aji-63	272	4	x	x	ADJ
aji-63	272	5	,	,	PUNCT
aji-63	272	6	tang	tang	PROPN
aji-63	272	7	x	x	PROPN
aji-63	272	8	-	-	PUNCT
aji-63	272	9	j	j	PROPN
aji-63	272	10	,	,	PUNCT
aji-63	272	11	shi	shi	PROPN
aji-63	272	12	q	q	PROPN
aji-63	272	13	-	-	PUNCT
aji-63	272	14	l	l	NOUN
aji-63	272	15	,	,	PUNCT
aji-63	272	16	et	et	PROPN
aji-63	272	17	al	al	PROPN
aji-63	272	18	.	.	PROPN
aji-63	273	1	clinical	clinical	ADJ
aji-63	273	2	and	and	CCONJ
aji-63	273	3	immunological	immunological	ADJ
aji-63	273	4	assessment	assessment	NOUN
aji-63	273	5	of	of	ADP
aji-63	273	6	asymptomatic	asymptomatic	ADJ
aji-63	273	7	sars	sar	NOUN
aji-63	273	8	-	-	PUNCT
aji-63	273	9	cov-2	cov-2	NOUN
aji-63	273	10	infections	infection	NOUN
aji-63	273	11	.	.	PUNCT
aji-63	274	1	nature	nature	NOUN
aji-63	274	2	medicine	medicine	NOUN
aji-63	274	3	.	.	PUNCT
aji-63	275	1	2020:1	2020:1	NUM
aji-63	275	2	-	-	SYM
aji-63	275	3	5	5	NUM
aji-63	275	4	.	.	PUNCT
aji-63	275	5	doi	doi	NOUN
aji-63	275	6	:	:	PUNCT
aji-63	275	7	http://doi:10.1038	http://doi:10.1038	PROPN
aji-63	275	8	/	/	SYM
aji-63	275	9	s41591	s41591	NOUN
aji-63	275	10	-	-	PUNCT
aji-63	275	11	020	020	NUM
aji-63	275	12	-	-	PUNCT
aji-63	275	13	0965	0965	NUM
aji-63	275	14	-	-	SYM
aji-63	275	15	6	6	NUM
aji-63	275	16	16	16	NUM
aji-63	275	17	.	.	PUNCT
aji-63	276	1	noh	noh	PROPN
aji-63	276	2	jy	jy	PROPN
aji-63	276	3	,	,	PUNCT
aji-63	276	4	seo	seo	PROPN
aji-63	276	5	yb	yb	PROPN
aji-63	276	6	,	,	PUNCT
aji-63	276	7	yoon	yoon	PROPN
aji-63	276	8	jg	jg	PROPN
aji-63	276	9	,	,	PUNCT
aji-63	276	10	et	et	PROPN
aji-63	276	11	al	al	PROPN
aji-63	276	12	.	.	PROPN
aji-63	276	13	seroprevalence	seroprevalence	NOUN
aji-63	276	14	of	of	ADP
aji-63	276	15	anti	anti	ADJ
aji-63	276	16	-	-	ADJ
aji-63	276	17	sars	sar	NOUN
aji-63	276	18	-	-	PUNCT
aji-63	276	19	cov-2	cov-2	NOUN
aji-63	276	20	antibodies	antibody	NOUN
aji-63	276	21	among	among	ADP
aji-63	276	22	outpatients	outpatient	NOUN
aji-63	276	23	in	in	ADP
aji-63	276	24	southwestern	southwestern	ADJ
aji-63	276	25	seoul	seoul	PROPN
aji-63	276	26	,	,	PUNCT
aji-63	276	27	korea	korea	PROPN
aji-63	276	28	.	.	PUNCT
aji-63	277	1	journal	journal	PROPN
aji-63	277	2	of	of	ADP
aji-63	277	3	korean	korean	PROPN
aji-63	277	4	medical	medical	ADJ
aji-63	277	5	science	science	NOUN
aji-63	277	6	2020;35(33	2020;35(33	NUM
aji-63	277	7	)	)	PUNCT
aji-63	277	8	.	.	PUNCT
aji-63	278	1	doi	doi	NOUN
aji-63	278	2	:	:	PUNCT
aji-63	278	3	http://dx.doi.org/10.3346	http://dx.doi.org/10.3346	ADJ
aji-63	278	4	/	/	SYM
aji-63	278	5	jkms.2020.35	jkms.2020.35	NOUN
aji-63	278	6	.e311	.e311	PROPN
aji-63	278	7	17	17	NUM
aji-63	278	8	.	.	PUNCT
aji-63	279	1	rostami	rostami	PROPN
aji-63	279	2	a	a	PRON
aji-63	279	3	,	,	PUNCT
aji-63	279	4	sepidarkish	sepidarkish	PROPN
aji-63	279	5	m	m	PROPN
aji-63	279	6	,	,	PUNCT
aji-63	279	7	leeflang	leeflang	PROPN
aji-63	279	8	m	m	PROPN
aji-63	279	9	,	,	PUNCT
aji-63	279	10	et	et	PROPN
aji-63	279	11	al	al	PROPN
aji-63	279	12	.	.	PUNCT
aji-63	280	1	sars	sars	PROPN
aji-63	280	2	-	-	PUNCT
aji-63	280	3	cov-2	cov-2	PART
aji-63	280	4	seroprevalence	seroprevalence	NOUN
aji-63	280	5	worldwide	worldwide	ADV
aji-63	280	6	:	:	PUNCT
aji-63	280	7	a	a	DET
aji-63	280	8	systematic	systematic	ADJ
aji-63	280	9	review	review	NOUN
aji-63	280	10	and	and	CCONJ
aji-63	280	11	metaanalysis	metaanalysis	NOUN
aji-63	280	12	.	.	PUNCT
aji-63	281	1	clinical	clinical	ADJ
aji-63	281	2	microbiology	microbiology	NOUN
aji-63	281	3	and	and	CCONJ
aji-63	281	4	infection	infection	NOUN
aji-63	281	5	;	;	PUNCT
aji-63	281	6	2020	2020	NUM
aji-63	281	7	.	.	PUNCT
aji-63	282	1	doi	doi	NOUN
aji-63	282	2	:	:	PUNCT
aji-63	282	3	https://doi.org/10.1016	https://doi.org/10.1016	PROPN
aji-63	282	4	/	/	SYM
aji-63	282	5	j.cmi.2020.10.0	j.cmi.2020.10.0	PROPN
aji-63	282	6	20	20	NUM
aji-63	282	7	18	18	NUM
aji-63	282	8	.	.	PUNCT
aji-63	283	1	duysburgh	duysburgh	PROPN
aji-63	283	2	e	e	NOUN
aji-63	283	3	ml	ml	PROPN
aji-63	283	4	,	,	PUNCT
aji-63	283	5	barbezange	barbezange	VERB
aji-63	283	6	c	c	NOUN
aji-63	283	7	,	,	PUNCT
aji-63	283	8	dierick	dierick	VERB
aji-63	283	9	k	k	PROPN
aji-63	283	10	,	,	PUNCT
aji-63	283	11	fischer	fischer	PROPN
aji-63	283	12	n	n	CCONJ
aji-63	283	13	,	,	PUNCT
aji-63	283	14	heyndrickx	heyndrickx	PROPN
aji-63	283	15	l	l	NOUN
aji-63	283	16	,	,	PUNCT
aji-63	283	17	et	et	PROPN
aji-63	283	18	al	al	PROPN
aji-63	283	19	.	.	PROPN
aji-63	283	20	persistence	persistence	NOUN
aji-63	283	21	of	of	ADP
aji-63	283	22	igg	igg	PROPN
aji-63	283	23	response	response	NOUN
aji-63	283	24	to	to	ADP
aji-63	283	25	sarscov-2	sarscov-2	PROPN
aji-63	283	26	.	.	PUNCT
aji-63	284	1	lancet	lancet	PROPN
aji-63	284	2	infect	infect	PROPN
aji-63	284	3	dis	dis	PROPN
aji-63	284	4	.	.	PUNCT
aji-63	285	1	2021;21:163	2021;21:163	NUM
aji-63	285	2	-	-	SYM
aji-63	285	3	64	64	NUM
aji-63	285	4	.	.	PUNCT
aji-63	286	1	doi	doi	NOUN
aji-63	286	2	:	:	PUNCT
aji-63	286	3	http://10.1016	http://10.1016	X
aji-63	286	4	/	/	SYM
aji-63	286	5	s1473	s1473	NOUN
aji-63	286	6	-	-	NOUN
aji-63	286	7	3099(20)309439	3099(20)309439	NUM
aji-63	286	8	19	19	NUM
aji-63	286	9	.	.	PUNCT
aji-63	287	1	huang	huang	PROPN
aji-63	287	2	j	j	PROPN
aji-63	287	3	mt	mt	PROPN
aji-63	287	4	,	,	PUNCT
aji-63	287	5	li	li	PROPN
aji-63	287	6	s	s	PROPN
aji-63	287	7	,	,	PUNCT
aji-63	287	8	wu	wu	PROPN
aji-63	287	9	l	l	PROPN
aji-63	287	10	,	,	PUNCT
aji-63	287	11	xu	xu	PROPN
aji-63	287	12	x	x	PROPN
aji-63	287	13	,	,	PUNCT
aji-63	287	14	li	li	PROPN
aji-63	287	15	h	h	PROPN
aji-63	287	16	,	,	PUNCT
aji-63	287	17	et	et	PROPN
aji-63	287	18	al	al	PROPN
aji-63	287	19	.	.	PROPN
aji-63	287	20	.	.	PUNCT
aji-63	288	1	long	long	ADJ
aji-63	288	2	period	period	NOUN
aji-63	288	3	dynamics	dynamic	NOUN
aji-63	288	4	of	of	ADP
aji-63	288	5	viral	viral	ADJ
aji-63	288	6	load	load	NOUN
aji-63	288	7	and	and	CCONJ
aji-63	288	8	antibodies	antibodie	VERB
aji-63	288	9	for	for	ADP
aji-63	288	10	sars	sar	NOUN
aji-63	288	11	-	-	PUNCT
aji-63	288	12	cov-2	cov-2	PART
aji-63	288	13	infection	infection	NOUN
aji-63	288	14	:	:	PUNCT
aji-63	288	15	an	an	DET
aji-63	288	16	observational	observational	ADJ
aji-63	288	17	cohort	cohort	NOUN
aji-63	288	18	study	study	NOUN
aji-63	288	19	.	.	PUNCT
aji-63	289	1	medrxiv	medrxiv	PROPN
aji-63	289	2	.	.	PUNCT
aji-63	290	1	2020:04.22.20071258v1	2020:04.22.20071258v1	NUM
aji-63	290	2	.	.	PUNCT
aji-63	291	1	doi	doi	NOUN
aji-63	291	2	:	:	PUNCT
aji-63	291	3	https://www.medrxiv.org	https://www.medrxiv.org	PROPN
aji-63	291	4	/	/	SYM
aji-63	291	5	content/10.11	content/10.11	PROPN
aji-63	291	6	01/2020.04.22.20071258v1	01/2020.04.22.20071258v1	NOUN
aji-63	291	7	20	20	NUM
aji-63	291	8	.	.	PUNCT
aji-63	292	1	burgess	burgess	PROPN
aji-63	292	2	s	s	PROPN
aji-63	292	3	,	,	PUNCT
aji-63	292	4	ponsford	ponsford	PROPN
aji-63	292	5	mj	mj	PROPN
aji-63	292	6	,	,	PUNCT
aji-63	292	7	gill	gill	PROPN
aji-63	292	8	d.	d.	PROPN
aji-63	292	9	are	be	AUX
aji-63	292	10	we	we	PRON
aji-63	292	11	underestimating	underestimate	VERB
aji-63	292	12	seroprevalence	seroprevalence	NOUN
aji-63	292	13	of	of	ADP
aji-63	292	14	sarscov-2	sarscov-2	PROPN
aji-63	292	15	?	?	PUNCT
aji-63	293	1	bmj	bmj	PROPN
aji-63	293	2	2020:370	2020:370	NUM
aji-63	293	3	:	:	PUNCT
aji-63	293	4	m3364	m3364	NOUN
aji-63	293	5	.	.	PROPN
aji-63	293	6	doi	doi	NOUN
aji-63	293	7	:	:	PUNCT
aji-63	293	8	https://doi.org/10.1136/bmj.m3364	https://doi.org/10.1136/bmj.m3364	X
aji-63	293	9	21	21	NUM
aji-63	293	10	.	.	PUNCT
aji-63	294	1	mousavi	mousavi	PROPN
aji-63	294	2	sm	sm	PROPN
aji-63	294	3	,	,	PUNCT
aji-63	294	4	anjomshoa	anjomshoa	NOUN
aji-63	294	5	m.	m.	NOUN
aji-63	294	6	covid-19	covid-19	PROPN
aji-63	294	7	in	in	ADP
aji-63	294	8	yemen	yemen	PROPN
aji-63	294	9	:	:	PUNCT
aji-63	294	10	a	a	DET
aji-63	294	11	crisis	crisis	NOUN
aji-63	294	12	within	within	ADP
aji-63	294	13	crises	crisis	NOUN
aji-63	294	14	.	.	PUNCT
aji-63	295	1	international	international	ADJ
aji-63	295	2	journal	journal	PROPN
aji-63	295	3	for	for	ADP
aji-63	295	4	equity	equity	NOUN
aji-63	295	5	in	in	ADP
aji-63	295	6	health	health	NOUN
aji-63	295	7	.	.	PUNCT
aji-63	296	1	2020;19(1):13	2020;19(1):13	X
aji-63	296	2	.	.	PUNCT
aji-63	297	1	doi	doi	NOUN
aji-63	297	2	:	:	PUNCT
aji-63	297	3	https://doi.org/10.1186/s12939-02001231-2	https://doi.org/10.1186/s12939-02001231-2	PROPN
aji-63	297	4	22	22	NUM
aji-63	297	5	.	.	PUNCT
aji-63	298	1	yonker	yonker	PROPN
aji-63	298	2	lm	lm	PROPN
aji-63	298	3	,	,	PUNCT
aji-63	298	4	neilan	neilan	NOUN
aji-63	298	5	am	be	AUX
aji-63	298	6	,	,	PUNCT
aji-63	298	7	bartsch	bartsch	VERB
aji-63	298	8	y	y	PRON
aji-63	298	9	,	,	PUNCT
aji-63	298	10	et	et	PROPN
aji-63	298	11	al	al	PROPN
aji-63	298	12	.	.	PROPN
aji-63	299	1	pediatric	pediatric	ADJ
aji-63	299	2	severe	severe	ADJ
aji-63	299	3	acute	acute	ADJ
aji-63	299	4	respiratory	respiratory	ADJ
aji-63	299	5	syndrome	syndrome	NOUN
aji-63	299	6	coronavirus	coronavirus	NOUN
aji-63	299	7	2	2	NUM
aji-63	299	8	(	(	PUNCT
aji-63	299	9	sars	sar	NOUN
aji-63	299	10	-	-	PUNCT
aji-63	299	11	cov-2	cov-2	NOUN
aji-63	299	12	):	):	PUNCT
aji-63	299	13	clinical	clinical	ADJ
aji-63	299	14	presentation	presentation	NOUN
aji-63	299	15	,	,	PUNCT
aji-63	299	16	infectivity	infectivity	NOUN
aji-63	299	17	,	,	PUNCT
aji-63	299	18	and	and	CCONJ
aji-63	299	19	immune	immune	ADJ
aji-63	299	20	responses	response	NOUN
aji-63	299	21	.	.	PUNCT
aji-63	300	1	the	the	DET
aji-63	300	2	journal	journal	NOUN
aji-63	300	3	of	of	ADP
aji-63	300	4	pediatrics	pediatric	NOUN
aji-63	300	5	.	.	PUNCT
aji-63	301	1	2020;227:45	2020;227:45	NUM
aji-63	301	2	-	-	SYM
aji-63	301	3	52	52	NUM
aji-63	301	4	.	.	PUNCT
aji-63	302	1	e5	e5	INTJ
aji-63	302	2	.	.	PUNCT
aji-63	303	1	doi	doi	PROPN
aji-63	303	2	:	:	PUNCT
aji-63	303	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-63	303	4	/	/	SYM
aji-63	303	5	j.jpeds.2020.08	j.jpeds.2020.08	NOUN
aji-63	303	6	.037	.037	NUM
aji-63	303	7	23	23	NUM
aji-63	303	8	.	.	PUNCT
aji-63	304	1	worldmeter	worldmeter	PROPN
aji-63	304	2	.	.	PUNCT
aji-63	305	1	yemen	yemen	PROPN
aji-63	305	2	demographics	demographic	NOUN
aji-63	305	3	:	:	PUNCT
aji-63	305	4	population	population	NOUN
aji-63	305	5	of	of	ADP
aji-63	305	6	yemen	yemen	PROPN
aji-63	305	7	;	;	PUNCT
aji-63	305	8	2020	2020	NUM
aji-63	305	9	.	.	PUNCT
aji-63	306	1	available	available	ADJ
aji-63	306	2	:	:	PUNCT
aji-63	306	3	https://www.worldometers.info	https://www.worldometers.info	ADJ
aji-63	306	4	/	/	SYM
aji-63	306	5	de	de	X
aji-63	306	6	mographics	mographic	NOUN
aji-63	306	7	/	/	SYM
aji-63	306	8	yemen	yemen	PROPN
aji-63	306	9	-	-	PUNCT
aji-63	306	10	demographics/.	demographics/.	NOUN
aji-63	306	11	24	24	NUM
aji-63	306	12	.	.	PUNCT
aji-63	307	1	cdc	cdc	PROPN
aji-63	307	2	.	.	PUNCT
aji-63	307	3	coronavirus	coronavirus	PROPN
aji-63	307	4	disease	disease	NOUN
aji-63	307	5	2019	2019	NUM
aji-63	307	6	in	in	ADP
aji-63	307	7	children	child	NOUN
aji-63	307	8	-	-	PUNCT
aji-63	307	9	united	united	PROPN
aji-63	307	10	states	states	PROPN
aji-63	307	11	usa	usa	PROPN
aji-63	307	12	:	:	PUNCT
aji-63	307	13	centers	center	NOUN
aji-63	307	14	for	for	ADP
aji-63	307	15	disease	disease	NOUN
aji-63	307	16	control	control	NOUN
aji-63	307	17	and	and	CCONJ
aji-63	307	18	prevention	prevention	NOUN
aji-63	307	19	;	;	PUNCT
aji-63	307	20	2020	2020	NUM
aji-63	307	21	.	.	PUNCT
aji-63	308	1	available	available	ADJ
aji-63	308	2	:	:	PUNCT
aji-63	308	3	https://www.cdc.gov	https://www.cdc.gov	NOUN
aji-63	308	4	/	/	SYM
aji-63	308	5	mmwr	mmwr	ADJ
aji-63	308	6	/	/	SYM
aji-63	308	7	volu	volu	PROPN
aji-63	308	8	mes/69	mes/69	PROPN
aji-63	308	9	/	/	SYM
aji-63	308	10	wr	wr	NOUN
aji-63	308	11	/	/	SYM
aji-63	308	12	mm6914e4.htmsept	mm6914e4.htmsept	NOUN
aji-63	308	13	2020	2020	NUM
aji-63	308	14	.	.	PUNCT
aji-63	309	1	25	25	NUM
aji-63	309	2	.	.	X
aji-63	310	1	clemente	clemente	PROPN
aji-63	310	2	-	-	PUNCT
aji-63	310	3	suárez	suárez	PROPN
aji-63	310	4	vj	vj	PROPN
aji-63	310	5	,	,	PUNCT
aji-63	310	6	hormeño	hormeño	NOUN
aji-63	310	7	-	-	PUNCT
aji-63	310	8	holgado	holgado	NOUN
aji-63	310	9	a	a	NOUN
aji-63	310	10	,	,	PUNCT
aji-63	310	11	jiménez	jiménez	PROPN
aji-63	310	12	m	m	PROPN
aji-63	310	13	,	,	PUNCT
aji-63	310	14	et	et	PROPN
aji-63	310	15	al	al	PROPN
aji-63	310	16	.	.	PUNCT
aji-63	311	1	dynamics	dynamic	NOUN
aji-63	311	2	of	of	ADP
aji-63	311	3	population	population	NOUN
aji-63	311	4	immunity	immunity	NOUN
aji-63	311	5	due	due	ADP
aji-63	311	6	to	to	ADP
aji-63	311	7	the	the	DET
aji-63	311	8	herd	herd	ADJ
aji-63	311	9	effect	effect	NOUN
aji-63	311	10	in	in	ADP
aji-63	311	11	the	the	DET
aji-63	311	12	covid-19	covid-19	PROPN
aji-63	311	13	pandemic	pandemic	NOUN
aji-63	311	14	.	.	PUNCT
aji-63	312	1	vaccines	vaccine	NOUN
aji-63	312	2	.	.	PUNCT
aji-63	313	1	2020;8(2):236	2020;8(2):236	X
aji-63	313	2	.	.	X
aji-63	313	3	doi	doi	NOUN
aji-63	313	4	:	:	PUNCT
aji-63	313	5	http://10.3390	http://10.3390	X
aji-63	313	6	/	/	SYM
aji-63	313	7	vaccines8020236	vaccines8020236	PROPN
aji-63	313	8	26	26	NUM
aji-63	313	9	.	.	PUNCT
aji-63	314	1	götzinger	götzinger	PROPN
aji-63	314	2	f	f	PROPN
aji-63	314	3	,	,	PUNCT
aji-63	314	4	santiago	santiago	PROPN
aji-63	314	5	-	-	PUNCT
aji-63	314	6	garcía	garcía	ADJ
aji-63	314	7	b	b	PROPN
aji-63	314	8	,	,	PUNCT
aji-63	314	9	noguerajulián	noguerajulián	PROPN
aji-63	314	10	a	a	X
aji-63	314	11	,	,	PUNCT
aji-63	314	12	et	et	PROPN
aji-63	314	13	al	al	PROPN
aji-63	314	14	.	.	PUNCT
aji-63	315	1	covid-19	covid-19	PROPN
aji-63	315	2	in	in	ADP
aji-63	315	3	children	child	NOUN
aji-63	315	4	and	and	CCONJ
aji-63	315	5	adolescents	adolescent	NOUN
aji-63	315	6	in	in	ADP
aji-63	315	7	europe	europe	PROPN
aji-63	315	8	:	:	PUNCT
aji-63	315	9	a	a	DET
aji-63	315	10	multinational	multinational	ADJ
aji-63	315	11	,	,	PUNCT
aji-63	315	12	multicentre	multicentre	NOUN
aji-63	315	13	cohort	cohort	NOUN
aji-63	315	14	study	study	NOUN
aji-63	315	15	.	.	PUNCT
aji-63	316	1	the	the	DET
aji-63	316	2	lancet	lancet	PROPN
aji-63	316	3	child	child	PROPN
aji-63	316	4	&	&	CCONJ
aji-63	316	5	adolescent	adolescent	ADJ
aji-63	316	6	health	health	NOUN
aji-63	316	7	.	.	PUNCT
aji-63	317	1	2020;4(9):653	2020;4(9):653	X
aji-63	317	2	-	-	SYM
aji-63	317	3	61	61	NUM
aji-63	317	4	.	.	PUNCT
aji-63	318	1	doi	doi	NOUN
aji-63	318	2	:	:	PUNCT
aji-63	318	3	https://doi.org/10.1016/s23524642(20)30177-2	https://doi.org/10.1016/s23524642(20)30177-2	NOUN
aji-63	318	4	27	27	NUM
aji-63	318	5	.	.	PUNCT
aji-63	319	1	infantino	infantino	PROPN
aji-63	319	2	m	m	PROPN
aji-63	319	3	,	,	PUNCT
aji-63	319	4	manfredi	manfredi	PROPN
aji-63	319	5	m	m	PROPN
aji-63	319	6	,	,	PUNCT
aji-63	319	7	grossi	grossi	PROPN
aji-63	319	8	v	v	NOUN
aji-63	319	9	,	,	PUNCT
aji-63	319	10	et	et	PROPN
aji-63	319	11	al	al	PROPN
aji-63	319	12	.	.	PUNCT
aji-63	320	1	closing	close	VERB
aji-63	320	2	the	the	DET
aji-63	320	3	serological	serological	ADJ
aji-63	320	4	gap	gap	NOUN
aji-63	320	5	in	in	ADP
aji-63	320	6	the	the	DET
aji-63	320	7	diagnostic	diagnostic	ADJ
aji-63	320	8	testing	testing	NOUN
aji-63	320	9	for	for	ADP
aji-63	320	10	covid‐19	covid‐19	PROPN
aji-63	320	11	:	:	PUNCT
aji-63	320	12	the	the	DET
aji-63	320	13	value	value	NOUN
aji-63	320	14	of	of	ADP
aji-63	320	15	anti‐sars‐cov‐2	anti‐sars‐cov‐2	PROPN
aji-63	320	16	iga	iga	PROPN
aji-63	320	17	antibodies	antibodie	VERB
aji-63	320	18	.	.	PUNCT
aji-63	321	1	journal	journal	PROPN
aji-63	321	2	of	of	ADP
aji-63	321	3	medical	medical	ADJ
aji-63	321	4	virology	virology	NOUN
aji-63	321	5	2021;93(3):1436	2021;93(3):1436	NUM
aji-63	321	6	-	-	SYM
aji-63	321	7	42	42	NUM
aji-63	321	8	.	.	PUNCT
aji-63	322	1	doi	doi	NOUN
aji-63	322	2	:	:	PUNCT
aji-63	322	3	https://doi.org/10.1002/jmv.26422	https://doi.org/10.1002/jmv.26422	PROPN
aji-63	322	4	28	28	NUM
aji-63	322	5	.	.	PUNCT
aji-63	323	1	sam	sam	PROPN
aji-63	323	2	ic	ic	PROPN
aji-63	323	3	,	,	PUNCT
aji-63	323	4	chong	chong	PROPN
aji-63	323	5	ym	ym	PROPN
aji-63	323	6	,	,	PUNCT
aji-63	323	7	tan	tan	PROPN
aji-63	323	8	cw	cw	NOUN
aji-63	323	9	,	,	PUNCT
aji-63	323	10	et	et	PROPN
aji-63	323	11	al	al	PROPN
aji-63	323	12	.	.	PROPN
aji-63	324	1	low	low	PROPN
aji-63	324	2	postpandemic	postpandemic	ADJ
aji-63	324	3	wave	wave	PROPN
aji-63	324	4	sars‐cov‐2	sars‐cov‐2	PROPN
aji-63	324	5	seroprevalence	seroprevalence	NOUN
aji-63	324	6	in	in	ADP
aji-63	324	7	kuala	kuala	PROPN
aji-63	324	8	lumpur	lumpur	PROPN
aji-63	324	9	and	and	CCONJ
aji-63	324	10	sallam	sallam	PROPN
aji-63	324	11	et	et	PROPN
aji-63	324	12	al	al	PROPN
aji-63	324	13	.	.	PROPN
aji-63	324	14	;	;	PUNCT
aji-63	324	15	aji	aji	PROPN
aji-63	324	16	,	,	PUNCT
aji-63	324	17	4(1	4(1	NOUN
aji-63	324	18	):	):	PUNCT
aji-63	324	19	146	146	NUM
aji-63	324	20	-	-	SYM
aji-63	324	21	153	153	NUM
aji-63	324	22	,	,	PUNCT
aji-63	324	23	2021	2021	NUM
aji-63	324	24	;	;	PUNCT
aji-63	325	1	article	article	NOUN
aji-63	325	2	no.aji.83681	no.aji.83681	VERB
aji-63	325	3	153	153	NUM
aji-63	325	4	selangor	selangor	PROPN
aji-63	325	5	,	,	PUNCT
aji-63	325	6	malaysia	malaysia	PROPN
aji-63	325	7	.	.	PUNCT
aji-63	326	1	journal	journal	PROPN
aji-63	326	2	of	of	ADP
aji-63	326	3	medical	medical	ADJ
aji-63	326	4	virology	virology	NOUN
aji-63	326	5	.	.	PUNCT
aji-63	327	1	2021;93(2):647	2021;93(2):647	NUM
aji-63	327	2	-	-	SYM
aji-63	327	3	48	48	NUM
aji-63	327	4	.	.	PUNCT
aji-63	328	1	doi	doi	NOUN
aji-63	328	2	:	:	PUNCT
aji-63	328	3	http://dx.doi.org/10.1002/jmv.26426	http://dx.doi.org/10.1002/jmv.26426	NOUN
aji-63	328	4	29	29	NUM
aji-63	328	5	.	.	PUNCT
aji-63	329	1	zhou	zhou	PROPN
aji-63	329	2	w	w	PROPN
aji-63	329	3	xx	xx	PROPN
aji-63	329	4	,	,	PUNCT
aji-63	329	5	chang	chang	PROPN
aji-63	329	6	z	z	PROPN
aji-63	329	7	,	,	PUNCT
aji-63	329	8	wang	wang	PROPN
aji-63	329	9	h	h	PROPN
aji-63	329	10	,	,	PUNCT
aji-63	329	11	zhong	zhong	PROPN
aji-63	329	12	x	x	SYM
aji-63	329	13	,	,	PUNCT
aji-63	329	14	tong	tong	PROPN
aji-63	329	15	x	x	PROPN
aji-63	329	16	,	,	PUNCT
aji-63	329	17	et	et	PROPN
aji-63	329	18	al	al	PROPN
aji-63	329	19	.	.	PUNCT
aji-63	330	1	the	the	DET
aji-63	330	2	dynamic	dynamic	ADJ
aji-63	330	3	changes	change	NOUN
aji-63	330	4	of	of	ADP
aji-63	330	5	serum	serum	NOUN
aji-63	330	6	igm	igm	PROPN
aji-63	330	7	and	and	CCONJ
aji-63	330	8	igg	igg	PROPN
aji-63	330	9	against	against	ADP
aji-63	330	10	sars‐cov‐2	sars‐cov‐2	PROPN
aji-63	330	11	in	in	ADP
aji-63	330	12	patients	patient	NOUN
aji-63	330	13	with	with	ADP
aji-63	330	14	covid‐19	covid‐19	PROPN
aji-63	330	15	.	.	PUNCT
aji-63	331	1	j	j	PROPN
aji-63	331	2	med	med	PROPN
aji-63	331	3	virol	virol	NOUN
aji-63	331	4	.	.	PUNCT
aji-63	332	1	2021;93:924–33	2021;93:924–33	X
aji-63	332	2	.	.	PUNCT
aji-63	333	1	doi	doi	PROPN
aji-63	333	2	:	:	PUNCT
aji-63	333	3	http://10.1002	http://10.1002	X
aji-63	333	4	/	/	SYM
aji-63	333	5	jmv.26353	jmv.26353	PROPN
aji-63	333	6	30	30	NUM
aji-63	333	7	.	.	PUNCT
aji-63	334	1	post	post	PROPN
aji-63	334	2	n	n	CCONJ
aji-63	334	3	,	,	PUNCT
aji-63	334	4	eddy	eddy	PROPN
aji-63	334	5	d	d	PROPN
aji-63	334	6	,	,	PUNCT
aji-63	334	7	huntley	huntley	PROPN
aji-63	334	8	c	c	PROPN
aji-63	334	9	,	,	PUNCT
aji-63	334	10	et	et	PROPN
aji-63	334	11	al	al	PROPN
aji-63	334	12	.	.	PUNCT
aji-63	335	1	antibody	antibody	NOUN
aji-63	335	2	response	response	NOUN
aji-63	335	3	to	to	ADP
aji-63	335	4	sars	sar	NOUN
aji-63	335	5	-	-	PUNCT
aji-63	335	6	cov-2	cov-2	PART
aji-63	335	7	infection	infection	NOUN
aji-63	335	8	in	in	ADP
aji-63	335	9	humans	human	NOUN
aji-63	335	10	:	:	PUNCT
aji-63	335	11	a	a	DET
aji-63	335	12	systematic	systematic	ADJ
aji-63	335	13	review	review	NOUN
aji-63	335	14	.	.	PUNCT
aji-63	336	1	plos	plos	PROPN
aji-63	336	2	one	one	NUM
aji-63	336	3	.	.	PUNCT
aji-63	337	1	2020;15(12):e0244126	2020;15(12):e0244126	NOUN
aji-63	337	2	.	.	PUNCT
aji-63	338	1	doi	doi	NOUN
aji-63	338	2	:	:	PUNCT
aji-63	338	3	https://doi.org/10.1371	https://doi.org/10.1371	ADJ
aji-63	338	4	/	/	SYM
aji-63	338	5	journal.pone.0	journal.pone.0	PROPN
aji-63	338	6	244126	244126	NUM
aji-63	338	7	,	,	PUNCT
aji-63	338	8	31	31	NUM
aji-63	338	9	.	.	PUNCT
aji-63	339	1	to	to	ADP
aji-63	339	2	kk	kk	PROPN
aji-63	339	3	-	-	PUNCT
aji-63	339	4	w	w	PROPN
aji-63	339	5	,	,	PUNCT
aji-63	339	6	tsang	tsang	PROPN
aji-63	339	7	ot	ot	PROPN
aji-63	339	8	-	-	PROPN
aji-63	339	9	y	y	PROPN
aji-63	339	10	,	,	PUNCT
aji-63	339	11	leung	leung	PROPN
aji-63	339	12	w	w	PROPN
aji-63	339	13	-	-	PUNCT
aji-63	339	14	s	s	PROPN
aji-63	339	15	,	,	PUNCT
aji-63	339	16	et	et	PROPN
aji-63	339	17	al	al	PROPN
aji-63	339	18	.	.	PUNCT
aji-63	339	19	temporal	temporal	ADJ
aji-63	339	20	profiles	profile	NOUN
aji-63	339	21	of	of	ADP
aji-63	339	22	viral	viral	ADJ
aji-63	339	23	load	load	NOUN
aji-63	339	24	in	in	ADP
aji-63	339	25	posterior	posterior	ADJ
aji-63	339	26	oropharyngeal	oropharyngeal	ADJ
aji-63	339	27	saliva	saliva	NOUN
aji-63	339	28	samples	sample	NOUN
aji-63	339	29	and	and	CCONJ
aji-63	339	30	serum	serum	NOUN
aji-63	339	31	antibody	antibody	NOUN
aji-63	339	32	responses	response	NOUN
aji-63	339	33	during	during	ADP
aji-63	339	34	infection	infection	NOUN
aji-63	339	35	by	by	ADP
aji-63	339	36	sars	sar	NOUN
aji-63	339	37	-	-	PUNCT
aji-63	339	38	cov-2	cov-2	NOUN
aji-63	339	39	:	:	PUNCT
aji-63	339	40	an	an	DET
aji-63	339	41	observational	observational	ADJ
aji-63	339	42	cohort	cohort	NOUN
aji-63	339	43	study	study	NOUN
aji-63	339	44	.	.	PUNCT
aji-63	340	1	the	the	DET
aji-63	340	2	lancet	lancet	ADJ
aji-63	340	3	infectious	infectious	ADJ
aji-63	340	4	diseases	disease	NOUN
aji-63	340	5	.	.	PUNCT
aji-63	341	1	2020;20(5):565	2020;20(5):565	NUM
aji-63	341	2	-	-	SYM
aji-63	341	3	74	74	NUM
aji-63	341	4	.	.	PUNCT
aji-63	342	1	_	_	PUNCT
aji-63	343	1	_	_	PUNCT
aji-63	344	1	_	_	PUNCT
aji-63	345	1	_	_	PUNCT
aji-63	346	1	_	_	PUNCT
aji-63	347	1	_	_	PUNCT
aji-63	348	1	_	_	PUNCT
aji-63	349	1	_	_	PUNCT
aji-63	350	1	_	_	PUNCT
aji-63	351	1	_	_	PUNCT
aji-63	352	1	_	_	PUNCT
aji-63	353	1	_	_	PUNCT
aji-63	354	1	_	_	PUNCT
aji-63	355	1	_	_	PUNCT
aji-63	356	1	_	_	PUNCT
aji-63	357	1	_	_	PUNCT
aji-63	358	1	_	_	PUNCT
aji-63	359	1	_	_	PUNCT
aji-63	360	1	_	_	PUNCT
aji-63	361	1	_	_	PUNCT
aji-63	362	1	_	_	PUNCT
aji-63	363	1	_	_	PUNCT
aji-63	364	1	_	_	PUNCT
aji-63	365	1	_	_	PUNCT
aji-63	366	1	_	_	PUNCT
aji-63	367	1	_	_	PUNCT
aji-63	368	1	_	_	PUNCT
aji-63	369	1	_	_	PUNCT
aji-63	370	1	_	_	PUNCT
aji-63	371	1	_	_	PUNCT
aji-63	372	1	_	_	PUNCT
aji-63	373	1	_	_	PUNCT
aji-63	374	1	_	_	PUNCT
aji-63	375	1	_	_	PUNCT
aji-63	376	1	_	_	PUNCT
aji-63	377	1	_	_	PUNCT
aji-63	378	1	_	_	PUNCT
aji-63	379	1	_	_	PUNCT
aji-63	380	1	_	_	PUNCT
aji-63	381	1	_	_	PUNCT
aji-63	382	1	_	_	PUNCT
aji-63	383	1	_	_	PUNCT
aji-63	384	1	_	_	PUNCT
aji-63	385	1	_	_	PUNCT
aji-63	386	1	_	_	PUNCT
aji-63	387	1	_	_	PUNCT
aji-63	388	1	_	_	PUNCT
aji-63	389	1	_	_	PUNCT
aji-63	390	1	_	_	PUNCT
aji-63	391	1	_	_	PUNCT
aji-63	392	1	_	_	PUNCT
aji-63	393	1	_	_	PUNCT
aji-63	394	1	_	_	PUNCT
aji-63	395	1	_	_	PUNCT
aji-63	396	1	_	_	PUNCT
aji-63	397	1	_	_	PUNCT
aji-63	398	1	_	_	PUNCT
aji-63	399	1	_	_	PUNCT
aji-63	400	1	_	_	PUNCT
aji-63	401	1	_	_	PUNCT
aji-63	402	1	_	_	PUNCT
aji-63	403	1	_	_	PUNCT
aji-63	404	1	_	_	PUNCT
aji-63	405	1	_	_	PUNCT
aji-63	406	1	_	_	PUNCT
aji-63	407	1	_	_	PUNCT
aji-63	408	1	_	_	PUNCT
aji-63	409	1	_	_	PUNCT
aji-63	410	1	_	_	PUNCT
aji-63	411	1	_	_	PUNCT
aji-63	412	1	_	_	PUNCT
aji-63	413	1	_	_	PUNCT
aji-63	414	1	_	_	PUNCT
aji-63	415	1	_	_	PUNCT
aji-63	416	1	_	_	PUNCT
aji-63	417	1	_	_	PUNCT
aji-63	418	1	_	_	PUNCT
aji-63	419	1	_	_	PUNCT
aji-63	420	1	_	_	PUNCT
aji-63	421	1	_	_	PUNCT
aji-63	422	1	_	_	PUNCT
aji-63	423	1	©	©	PROPN
aji-63	423	2	2021	2021	NUM
aji-63	423	3	sallam	sallam	NOUN
aji-63	423	4	et	et	PROPN
aji-63	423	5	al	al	PROPN
aji-63	423	6	.	.	PROPN
aji-63	423	7	;	;	PUNCT
aji-63	423	8	this	this	PRON
aji-63	423	9	is	be	AUX
aji-63	423	10	an	an	DET
aji-63	423	11	open	open	ADJ
aji-63	423	12	access	access	NOUN
aji-63	423	13	article	article	NOUN
aji-63	423	14	distributed	distribute	VERB
aji-63	423	15	under	under	ADP
aji-63	423	16	the	the	DET
aji-63	423	17	terms	term	NOUN
aji-63	423	18	of	of	ADP
aji-63	423	19	the	the	DET
aji-63	423	20	creative	creative	ADJ
aji-63	423	21	commons	common	NOUN
aji-63	423	22	attribution	attribution	NOUN
aji-63	423	23	license	license	NOUN
aji-63	423	24	(	(	PUNCT
aji-63	423	25	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-63	423	26	)	)	PUNCT
aji-63	423	27	,	,	PUNCT
aji-63	423	28	which	which	PRON
aji-63	423	29	permits	permit	VERB
aji-63	423	30	unrestricted	unrestricted	ADJ
aji-63	423	31	use	use	NOUN
aji-63	423	32	,	,	PUNCT
aji-63	423	33	distribution	distribution	NOUN
aji-63	423	34	,	,	PUNCT
aji-63	423	35	and	and	CCONJ
aji-63	423	36	reproduction	reproduction	NOUN
aji-63	423	37	in	in	ADP
aji-63	423	38	any	any	DET
aji-63	423	39	medium	medium	NOUN
aji-63	423	40	,	,	PUNCT
aji-63	423	41	provided	provide	VERB
aji-63	423	42	the	the	DET
aji-63	423	43	original	original	ADJ
aji-63	423	44	work	work	NOUN
aji-63	423	45	is	be	AUX
aji-63	423	46	properly	properly	ADV
aji-63	423	47	cited	cite	VERB
aji-63	423	48	.	.	PUNCT
aji-63	424	1	peer	peer	NOUN
aji-63	424	2	-	-	PUNCT
aji-63	424	3	review	review	NOUN
aji-63	424	4	history	history	NOUN
aji-63	424	5	:	:	PUNCT
aji-63	424	6	the	the	DET
aji-63	424	7	peer	peer	NOUN
aji-63	424	8	review	review	NOUN
aji-63	424	9	history	history	NOUN
aji-63	424	10	for	for	ADP
aji-63	424	11	this	this	DET
aji-63	424	12	paper	paper	NOUN
aji-63	424	13	can	can	AUX
aji-63	424	14	be	be	AUX
aji-63	424	15	accessed	access	VERB
aji-63	424	16	here	here	ADV
aji-63	424	17	:	:	PUNCT
aji-63	424	18	https://www.sdiarticle5.com/review-history/83681	https://www.sdiarticle5.com/review-history/83681	VERB
aji-63	424	19	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	X